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ABSTRACT
Cardiovascular disease is the leading cause of death and an important cause of morbidity in 
postmenopausal women, the incidence being particularly high in the West of Scotland. 
Retrospective studies strongly suggest an aetiological link between oestrogen deficiency and 
cardiovascular risk, and moreover have suggested that mortality can be reduced by up to 50% 
by the administration of hormone replacement therapy. However, recently reported randomised 
controlled studies have challenged this view (Hulley et al, 1998). The mechanism by which the 
apparent cardioprotective benefit occurs is multi-factorial and incompletely understood. Direct 
effects on the vessel wall particularly at the level of the endothelium, as well as indirect effects 
on metabolic risk factors such as lipid and carbohydrate metabolism, may play an important role 
in any underlying protective mechanism. The aim of this project was to study the effect of 
oestrogen on the vessel wall, more specifically by examining its effect on vascular reactivity 
and its influence on nitric oxide synthesis and release from the vascular endothelium. In vivo 
studies using forearm venous occlusion plethysmography were used to assess the effect of 
oestrogen on forearm vasodilator responses, and on the release of nitric oxide from the intact 
endothelium. To compliment this work, the effect of sex steroids on the growth and function of 
endothelial cells, and on the synthesis and release of nitric oxide from vascular endothelial cells, 
was studied in vitro using cultured human aortic endothelial cells. The effect of short and long­
term oestrogen on endothelial nitric oxide synthase (eNOS) gene expression was studied in 
cultured cells using northern analysis. No change in forearm blood flow was observed following 
intra-arterial infusion of 17p-oestradiol, suggesting that oestrogen is not an acute vasodilator in 
the forearm vasculature. Forearm blood flow responses to N°-monomethy 1-L-arginine, a 
stereospecific inhibitor of nitric oxide which provides an index of basal nitric oxide synthesis, 
were unchanged following 4 weeks’ of transdermal 17p-oestradiol treatment, suggesting that 
oestrogen supplementation did not enhance basal nitric oxide release in the forearm vascular 
bed. In cultured endothelial cells, a significant increase cell number was observed following 
long term oestradiol treatment. The underlying mechanism for this observation is unclear. 
Expression of messenger RNA for the eNOS gene was confirmed by northern analysis, however 
the results of these studies did not demonstrate any change in eNOS mRNA expression 
following oestrogen treatment, supporting the findings of the in-vivo study. With the exception 
of the growth studies which yielded interesting results requiring further evaluation, the negative 
results of the remaining carefully designed and well executed studies, while at variance with the 
results of other investigators, nevertheless generate interesting new data which appears to be in 
broad agreement with the albeit limited results of the randomised control studies currently 
available. From our present knowledge base, there remain many unanswered questions about 
the true risks and benefits of hormone replacement therapy, and a better understanding of the 
mechanisms contributing to any beneficial effects will lead to better prescribing practices and 
may ultimately lead to improvements in womens’ health.
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CHAPTER ONE
INTRODUCTION
1.1 Background
1.1.1 Introduction
In 1868 the life expectation for a newborn female infant was 40 years (Felstein, 1973). 
By 1995 the female life expectation in Scotland had risen to 77.6 years, and by the year 
2025 almost one quarter of the population will be aged 60 or over, and a higher 
proportion of this group will be female (Health in Scotland, 1995). Thus, most women 
are living at least one third of their lives after reproductive function has ceased.
The climacteric, derived from the Greek ‘klimakter’ (the rung of the ladder), is a normal 
ageing phenomenon in women which reflects the gradual transition from the 
reproductive to the non-reproductive phase of life, and represents a period of physical 
and mental transition from fertility and normal ovarian function to infertility and 
ovarian failure. The menopause or last menstrual period, which is derived from the 
Greek ‘menos’ (month) and ‘pausis’ (to stop), is defined by the World Health 
Organisation as The permanent cessation of menstruation resulting from the loss of 
ovarian follicular activity’. It forms part of the climacteric process and marks the end of 
ovulation. In Western society cessation of menses occurs at a median age of 50 years, 
however the climacteric occurs over a ten-year period from the mid-forties onwards.
A vast increase in the total number of women passing through the climacteric period 
during the last century, has transformed the menopause from being a subject peripheral 
to medical interest, to one which has become central to clinical practice and about 
which there is considerable debate both in the medical and lay press. With the 
increasing longevity now seen in women the clinical features of the climacteric are 
more readily appreciated by physicians and there is better understanding of the 
underlying endocrine physiology.
1.1.2 Historical perspectives
In the late 17^  ^ and early 18**‘ centuries with changing political and economic events 
around Europe a new stability emerged. This, accompanied by an abatement in the 
plagues which regularly devastated the continent, led to a rise in the expectation of life, 
both at birth and during adulthood. Many women, particularly those from the upper
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classes, were experiencing the climacteric and some were reaching the menopause and 
beyond. However the climacteric changes were perceived to rob these women of their 
sexuality, and usually marked the start of the decline in their status.
The first English reference to the features associated with the climacteric period 
appeared in a guide for women published in 1927 by an anonymous physician 
(Wilbush, 1988). In 1857 a physician named Edward Tilt wrote the first English book 
devoted to climacteric disorders. He was the first to suggest that not only the menopause 
but also the symptoms and disturbances of the climacteric, were due to ovarian 
involution (Wilbush, 1980). Nevertheless, his work had little impact at this time, most 
probably because of its perceived unimportance as climacteric patients seldom 
complained. Women in the climacteric generally accepted their fate as an act of nature, 
and with their offspring as their compensation, did not feel demoted or diminished. 
However, by the turn of the last century Europe was deep in economic depression, 
families became smaller (partly due to economic considerations and partly due to the 
greater availability of contraceptive methods), children increasingly moved away from 
their home towns to follow economic opportunities, and women found themselves alone 
with their role in family life decimated. Unable to accept their position they often 
became ill. Concurrently the number of women who reached and passed the menopause 
continued to increase, and the largely middle and lower-middle classes became the 
principal sufferers. Thus, there was a renewed interest in the whole dimension of the 
menopause at the beginning of the 20‘^  century.
The early part of the century saw a great upsurge in the study of the endocrinology of 
the climacteric and the menopause. Nineteen twenty-three marked the discovery of 
oestrogens in follicular fluid and thereafter, there was rapid isolation of the various 
ovarian hormones such that by the mid 1930’s they were being therapeutically assayed 
in North America and Germany (Wilbush, 1988). The 1940’s and 1950’s saw a great 
increase in experimental and therapeutic hormone therapy including treatment of 
climacteric symptoms with oestrogen. This marked a new era in womens’ health and 
has shaped the recent developments in the menopausal milieu and hormonal 
replacement therapy (HRT).
1.2 Steroid hormones
1.2.1 Introduction
The steroid hormones are a group of small and phylogenetically very old molecules, 
with strikingly similar structures which are based on a common structural subunit - the 
perhydroxycyclopentanephanthrene molecule (figure 1), consisting of four fused 
hydrocarbon rings - three 6-C rings and one 5-C ring (Birkhauser, 1996).
Figure 1.1 -  Basic steroid structure
They are classified according to the number of carbon atoms (C) thus: C-21 steroids 
(pregnane nucleus) - progesterone, cortisol, and aldosterone; C-19 steroids (androstane 
nucleus) - testosterone, and androstendione; C-18 steroids (oestrone nucleus) - 
oestrogen (figure 1.2), (Birkhauser, 1996).
1.2.2 Steroid hormone biosynthesis
Cholesterol is the common pre-cursor of all steroid hormones and is the basic molecule 
for biosynthesis. The cholesterol used for steroid hormone biosynthesis is derived 
principally from dietary sources entering the steroid producing cells via the 
bloodstream, although with the exception of the placenta, all molecules involved in 
steroidogenesis can also synthesise cholesterol de-novo from acetate (figure 1.3) (Chard 
& Lilford, 1995).
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Figure 1.2 -  Steroid hormone structure (adapted from Birkhauser, 1996)
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Figure 1.3 -  Steroid hormone biosynthesis (adapted from Birkhauser, 1996)
All of the steps in steroidogenesis from cholesterol to pregnenolone are mediated by a 
single enzyme known as P450scc, which is controlled by a single gene on chromosome 
15 (Speroff, Glass & Kase, 1994). This reaction, the rate limiting step in the steroid 
synthetic pathway, occurs within the mitochondria by hydroxylation at positions C20 
and C22, and is followed by cleavage of the side chain. Thereafter, in all steroid- 
producing organs, steroidogenesis follows one of two basic pathways, either the 
pregnenolone or A-5 pathway via pregnenolone and dehydroepiandrostenedione, or the 
progesterone (A-4) pathway via progesterone and 17-hydroxyprogesterone (Jeffcoate, 
1992).
1.2.3 Sex steroids
The sex steroids are a subgroup of the steroid hormones and are classified into three 
groups according to the number of carbon atoms as previously described.
The ovary possesses the full capability of every steroid-secreting endocrine organ and is 
thus able to synthesise all three classes of natural sex steroids namely progestogens, 
androgens and oestrogens, however since the ovaries are deficient in 21-hydroxylase 
and 11-hydroxylase enzymes, they are therefore incapable of producing glucocorticoids 
and mineralocorticoids (Birkhauser, 1996). Natural progesterone is secreted by the 
ovary, principally by the corpus luteum. In the female androgens are produced by the 
ovaries and the adrenal glands. Ovarian androgens are synthesised by the theca cells and 
pass into the granulosa cells where they are aromatised to oestrogens. The initial growth 
of the primordial follicle is not hormone-dependent and is not controlled by 
gonadotrophins. Later, follicular growth is dependent on follicle-stimulating hormone 
(FSH), as is oestradiol secretion. FSH induces its own receptors on the cell membrane 
of granulosa cells. Theca cells are dependent on luteinising hormone (LH) and are 
responsible for the synthesis of androgens. These diffuse into the granulosa cell layer, 
where the FSH-dependent aromatase (P450arom) reaction converts them into 
oestrogens (Erikson, 1986).
During the fertile period, oestradiol is the dominant oestrogen, secreted mainly by the 
ovary. Androstendione and testosterone are synthesised by theca cells (under the control 
of LH) and then pass to the granulosa cells, where they are aromatised (under FSH 
control) to oestrone and oestradiol (Birkhauser, 1996). After the menopause, the main
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oestrogen source is peripheral or acyclical aromatisation of androgens to oestrone in 
adipose tissue, skin, and muscle (Chard & Lilford, 1995). Oestrone is the dominant 
oestrogen after menopause, circulating mainly in the reversible form of oestrone 
sulphate, which is 90% bound to albumin. Oestradiol binds specifically (60%) to sex 
hormone binding globulin (SHBG) which has a high affinity for testosterone and 
oestradiol and non-specifically (38%), to albumin which has a low affinity for sex 
steroids (Rosner, 1990). Only 2-3% of oestradiol circulates freely (i.e. unbound), and is 
able to diffuse across cell membranes. Oestrone, oestrone-sulphate, and oestriol have a 
much lower affinity to SHBG than oestradiol but have a greater affinity for albumin. 
Alterations in SHBG levels change the concentration of free oestradiol and therefore its 
bioavailability. The production rate of oestrogens represents the sum of glandular 
secretion and extraglandular (peripheral) conversion from androgens to oestrogens, 
although the secretion rate represents only the direct (i.e. glandular) ovarian secretion of 
oestrogens. Circulating oestrone and oestradiol are in constant equilibrium. Their main 
metabolite is oestriol through hydroxylation at position sixteen (D-ring). Hydroxylation 
at positions two or four (A-ring) results in catecholoestrogens, which are involved in the 
control of gonadotrophin-releasing hormone (GnRH) secretion through modulation of 
several neurotransmitters (Birkhauser, 1996). Conjugation of oestrogens to water- 
soluble sulphates and glucuronides in the kidney and liver permits their rapid urinary 
and biliary excretion, although 80% of the oestrogens eliminated in bile are reabsorbed 
from the gut via the enterohepatic circulation (Jeffcoate, 1992).
1.2.4 Exogenous steroids
The pharmacological actions of exogenous steroids are in essence similar to the 
physiological actions of the endogenous hormones, particularly when they are 
administered as replacement therapy. In ovarian failure, oestrogen replacement therapy 
is the most appropriate treatment for the associated hypo-oestrogenic symptoms, with 
the aim of the therapeutic regimen being to provide the most effective treatment with 
the fewest side effects.
Oestrogens can be administered orally or parenterally, for example percutaneously, 
transvaginally or subcutaneously as implants. The biochemical and pharmacological 
effects of exogenous oestrogens will thus be dependent on the route of administration.
Natural oestrogens (oestradiol, oestrone and oestriol) have the most appropriate profile 
for HRT. When administered orally, pure oestrogens are metabolised by the intestinal 
mucosa thus limiting their oestrogenic activity (Kuhl, 1990). The absorbed steroid is 
then rapidly transferred to the liver via the portal venous system where further 
metabolism occurs thus inactivating the steroid before it reaches the systemic 
circulation (‘first-pass’ effect). In part, this can be overcome by the use of micronised 
oestrogen but because of the first-pass effect oral oestrogen must be given in higher 
doses than parenteral therapy in order to achieve symptom relief.
The use of synthetic steroids and conjugated equine oestrogens to some extent 
overcomes the problems associated with natural oral oestrogens. Conjugated equine 
oestrogens (CEE) are prepared from pregnant mares’ urine and contain principally 
sodium oestrone sulphate, equilin sulphate and 17a-dihydroequilin. The oestrone 
sulphate is then absorbed in its natural form but is then hydrolysed to oestrone and 
oestradiol (Davey, 1995). The synthetic steroids, the most important of which is 
ethinyloestradiol, are rapidly absorbed from the intestine but undergo little metabolism 
in the liver. Unlike natural oestrogens however, they do not bind with SHBG but are 
converted into a sulphate resulting in the formation of a reservoir of hormone. On a 
weight-for-weight basis, the potency of synthetic oestrogens is considerably greater than 
that of natural oestrogens (Davey, 1995).
The use of parenteral oestrogen preparations is particularly helpful when oral therapy 
causes gastrointestinal upset and where bypassing first-pass hepatic metabolism is 
desirable. Percutaneous delivery systems are perhaps the most widely used parenteral 
route of administration, in particular transdermal oestrogen patches. These can 
administer oestrogen at controlled rates of 0.025 -  O.lmg/day depending on the surface 
area of the patches and steady-state concentrations can be achieved by changing the 
patches once or twice weekly, ensuring that the site of application is changed regularly 
to avoid any skin irritation. A variety of preparations are currently available using either 
the original reservoir type or the more recent matrix patches. Both oestrogen and 
combined oestrogen and progestogen patches are now available. Percutaneous creams 
or gels are increasingly popular in Europe and are gaining some popularity in the United 
Kingdom. A once daily dose of gel containing 3g oestradiol appears to give good 
symptom relief, however the daily application of the gel requires good patient 
compliance particularly as it is sticky when first applied. Subcutaneous oestradiol
9
implants (50-1 OOmg) avoid the need for daily patient compliance and give good 
symptomatic relief for up to six months. The implants can easily be inserted in an 
outpatient clinic under local anaesthetic, and have the advantage of enabling 
simultaneous insertion of a testosterone implant for relief of lethargy and loss of libido.
Like natural oestrogen, pure progesterone must be given orally in a micronised form. 
However, unlike different oestrogen formulations which have strikingly similar effects 
when given in equipotent doses, progestogens have significantly different effects 
depending on whether they are oestrane, gonane or pregnane derivatives (Davey, 1995). 
Oestrane and gonane derivatives such as levonorgestrel and norethisterone are more 
potent and have more androgenic effects than pregnane derivatives such as 
medroxyprogesterone acetate (MPA). With the exception of MPA 150mg and 
norethisterone 200mg which are high dose progestogens used as injectable 
contraceptives, progestogens are otherwise generally administered orally although 
norethisterone can be administered topically.
The principal use of progestogen therapy in HRT preparations is to counteract the 
potential adverse effects of oestrogen on the endometrium, with the dose of progestogen 
being kept to the minimum required to prevent endometrial hyperplasia and the choice 
of progestogen being limited to the one with the least adverse effects. In patients in 
whom there is an absolute contraindication to oestrogen therapy, single agent 
unopposed progestogens may offer some relief of menopausal symptoms if adequate 
doses are used, for example a minimum of 20mg MPA per day (Schiff et al, 1980; Lobo 
et al, 1984) and in the case of norethisterone bone protection also (Mandell et al, 1982; 
Abdalla et al, 1985).
As it has been reported that the use of continuous unopposed oestrogen results in an 
increased incidence of both endometrial hyperplasia and endometrial carcinoma, the 
importance of using combined oestrogen/progestogen preparations (either as monthly or 
three monthly cyclical preparations or as combined continuous regimens) in non­
hysterectomised women has been established (Gambrell, 1978; 
Grady et al, 1995, Weiderpass et al, 1999). Recent evidence however has challenged the 
view that the addition of a progestogen eliminates the excess risk for endometrial 
carcinoma. Long cycle HRT regimens (progestogen administered following twelve 
weeks of oestrogen administration) appear to be associated with an increased incidence
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of both endometrial hyperplasia and carcinoma compared with monthly cyclical HRT 
regimens (Bjarnason et al, 1999). Compared with non-users, postmenopausal women 
who use combined therapy of oestrogen and long cycle progestogen (greater than ten 
days per month) may also have an increased risk of endometrial cancer, although this 
risk appears to be much smaller that for unopposed oestrogen or long cycle regimens 
(Beresford et al, 1997, Gruber et al, 1999). The use of combined continuous HRT 
regimens does however appear to confer endometrial protection. (Bertone & 
Weiderpass, 2000; Sturdee et al, 2000) Although the risk of developing endometrial 
cancer is increased with certain HRT regimens, the risk of death from this type of 
endometrial cancer does not increase proportionately. Oestrogen associated endometrial 
cancer is thought to be a less aggressive variant than spontaneously occurring disease, 
and is more likely to be diagnosed earlier in women taking oestrogen, which may 
account for the better survival rates reported.
Early estimates of the HRT-related risk of breast cancer were reported as a relative risk 
(RR) of 1.1 for all oestrogen use, suggesting a 10% increase in risk relative to no 
oestrogen use (Henderson, Paganini-Hill and Ross, 1991) However recent analysis of 
pooled data from 51 epidemiologic studies on breast cancer in HRT users, reported an 
overall 14% increase in RR with ever-use of HRT. The excess risk was largely confined 
to current and recent users, in whom the relative risk increased by 2.3% for each year of 
use. Overall, short-term use of oestrogen (1-2 years duration) was not associated with an 
increased risk of breast cancer, however a small increased risk of breast cancer related 
to longer duration of HRT use was identified (47 cases/1000 women using HRT for five 
years compared with 45/1000 in non-users) (Collaborative Group on Hormonal Factors 
in Breast Cancer, 1997). Comparable findings have been reported in a large 
epidemiological study from Sweden (Magnusson et al, 1999), and by the Iowa 
Women’s Health Study, a prospective study of HRT and various types of invasive 
carcinoma. In the above studies the majority of women (over 80% in the 1997 meta­
analysis) were using oestrogen-only preparations. The effect of addition of 
progestogens on the incidence of breast cancer has recently been evaluated in a number 
of studies (Ross et al, 2000; Schairer et al, 2000). The results of these studies are in 
broad agreement that the risk of breast cancer is significantly increased beyond that 
associated with oestrogen alone following addition of a progestogen. Moreover, it 
appears that the risk is greater with continuous combined HRT than with opposed 
cyclical preparations. In spite of the increase in incidence of breast cancer an increase in
11
breast-cancer related mortality does not appear to be associated with HRT use, and 
indeed may in fact be better in HRT users which may be a reflection of earlier 
diagnosis. Among 984 women diagnosed with breast cancer, those who had previously 
used HRT had significantly longer survival overall than those who had never used HRT 
(RR 0.78) (Jenstrom et al, 1999). Furthermore it appears that the clinical and biological 
characteristics of breast cancer in users of HRT are more favourable than in non-users 
(Salmon et al, 1999).
The issue of HRT use in women previously treated for breast and gynaecological 
cancers is becoming an increasingly important area of interest. A review of the literature 
for studies of HRT in women treated for gynaecological malignancies, concluded on the 
basis of circumstantial evidence that women with stage I or II endometrial cancer could 
be offered HRT without increasing the risk of disease recurrence of death (Burger et al, 
1999). With regard to breast cancer and subsequent HRT use there is evidence to 
suggest that HRT does not appear to increase breast cancer events (Vassilopoulou-Sellin 
et al, 1999). Nevertheless, in breast cancer survivors it would be prudent to use the 
lowest effective dose of oestrogen and arrange careful monitoring.
Recent observational studies have also shown a slightly increased risk (2- to 4-fold) of 
deep venous thrombosis and of pulmonary embolism in women currently taking HRT 
particularly on initiation of therapy (Daly et al, 1996; Grodstein et al, 1996 & Jick et al, 
1996). These findings were supported by the findings of the HERS study (Heart and 
oestrogen-progestin replacement study) in which an increased risk for venous 
thromboembilism among women taking HRT was noted (Hulley et al, 1998). An 
interim report from the ongoing Women’s Health Initiative (WHI) in the United States 
has reported similar findings (WHI, 2000). Furthermore it appears that the risk of such 
events is not uniform across the population. The risks are greatly increased in the 
presence of thrombophilias particularly if there are multiple risks (Lowe et al, 2000). 
Accordingly, women with proven thrombophilic defects should be counselled about this 
increased risk prior to commencing HRT.
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1.3 Female reproductive physiology
1.3.1 Introduction
Reproductive function is controlled by the hypothalamic-pituitary-gonadal axis which 
functions as an integrated unit, but consists of a complex series of connections and 
feedback loops between the higher centres of the central nervous system and the target 
end organs (Browning, 1988).
The hypothalamus is composed of neural tissue and lies in the lower part of the lateral 
wall of the third ventricle, extending from the optic chiasma anteriorly to the mamillary 
bodies posteriorly. It is connected to higher centres by afferent fibres from parts of the 
frontal lobes and medial aspects of the temporal lobes, and by efferent fibres which pass 
to higher cortical areas via the thalamus. Inferiorly, it is connected to the pituitary gland 
by the pituitary stalk (Jeffcoate, 1992). The hypothalamus produces pituitary regulating 
hormones which pass down the pituitary portal system to regulate the production of 
pituitary trophic hormones by the anterior pituitary. The hypothalamic regulatory 
hormones are a diverse group of peptide hormones and include: GnRH or luteinising 
hormone-releasing hormone (LH-RH), corticotrophin-releasing hormone (CRH), 
growth hormone-releasing hormone (GH-RH), thyrotrophin-releasing hormone (TRH), 
growth hormone-release inhibiting hormone (somatostatin) and prolactin-inhibiting 
factor (PIF) or dopamine. In addition vasopressin and oxytocin released from the 
hypothalamic nuclei pass via the neural connections to the posterior pituitary where 
they are stored.
The mode of production of the regulating hormones is a neurosecretory mechanism. The 
hypothalamic nerve cells act both as neurones and endocrine cells. The hormones are 
synthesised in the cytoplasm of the neurone, pass along the nerve axon to the nerve 
terminal, from which they are released into the hypophyseal portal blood vessels 
passing to the anterior pituitary. The production of the hormones is under both tonic and 
cyclic control by the hypothalamus, the former being responsible for the constant day- 
to-day production of gonadotrophins, while the latter for the LH and FSH surges which 
lead to ovulation. Tonic control is principally under negative feedback control, whereas 
cyclic control is by a positive feedback mechanism. The secretion of hypothalamic 
peptides is controlled both by the higher neural centres, which receive input from
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external stimuli, particularly of emotional origin, and by the feedback loop mechanisms 
(Jeffcoate, 1992).
In the adult male, the pituitary gland weighs approximately 5OOmg; it is slightly larger 
in women and increases in size during pregnancy. The pituitary gland lies within the 
sella turcica of the sphenoid bone situated below the hypothalamus with the cavernous 
sinuses lying laterally and the intercavernous sinuses lying anteriorly and posteriorly, 
and is divided into two regions with distinctive functions reflecting their differing 
embryological origin. The anterior pituitary or adenohypophysis arises from Rathke’s 
Pouch, an upward invagination of the ectoderm of the roof of the primitive pharynx. 
The posterior pituitary or neurohypophysis arises as a similar downgrowth of neuro­
ectoderm from the third ventricle in the floor of the midbrain. The hypothalamus lies 
immediately above the pituitary gland connected to it by the pituitary stalk. The blood 
supply of the pituitary gland is derived from the inferior and superior hypophyseal 
arteries which originate from the internal carotid arteries. The posterior lobe is supplied 
directly by branches of the inferior hypophyseal arteries. Branches of the superior 
hypophyseal arteries supply the hypothalamus and the pituitary stalk. The anterior lobe 
of the pituitary has no direct arterial supply and receives its blood from a capillary 
venous plexus known as the pituitary portal system (Jeffcoate, 1992).
The anterior pituitary secretes a variety of important trophic hormones. These include 
the glycoproteins FSH, LH (gonadotrophin hormones) and thyroid stimulating hormone 
(TSH), and the peptide hormones growth hormone (GH), adrenocorticotrophin hormone 
(ACTH) and prolactin. The anterior lobe of the pituitary gland is devoid of neural 
elements but consists of three distinct groups of cells, characterised by their staining 
with haemotoxylin and eosin, into chromophils (acidophils and basophils) and 
chromophobes. The chromophobes are thought to be reserve or resting cells capable of 
developing into acidophils and basophils. The chromophil cells are responsible for 
producing GH and prolactin (acidophils), TSH, LH and FSH (basophils) (Chard & 
Lilford, 1995).
FSH and LH are glycoproteins consisting of two subunits - a  and p. The a  subunit is 
the same in all pituitary glycoproteins but the (3 subunits differ giving each hormone its 
specificity. These hormones have an important combined action on the ovary, and in the 
hormonal control of the menstrual cycle.
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Thyroid stimulating hormone is a glycoprotein which stimulates the thyroid gland to 
secrete two iodine-containing hormones, thyroxine (T4) and tri-iodothyronine (T3) 
which have an important role stimulating oxygen consumption, heat production and 
glucose mobilisation. In young children, thyroxine is essential for adequate growth and 
maturation.
Growth hormone is a protein hormone produced by the a  cells of the anterior pituitary 
under the influence of GHRH and somatostatin. It is responsible for growth in children, 
and with other factors, for control of carbohydrate metabolism (via insulin antagonism) 
and lipid metabolism (principally lipolysis). It is secreted in short bursts mostly in the 
early nocturnal period, but secretion can be stimulated by stress, hypoglycaemia and 
inhibited by glucose and corticosteroids.
Prolactin is a protein hormone with a similar chemical structure to GH and human 
placental lactogen (HPL). Like GH, it is produced by the a  cells of the anterior 
pituitary, however the use of specialised staining techniques has shown that it arises 
from a different subgroup of cells from GH. Prolactin is the only anterior pituitary 
hormone which is inhibited rather than stimulated by hypothalamic factors, principally 
by prolactin inhibiting factor or dopamine, which maintains the hormone in a state of 
tonic inhibition. The primary action of prolactin is on the breast, in the initiation of 
lactation.
Adrenocorticotrophic hormone is a polypeptide which stimulates the adrenal cortex 
(zona glomerulosa and zona fasciculata) to produce corticosteroids, notably cortisol 
which are involved in the control of protein, carbohydrate and lipid metabolism.
The posterior pituitary comprises numerous glial cells called pituicytes, which give the 
gland its distinct white appearance. These cells are concentrated principally in the main 
part of the gland but to a lesser extent are also found in the infundibulum. The 
remainder of the gland is composed of a multitude of nerves connecting the gland to 
specific hypothalamic nuclei by a rich plexus of nerves in the interior of the pituitary 
stalk (Jeffcoate, 1992).
The posterior pituitary produces two hormones namely oxytocin and antidiuretic 
hormone (ADH). The hormones synthesised in the nerve endings of the paraventricular
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and supraoptic nuclei combine with protein carrier molecules (neurophysins) and are 
transported down the nerve axons within the pituitary stalk to the posterior lobe where 
they are stored in vesicles prior to release.
Both oxytocin and ADH are nonapeptides and have similar structures. ADH has its 
primary action on the kidney where it increases the permeability of the renal collecting 
system to water, and is secreted in response to alterations in plasma volume and 
osmolality. Oxytocin has two main actions - stimulation of the uterus and stimulation 
of the myoepithelial cells of the breast to cause milk ejection. It is released into the 
bloodstream as a result of neurogenic stimuli notably from the uterus and breast.
1.3.2 General principals of feedback control
Physiologic hormone control levels in the blood are maintained by a variety of 
homeostatic mechanisms which entail precise signalling between the hormone-secreting 
gland and the target organ. Negative feedback control (figure 1.4) is commonly 
employed, especially in the hypothalamic-pituitary target gland systems (Jennett, 1989)
A hypothalamic releasing hormone stimulates the synthesis and release of an anterior 
pituitary hormone, which in turn stimulates the production of the target organ hormone. 
High levels of the latter inhibit the system by decreasing hypothalamic releasing 
hormone synthesis and action, or by decreasing secretion of pituitary releasing 
hormones (long feedback loops), while low levels result in the system being activated 
both at hypothalamic and pituitary levels. Short loop negative feedback mechanisms 
exist between the pituitary and hypothalamus (in response to high levels of pituitary 
hormones), and an ultrashort feedback system appears to exist with self-inhibition of 
hypothalamic regulating hormones as their production rises (Jeffcoate, 1992). In some 
systems, notably the hypothalamic-pituitary-gonadal axis, there are additionally long 
positive feedback control mechanisms mainly between the target organ and the 
pituitary, but there may be a direct hypothalamic effect also (Jennett, 1989).
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Figure 1.4 -  General principals of feedback control
1.3.3 The hypothalamic-pituitary-gonadal axis
In the adult female, the control of reproductive function is a complex process dependent 
upon input from higher cerebral centres, and feedback from the ovaries (figure 1.5).
During the reproductive years GnRH is released in a pulsatile manner, dependent on the 
phase of the menstrual cycle. On reaching the anterior pituitary, the release of GnRH 
stimulates the synthesis and release of the gonadotrophins FSH and LH. Follicle 
stimulating hormone stimulates follicular development, which occurs in several phases: 
recruitment, selection and dominance (Shaw, 1997). During each cycle, many follicles 
are recruited from the pool of primordial follicles, however only one of these will be 
destined to ovulate. The granulosa cells of the selected follicles acquire FSH receptors 
and respond by proliferation, differentiation and increased aromatase activity resulting 
in oestrogen secretion. The rising levels of oestradiol exert a negative feedback effect at 
the hypothalamic-pituitary level resulting in a fall in FSH and a reduction in aromatase 
activity in all but the largest follicle. This dominant follicle has more granulosa cells 
and therefore more FSH receptors, and hence it is able to maintain its growth in spite of 
the low FSH levels. The continued oestradiol production in the dominant follicle 
accounts for the rise in serum oestradiol levels seen in the late
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follicular phase of the cycle, and results in activation of a positive feedback mechanism 
inducing a sudden surge and release of LH (and to a lesser extent FSH), resulting in 
ovulation within twenty-four hours of this peak (Shaw, 1997). A temporary fall in 
oestrogen production that occurs with ovulation inactivates the positive-feedback 
mechanism. Following ovulation, LH induces the theca-granulosa cells of the collapsed 
follicle to transform into lutein cells, which synthesise oestrogen and progesterone, 
which then feedback to the hypothalamus and pituitary gland. The rising levels of 
oestrogen and progesterone initially inhibit FSH release, but in the absence of 
pregnancy the levels fall releasing the negative inhibition, and initiating a new cycle 
(Shaw, 1997).
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Figure 1.5 - Hypothalamic-pituitary-gonadal axis (Llewellyn-Jones, 1990)
18
1.3.4 The endocrinology of the perimenopause and menopause
In some women ovarian function ceases abruptly, however in general immediately prior 
to the menopause as a result of anovulatory cycles, there is decreased oestradiol 
secretion, decreased or absent progesterone secretion and a compensatory hyperactivity 
of the hypothalamus and pituitary gland.
The menopause is essentially an endocrinopathy characterised by ovarian failure and 
resulting in oestrogen deficiency. The mechanism underlying the menopause appears to 
be the disappearance of ovarian follicles (Faddy & Gosden, 1995). The process starts 
before birth, continues throughout the reproductive years, and eventually ceases during 
the perimenopausal period (Sherman, West & Korenman 1976). Human primordial 
germ cells separate from the somatic cells at an early stage of embryogenesis, migrating 
to the genital ridge, where they rapidly multiply to reach a maximum of seven million in 
each ovary around the fifth month of intrauterine life. Thereafter, multiplication ceases 
and the primordial follicles begin to regress leaving approximately two million follicles 
remaining at birth, of which fewer than 0 .0 2 % will ovulate during the reproductive 
phase of life. The remaining follicles will continue to degenerate throughout life, the 
rate of loss accelerating immediately prior to the menopause, which occurs when the 
number of follicles has fallen below a critical number (Richardson, Senikas & Nelson, 
1987), and insufficient oestradiol is secreted to produce adequate endometrial 
proliferation.
From around the age of 35 years onwards, the primordial follicles which remain in the 
ovary become more resistant to stimulation by gonadotrophins so that in the latter stages 
of menstrual life the cycles become anovulatory and irregular. This ovulation failure or 
deficiency in corpus luteal function causes an absent or reduced progesterone secretion. 
Initially these anovulatory cycles are isolated occurrences, but become increasingly 
more frequent with increased periods of unopposed oestrogen secretion 
perimenopausally. The resulting fall in plasma oestradiol levels triggers the negative 
feedback hypothalamic-pituitary feedback mechanism resulting in an increase in FSH 
secretion and consequently in LH secretion also. Follicle stimulating hormone levels 
appear to increase from the late thirties onwards and may be related to the exponential 
increase in the follicular loss occurring at this time.
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Immediately after the menopause the normal negative feedback mechanism of oestrogen 
on the higher brain centres is maintained and the reduced plasma oestradiol results in 
increased hypothalamic — pituitary activity causing plasma FSH and LH levels to 
increase rapidly to reach a maximum around two or three years after the menopause. 
Thereafter, the feedback mechanism appears to become reset at a lower level and both 
GnRH and gonadotrophin levels fall progressively over the next two decades despite the 
low oestradiol levels.
Gonadal glycoprotein molecules such as inhibins or activins also contribute to the 
synthesis and/or release or FSH. There are two major inhibin species, A and B, which 
comprise a dimeric structure consisting of a common a-subunit and one of two 
different p-subunits, Pa and Pb. Activins are dimers of the p-subunits (Burger, 1992). 
Inhibins appear to suppress the synthesis and/or secretion of FSH secretion by direct 
pituitary action, whereas the activins are probably more important in regulation of 
autocrine and paracrine activities, paradoxically stimulating, rather than inhibiting FSH. 
Inhibin levels decrease with age to undetectable levels postmenopausally. Additionally, 
there is considerable fluctuation during the menstrual cycle (McLachlan et al, 1987). 
Oestradiol levels per se are remarkably constant throughout life, suggesting that there 
may be a role for serum inhibin in FSH regulation during the follicular phase of the 
menstrual cycle as a function of increasing age. One possible explanation is that 
follicular exhaustion leads to decreased inhibin production resulting in a corresponding 
rise in FSH. Since the ovarian granulosa cells are the principal source of inhibin, the 
decreasing inhibin levels are consistent with the decline in primordial follicles.
During reproductive life the main circulating oestrogen is oestradiol which is produced 
cyclically with low levels in the early follicular phase, a peak in the late follicular phase 
and a second peak in the luteal phase of the cycle. Oestrone is produced in smaller 
amounts cyclically by the ovary, but also continuously by peripheral conversion of 
androstenedione. Postmenopausally, the predominant circulating plasma oestrogen 
changes from ovarian produced oestradiol to oestrone produced from extra-ovarian 
sources (Chard & Lilford, 1995). Plasma oestriol levels in postmenopausal women are 
similar to premenopausal women in the early follicular phase of the cycle, but are 
considerably less than late follicular phase levels. The plasma oestradiol:oestrone ratio 
therefore falls postmenopausally. The efficiency of conversion of androstenedione to 
oestrone increases considerably with increasing age, although the biological activity of
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the resulting circulating pool of oestrogen remains low since the potency of oestrone is 
approximately one-tenth of that of oestradiol. Oestriol is a low potency oestrogen 
produced in large amounts primarily during pregnancy.
To some extent, the climacteric and the menopause could also be considered to be a 
progesterone deficiency state. Postmenopausally, the plasma progesterone and 17- 
hydroxy progesterone levels are reduced as a consequence of anovulation and corpus 
luteal failure, although there is continued background progesterone production, almost 
exclusively of adrenal origin.
In Westernised industrialised societies the median age of the menopause is consistently 
reported as 50 years, the median rather than mean age being used to describe the 
distribution since it is negatively skewed (Lindquist, 1982). Women who smoke 
experience the menopause up to two years earlier than non-smokers, and moreover the 
effects of smoking appear to be dose related (Baron, Adams & Ward, 1988; Longcope 
& Johnstone, 1988).
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1.4 Cardiovascular disease and the menopause
1.4.1 Introduction
Cardiovascular disease (CVD) is the leading cause of death and an important cause of 
disability in Western society. The well-recognised male excess in CVD has often 
obscured the fact that it is also the commonest cause of death in women, however the 
demography of the disease clearly differs between the sexes. The incidence of CVD in 
women prior to the menopause is lower than that in age-matched men, however after the 
menopause the incidence is similar to that in men, suggesting that women are relatively 
more protected from CVD until after the menopause when a steep rise in the incidence 
of CVD is observed (table 1.1).
Although men and women share many risk factors for CVD including the non- 
modifiable factors such as age, family history and genetic predisposition, and the so- 
called modifiable risk factors such as cigarette smoking, hypertension, dyslipidaemias 
and diabetes, the menopause appears to be an additional risk factor for women.
1.4.2 Cardiovascular disease epidemiology in women
Evidence from retrospective observational studies comparing the incidence and severity 
of CVD in men and women has shown, almost without exception, that the incidence of 
CVD in premenopausal women is much lower than in men of similar age (Castelli WP, 
1984; Barrett-Connor & Bush, 1991; Wenger, Speroff & Packard, 1993). The 
association of premature menopause with increased cardiovascular risk (Colditz et al, 
1987), and correspondingly of late menopause with reduced risk, (Persson et al, 1997) 
lend further support to this argument. Moreover, with the exception of the Framingham 
data (Gordon et al, 1978), there is an abundance of evidence in the literature that HRT 
has a favourable influence on cardiovascular morbidity and mortality (Stampfer & 
Colditz, 1991; Grodstein & Stampfer, 1995, Barrett-Connor, 1996).
Observational data is of course subject to the criticism that it is likely to be biased and 
the interpretation of these observational data has recently been questioned, and is now 
the subject of considerable debate. It is argued that if age-specific mortality rates are 
plotted on a semi-logarithmic scale, the exponential increase with age appears to be
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remarkably constant in both sexes, with no sudden change in the rate in women around 
the time of the menopause and no apparent closure of the gender gap (Newton, 1998; 
Tunstall-Pedoe, 1998). This debate is likely to continue until the results of adequately 
powered long term randomised controlled studies are available, although early evidence 
from the HERS study would tend to favour the arguments of Tungstall-Pedoe and 
Newton. Despite the obvious limitations of the observational data, it is a widely held 
belief that the undoubted trend towards cardioprotection seen in the vast majority of 
studies published would refute the idea that this is an entirely spurious observation.
Age Sex Ischaemic heart disease Stroke Cancer 
(all causes)
15-34 M 1 . 6 1.3 6 . 1
F 2 . 6 3.7 16.8
35-44 M 15.2 4.2 16.7
F 3.7 6.9 43.4
45-64 M 30.9 5.7 32.7
F 17.2 7.3 45.2
65-74 M 31.7 8 . 8 32.6
F 25.1 10.7 34.7
>75 M 26.2 13.2 23.1
F 23.3 19.3 16.0
Table 1.1 -  Cause of death by age and sex (expressed as % total deaths) 
(Health in Scotland, 1995)
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1.5 Pathophysiology of atherosclerosis
1.5.1 Introduction
Atherosclerosis is a complex disease of multiple aetiology resulting from a series of 
molecular and cellular changes arising from within the vessel wall amid a variety of 
genetic and environmental influences. In the 19th century there were two main 
hypotheses to explain the pathogenesis of atherosclerosis. The 'incrustation’ hypothesis 
of von Rokitansky proposed in 1852 and subsequently modified by Duguid in 1946 
(cited by Fuster, 1992), suggested that intimai thickening resulted from fibrin deposition 
with subsequent organisation by fibroblasts and secondary lipid accumulation. The 'lipid 
hypothesis' proposed by Virchow in 1856 (cited by Fuster, 1992), suggested that the 
lipid which accumulated in the arterial wall was a transudate of blood lipid which 
subsequently formed complexes with acid mucopolysaccharides. Lipid then 
accumulated in the arterial walls because the mechanisms of lipid deposition dominated 
over those of removal. These two hypotheses have subsequently been integrated into a 
more complex 'response to injury' theory proposed by Ross (Ross, 1986).
1.5.2 Atherosclerotic lesions
Atherosclerosis begins in the first decade of life with the appearance of fatty streaks, the 
first grossly visible evidence of this disease (Strong, 1992). The term fatty streak or 
Type II lesion refers to the appearance of yellow, slightly raised areas that can be seen 
as dots or streaks on gross inspection of the endothelial surface of large arteries. Fatty 
streaks appear microscopically in the intima as slightly raised areas composed of fat- 
filled cells known as foam cells. Both macrophage-derived and smooth muscle cell- 
derived foam cells can be seen, although macrophage foam cells are thought to be the 
first to appear and predominate in fatty streaks (Stary et al, 1995). Cholesterol esters are 
the primary lipid of fatty streaks and at this stage, most are present as droplets within 
macrophage foam cells. The extracellular space does however also contain minute lipid 
droplets and vesicules which may represent the initial changes that lead to fatty streak 
formation (Simionescu & Simionescu, 1993).
Up to about 20 years of age, the frequency of fatty streaks in the aorta and coronary 
arteries is similar for all populations, regardless of the prevalence of atherosclerosis and
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the rate of coronary heart disease in that population as adults (McGill, 1968). Thus, the 
development of fatty streaks may be a normal response that initially protects the arterial 
wall from the effects of accumulating plasma lipoproteins, but which ultimately 
provides the foundation of a pathologic process that is accelerated in the presence of 
excess environmental risk factors.
Some fatty streaks appear to progress to more advanced atherosclerotic lesions. 
Intermediate or Type III lesions have been identified in atherosclerotic arteries from 
human and animal models which appear to bridge the gap in the continuum between 
fatty streaks and the more complex lesions. Macrophages continue to predominate in 
intermediate lesions, but smooth muscle cells are present in greater numbers. There is 
more extracellular lipid, and small pools of lipid droplets can be seen aligned along 
layers of smooth muscle cells. These lesions appear to progress to atheromatous (Type
IV lesions) and ultimately to fibroatheromatous lesions (Type V lesions), which 
together represent the first of the clinically dangerous advanced lesions. True 
atheromatous lesions are characterised by a dense extracellular lipid core and both 
macrophages and smooth muscle cells are present, with and without lipid droplets, 
along with some lymphocytes and occasional mast cells. There is often a proteoglycan- 
rich layer between the lipid core and the endothelium, but at this stage there may be 
little evidence of a fibrous cap. Type V lesions are very similar, with the exception that 
there is an increase in fibrous tissue, particularly collagen, over the lipid core, and 
complicated features such as calcification and fibrosis often are seen. The Type IV and
V lesions can restrict the lumen of the artery by up to about 50%, but are not occlusive. 
Nevertheless, these types of lesions represent the most clinically dangerous of the 
atherosclerotic plaques because of their susceptibility to plaque rupture and thrombosis 
(Brown et al, 1993). Eccentric Type IV and V atherosclerotic plaques that are rich in 
macrophage foam cells at the periphery of the lesion appear most susceptible to rupture. 
Type VI lesions are often referred to as complicated plaques because of the presence of 
disruptions in the integrity of the endothelial surface, such as ulceration, calcification, 
and thrombosis.
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1.5.3 Cellular events in atherosclerosis
The hallmark of atherosclerosis is the accumulation of cholesterol, particularly 
cholesterol esters in the arterial wall. This occurs initially in macrophage foam cells, 
however as the lesions become more severe, cholesterol esters and cholesterol 
monohydrate crystals are also found extracellularly. Many of the subsequent changes 
associated with more severe atherosclerotic lesions can be attributed to macrophage 
foam cells and their secretory products. The origin of the cholesterol that accumulates in 
the atherosclerotic plaque is the plasma lipoproteins (Dayton & Hashimoto, 1970). It is 
now known that plasma lipoproteins normally pass from the blood into the arterial wall. 
As long as endothelial cells remain intact, their junctions are too tight to allow 
molecules much larger than albumin to pass between cells. Because lipoproteins are 
much larger than albumin, these normally pass through endothelial cells by a process of 
transecytosis via plasmalemma vesicles to the subendothelial compartment (Simionescu 
& Simionescu, 1993). This process is independent of lipoprotein receptors and functions 
for all lipoproteins. Because of this, the absolute amount of lipoprotein transported into 
the arterial wall is largely dependent on the concentration of lipoproteins in the blood.
Atherosclerosis does not occur uniformly in all arteries or regions of the same artery but 
instead occurs focally at specific sites, such as the proximal main coronary arteries, 
abdominal aorta, bifurcations and branch points of arteries. This has led to speculation 
that this site-specific predilection may be caused by localised damage of endothelial 
cells by haemodynamic factors, resulting in greater entry of plasma lipoproteins at these 
sites. Although not much is known about the nature of these early events, several 
investigators have identified lipoprotein-like particles from the arterial wall of 
experimental animals with altered physiochemical properties that may represent the 
form by which lipoprotein cholesterol first accumulates in the intima before being taken 
up by macrophages (Simionescu & Simionescu, 1993). This is also consistent with the 
initial or type I lesion that includes the appearance in the intima of microscopically and 
chemically detectable lipid-containing vesicles and associated small isolated groups of 
macrophage foam cells (Stary et al, 1995). The extracellular lipid vesicles resemble the 
lipoprotein-like particles from the arterial wall of cholesterol-fed animals. One 
explanation for these observations is oxidation of the lipid trapped within the intima 
resulting in chemical signals being sent to the overlying endothelial cells causing 
expression of adhesion molecules that bind monocytes and T-cells (Berliner et al,
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1990). Monocyte adhesion is probably one of the earliest morphologically detectable 
cellular events in the pathogenesis of atherosclerosis (Joris et al, 1983), however it is 
not clear whether oxidation of extracellular lipoprotein-like vesicles represents the only 
trigger for monocyte recruitment into the artery wall. The principal monocyte adhesion 
molecules on endothelial cells include intercellular adhesion molecules (ICAM-1&2), 
E-selectin, and vascular cell adhesion molecule-1 (VCAM-1) (Faruqui & Dicorleto, 
1993). Leucocyte recruitment is a complex process that includes a cell rolling phase 
followed by adhesion to endothelial cells via some of the previously described adhesion 
molecules, and ultimately migration down a chemoattractant gradient (Lasky, 1992). 
This process has characteristic features of a chronic inflammatory response. Consistent 
with this, neutrophils are not generally seen in atherosclerotic plaques. The reason for 
this cellular specificity appears to be the type of endothelial adhesion molecules which 
are expressed. In addition to the generation of adhesion molecules on endothelial cells, 
the oxidation of lipids in lipoproteins results in the production of chemoattractant 
molecules that attract monocyte macrophages to specific sites.
Smooth muscle cells and smooth muscle derived foam cells are also found in 
atherosclerotic plaques, although are usually found at a later stage in plaque 
development than macrophages (Ross, 1986). Macrophages appear early in the 
pathogenesis of atherosclerosis. Included in the many proteins secreted by macrophages 
are a number of growth factors including platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF) and chemoattractants such as monocyte chemotactic 
protein-1 (MCP-1) (Ross, 1993). The secretion of these factors probably represents the 
principal stimulus for recruitment of smooth muscle cells from the media of the artery 
into the intima, where they are stimulated to proliferate. The smooth muscle cells of 
atherosclerotic lesions exist primarily in a synthetic phenotype in which they express 
genes for a number of growth-regulatory molecules and cytokines (Libby et al, 1988), 
and additionally can synthesise extracellular matrix proteins (Ross, 1993). Smooth 
muscle cells may also have an important role in stabilising atherosclerotic plaques by 
virtue of their role in formation of a fibromuscular cap. Smooth muscle cells produce a 
variety of collagen subtypes which accumulate in atherosclerotic plaques, as well as 
proteoglycans found in the extracellular matrix and on the surface of cells (Wight, 
1989). The proteoglycans, by virtue of their ability to bind some lipoproteins more 
avidly than others, are thought to play an important role in mediating the flux of plasma 
lipoproteins through the arterial wall and also perhaps the length of time a lipoprotein
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spends in the arterial wall. This could be important relative to susceptibility to oxidation 
or any other change that would cause the lipoprotein to be recognised for uptake by 
macrophages. Proteoglycans may also mediate cell proliferation and the binding of 
lipoproteins to macrophages and smooth muscle cells (Wight, 1989). Smooth muscle 
cells can accumulate cholesterol esters to become foam cells and are seen in types IV, 
V, and VI lesions, although the precise mechanisms of smooth muscle foam cell 
formation are unknown. One potential mechanism is via active scavenging of lipids 
with subsequent formation of lipid inclusion bodies (WoHbauer et al, 1986).
Macrophage proliferation in atherosclerotic plaques has been recognised and this in part 
accounts for necrotic debris found in atherosclerotic lesions (Rekhter & Gordon, 1995). 
It also has been shown that dead macrophages are phagocytosed by other macrophages 
(Lewis, Taylor & Jerome, 1985), and that they have the potential to migrate out of the 
atherosclerotic plaque, possibly carrying lipids and other plaque constituents after 
phagocytosing debris, (Gerrity, 1981) and thus may have a potential role in preventing 
severe atherosclerotic lesions from forming.
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1.6 Cardiovascular disease mechanisms and vascular protective effects of 
oestrogen
1.6.1 Introduction
Since CVD rarely affects women before the menopause, and the incidence appears to 
accelerate after the menopause, oestrogen deficiency has been strongly implicated in the 
aetiology of the disease in women and suggests that oestrogen replacement therapy will 
decrease subsequent risk of CVD.
Loss of ovarian function at the menopause with a consequent decrease in plasma 
oestrogen levels, results in a number of detrimental effects on cardiovascular risk 
factors including both direct arterial effects and adverse effects on metabolic risk factors 
such as plasma lipids, insulin sensitivity, body fat distribution and haemostasis. 
Oestrogen replacement therapy appears to have the capacity to reverse the negative 
effects of the menopause on some or all of these cardiovascular risk factors. A clearer 
understanding of the mechanisms whereby oestrogen exerts its cardiovascular benefits, 
will allow optimisation of hormone replacement therapy to achieve maximum benefit, 
whilst eliminating unwanted side effects.
1.6.2 Oestrogen receptors
The presence of oestrogen receptors in vascular tissues has been inferred from a number 
of animal studies which have demonstrated specific binding of oestrogen to vascular 
cells (Colburn & Buonassisi, 1978; Nakao et al, 1981; Horwitz & Horwitz, 1982). 
Oestrogen, like all steroid hormones, classically acts by binding to nuclear receptors and 
initiating a sequence of events leading to modulation of gene expression.
The oestrogen receptor belongs to a nuclear receptor superfamily, a group of ligand- 
activated transcription factors (Mangelsdorf et al, 1995). Steroid hormone receptors 
consist of a hypervariable N-terminal domain that contributes to the transactivation 
function; a highly conserved central domain responsible for specific DNA binding 
(steroid response elements), dimérisation, and nuclear localisation, and a C-terminal 
domain involved in ligand binding and ligand-dependent transactivation function. 
Following binding of oestrogen to the receptor, resulting in homodimerisation of the
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receptor and activation of the oestrogen response elements and transcriptional co­
activators, there is alteration in the level of transcription of specific genes, leading to 
altered messenger ribonucleic acid (mRNA) synthesis and ultimately to altered protein 
synthesis.
Until recently, only a single major form of the oestrogen receptor (ER-a) had been 
identified (Green et al, 1986; Greene et al, 1986). However, a second protein encoding a 
separate subtype (ER-p) has now been detected although the significance of this 
observation is not fully appreciated but may explain the selective actions of oestrogens 
in a variety of target tissues (Kuiper et al, 1996; Mosselmann, Polman & Dijkema, 
1996; Venko, Rankin & Vaughan,1996). Both ER-a and ER-P bind oestradiol with 
similar high affinity, however the relative tissue distributions of the receptor subtypes 
appear less uniform (Enmark et al, 1997).
Oestrogen receptors have been identified in myocardial, vascular smooth muscle cells 
and endothelial cells in both humans and animals (Orimo et al, 1993; Karas, Patterson 
& Medelsohn, 1994; Bayard et al, 1995). Additionally, heterogeneity of oestrogen 
receptor distribution between vascular beds in male and female animals, and altered 
oestrogen receptor expression between normal and atherosclerotic vessels has been 
reported (Knauthe et al, 1996; Losordo et al, 1994). These observations suggest that the 
cardioprotective effects of oestradiol may in part be mediated via altered oestrogen 
receptor expression in the vasculature.
1.6.3 Metabolic risk factors
1.6.3.1 Lipids
An association between high circulating levels of cholesterol and an increased incidence 
of CVD is well established. Low density lipoproteins (LDL) form a large portion of 
total plasma cholesterol in most individuals, and increased concentrations are positively 
correlated with an increased risk of CVD. Conversely, high density lipoproteins (HDL) 
are inversely associated with cardiovascular risk with high levels conferring 
cardioprotection. (Miller, 1987) Hypertriglyceridaemia is also a risk factor for CVD, 
and appears to be a particularly important risk factor in postmenopausal women 
(Bengstsson et al, 1993).
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LDL cholesterol comprises of various subclasses which differ in size and structure. 
Lipoprotein (a) is an LDL which contains two distinct apolipoproteins, apolipoprotein B 
and apolipoprotein (a), the latter being cited as an independent marker for ischaemic 
cardiovascular disease with high levels being associated with an increased risk 
(Utermann, 1989). Lipoprotein (a) is atherogenic largely because of its propensity for 
retention into the arterial wall as it binds readily with arterial proteoglycans and also 
enhances LDL retention (Dahlen, Ericson & Berg, 1978; Yashiro, O’Neil & Hoff, 
1993). LDL particle size varies and can be classified into subgroups accordingly. Small 
dense LDL particles (subtype B) appear to be clinically important due to their strong 
association with cardiovascular disease (Austin et al, 1988). The clearance of LDL from 
the circulation is via hepatic receptors which operate at near saturation and thus if LDL 
levels are high the process of clearance will be slow (Krauss, 1991). Like LDL, HDL 
cholesterol exists in various subtypes of which the HDL2  subfraction is considered to be 
the most beneficial. HDL participates in reverse cholesterol transport removing 
cholesterol from the tissues then returning it to the liver where it is catabolised by the 
action of hepatic lipase and excreted.
The changes in lipids associated with the menopause are all in a direction consistent 
with increased cardiovascular risk. With ageing, total cholesterol, LDL cholesterol and 
triglyceride levels all increase while HDL cholesterol levels fall, however at the 
menopause these changes are more marked and the detrimental change in lipid profile is 
greater (Stevenson, Crook & Godsland, 1993). Other adverse changes reported include 
an increase in lipoprotein (a) (Meilahn et al 1991) and a shift towards smaller more 
dense LDL particles (Campos, McNamara & Wilson, 1988).
Approximately 50% of the cardioprotective benefit attributed to HRT is thought to be as 
a result of beneficial effects on lipid profiles (Stampfer & Colditz, 1991). The effects of 
HRT on lipids and lipoproteins will depend on the type of oestrogen, its dose and its 
route of administration. In addition, the oestrogenic effects will be modified if 
progestogens are used in combination with oestrogen. Independent of the type of steroid 
or the dose of oestrogen, there is sustained reduction in total cholesterol with long term 
oestrogen therapy (Whitcroft et al, 1994). This action is primarily via a reduction in 
LDL cholesterol by upregulation of apolipoprotein B receptors and is most efficient 
with oral administration. Additionally, protection against lipoprotein oxidation (Sack, 
Rader & Cannon, 1994) and improvements in postprandial clearance of potentially
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atherogenic lipoprotein particles has been reported with oestrogen use (Westerveld et al, 
1995). Oral oestrogens increase HDL cholesterol, particularly the protective HDL2  
subfraction, however transdermal preparations appear to have a less marked effect 
(Crook et al, 1992). The effect of HRT on triglycerides is dependent on both the type 
and route of administration. Conjugated equine oestrogens increase triglycerides (Crook 
et al, 1992), and other oral oestrogens may exert similar effects (Crook et al, 1997). 
Conversely transdermal oestradiol causes a reduction in triglycerides (Crook et al,
1992). The effect of progestogens on lipid profiles is largely dependent on the 
androgenicity of the progestogen used, but overall does not appear to negate the 
beneficial effects of oestrogens.
16.3.2 Carbohydrate metabolism
Diabetes is strongly associated with cardiovascular disease. Additionally, diabetic 
women have a higher incidence of cardiovascular disease than diabetic men (Abbott et 
al, 1987), suggesting that women are more adversely affected by diabetes and thus that 
the effects of sex steroids on glucose and insulin metabolism may be significant. 
Impaired glucose tolerance resulting from reduced sensitivity of target tissues to insulin- 
mediated glucose uptake is associated with an approximate doubling in the risk of 
ischaemic heart disease (Jarrett, McCartney & Keen, 1982; Fuller et al, 1983), and it has 
been proposed that insulin resistance and hyperinsulinaemia are pivotal disturbances in 
the aetiology of coronary heart disease in non-diabetic subjects (Reaven, 1988) either 
directly by promoting atherogenesis (Stout, 1990) or by adversely affecting other 
cardiovascular risk factors such as dyslipidaemias (Ley, Lees & Stevenson, 1992) or 
hypertension.(Ferrannini et al, 1987).
Glucose metabolism deteriorates with increasing age (Stevenson et al, 1994) and is also 
influenced by the menopause although it is difficult to determine changes due to the 
menopause from changes attributed to age alone. Glucose and insulin profiles of pre- 
and postmenopausal women are similar, however there is evidence suggesting changes 
in insulin metabolism in postmenopausal women with an increase in insulin sensitivity, 
a decrease in non-insulin dependent glucose disposal, plasma C-peptide response and 
pancreatic insulin secretion (Walton et al, 1993).
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Studies of insulin sensitivity in postmenopausal women using hormone replacement 
therapy are complicated by the use of different methods of measurement and 
experimental design and in consequence their results are not uniform. Some of the 
discrepancies may however be due to the route of hormone administration. Oral 
administration of oestrogen is associated with a decrease in insulin sensitivity (Barrett- 
Connor & Laakso, 1990) while transdermal preparations appear to have either a neutral 
or beneficial effect (Cagnacci et al, 1992; Duncan et al, 1999).
1.6.3.3 Body fat distribution
Although obesity itself is a risk factor for CVD, there is additionally an association 
between body fat distribution and cardiovascular risk that is independent of obesity. 
Premenopausal gynoid or peripheral fat distribution is associated with low 
cardiovascular risk, however android or central body fat distribution found 
postmenopausally is associated with increased cardiovascular risk (Ley, Lees & 
Stevenson, 1992). This apparent redistribution of fat in women after the menopause 
therefore predisposes to an increased cardiovascular risk and is suggestive of a role for 
oestrogen in its aetiology. Additionally there is evidence that HRT prevents an increase 
in abdominal fat and redistributes it to the more favourable gynoid distribution with 
relatively little effect on the overall total body fat. (Haarbo et al, 1991)
1.6.3.4 Haemostasis
Thrombogenesis has a pivotal role in the pathogenesis of atherosclerosis and 
haemostatic factors have an important role in this process. The haemostatic system 
exists in a state of dynamic equilibrium which is achieved by a complex interplay 
between coagulation and fibrinolysis. Haemostatic regulation occurs at the endothelial 
surface and exhibits continuous baseline activity. Reduced baseline fibrinolytic activity 
and increased baseline coagulatory activity are both implicated in the development of 
CVD.
The menopause appears to have a variety of effects on haemostasis although it is 
difficult to separate these effects from ageing alone. The pro-coagulatory factors Factor 
VII (F VII) (Scarabin et al, 1990) and plasma fibrinogen (Folsom et al, 1991) increase 
predisposing to an increased risk of arterial thrombosis due to hypercoagulability.
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Plasminogen activator inhibitor-1 (PAI-1), the principal intra- and extra-vascular 
inhibitor of fibrinogen activity is also increased (Heinrich et al, 1991). The pro­
fibrinolytic factors anti-thrombin III and plasminogen also increase. The overall effect is 
that the balance between coagulation and fibrinolysis is not significantly altered.
The effect of HRT on haemostasis is complex and the magnitude of the effect observed 
will depend on the type and dose of the preparation as well as the mode of delivery. 
Oral oestrogen therapy is associated with an increase in both F V I1 antigen and 
activated F VII levels (Cushman^ et al, 1999; Vehkavaara et al, 2001). However, a 
reduction in plasma fibrinogen levels towards premenopausal values can be achieved by 
oestrogen administration (Writing group for the PEPI trial, 1995; Cushman^ et al, 1999). 
A reduction in PAI-1 levels with oral oestrogen (either alone or in combination with a 
progestogen) has consistently been reported (Scarabin et al, 1993; Vehkavaara et al, 
2 0 0 1 ), although similar reductions have not been observed with transdermal oestrogen 
use (Koh et al, 1997; Vehkavaara et al, 2001). Antithrombin III levels also fall in a dose 
dependent fashion with oral oestrogen (Kroon, Silfverstolpe & Tengborne 1994). A 
reduction in tPA in association with oral oestrogen may impair fibrinolysis and thus 
promote an adverse pro-coagulatory shift (van Baal et al, 2000; Giltay et al, 2000).
The liver is an important site for the manufacture and metabolism of coagulation 
factors. Evidence suggests that the effect of transdermal HRT on haemostatic variables 
is less significant than oral oestrogen therapy and it is suggested that this is due to the 
reduced first pass hepatic metabolism which occurs with transdermal preparations 
(Kroon, Silfverstolpe & Tengborne 1994). Although not yet proven, it may be that 
transdermal preparations reduce the risk of deep venous thrombosis.
16.3,5 Inflammatory Mediators
C-Re active protein (CRP) is a mediator of inflammation and a strong predictor of 
cardiovascular events (Ridker et al, 2000). Increased levels of CRP have been reported 
following unopposed oestrogen use (Cushman^ et al, 1999) and similarly following 
combined therapy with conjugated oestrogen and MPA (Walsh et al, 2000). Again there 
appears to be a differential response relating to the mode of delivery, with no apparent 
effect on CRP levels with the transdermal route of administration (Vehkavaara et al, 
2001). Elevated plasma homocysteine levels are also a marker of increased risk of
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CVD. Recent evidence suggests that both opposed and unopposed HRT regimens may 
reduce fasting homocysteine levels (van Baal et al, 2000; Walsh et al, 2000).
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1.7 Vascular reactivity
1.7.1 Introduction
Sex steroids are vasoactive substances which have systemic vascular effects that are 
independent of effects of oestrogen on the reproductive vascular system. Genomic 
dependent mechanisms are thought to be involved in long term vascular protection 
following chronic exposure to oestrogen, however acute responses in the vasculature are 
unlikely to be mediated by genomic mechanisms as they occur very rapidly. A number 
of mechanisms have thus been suggested to explain the direct vascular effects of 
oestrogen including direct effects on vascular smooth muscle resulting in relaxation and 
indirect effects via the endothelium.
1.7.2 Endothelium independent mechanisms of smooth muscle relaxation
Animal and human studies have shown that oestrogen can induce direct relaxation of 
blood vessels in the coronary vasculature via direct smooth muscle relaxation 
independently of the endothelium (Jiang et al, 1991; Mugge et al, 1993; Chester et al, 
1995). A number of potential mechanisms to explain these observations have been 
proposed including inhibition of the release of, or response to, vascular constricting 
factors such as endothelin (Mueck et al, 1993; Polderman et al, 1993) and angiotensin II 
(Cheng & Gruetter, 1992) or via a calcium antagonistic mechanism. (Jiang et al, 1991; 
Jiang et al, 1992; Han et al, 1995).
1.7.3 Endothelium dependent mechanisms of smooth muscle relaxation
1.7.3.1 Introduction
The endothelium is a monolayer of cells lining the intimai surface of the vasculature. It 
has a pivotal role in the modulation of vasomotor tone primarily by elaboration of a 
variety of substances, the most important of which is nitric oxide (NO).
In 1980 Furchgott identified that endothelial cells had an obligatory role in the vascular 
relaxation to the vasodilator acetylcholine (ACh) (Furchgott & Zawadzki, 1980). He 
proposed that endothelial muscarinic receptors liberated a substance which activated the
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underlying vascular smooth muscle cells when activated by ACh, and referred to this 
substance as endothelial derived relaxing factor (EDRF). Six years after this initial 
discovery Furchgott suggested that EDRF might be NO, and within a year it was 
confirmed that the release of NO could account for the bioactivity of EDRF (Palmer, 
Ferrige & Moncada 1987; Ignarro et al 1987).
Nitric oxide is a ubiquitous, naturally occurring gaseous molecule found in a wide 
variety of cell types and organ systems. It is a small diatomic free radical with a very 
short half-life and is thus highly reactive combining readily with other free radicals. It is 
soluble in many solvents, although its solubility in water is low, and can diffuse 
relatively easily across biological membranes. In biological systems it decomposes very 
rapidly to nitrate and nitrite. The very short half-life of NO and its high reactivity 
suggests a likely role as a local messenger transferring messages within and between 
individual cells.
1.7.3.2 Nitric oxide synthase enzymes
Nitric oxide is synthesised via a five electron oxidation of a terminal guanidinium 
nitrogen on the amino acid L-arginine. The reaction, which is catalysed by a nitric oxide 
synthase (NOS) enzyme, is both oxygen and nicotinamide adenine dinucleotide 
phosphate (NADPH) dependent and yields the co-product L-citrulline in addition to NO 
(Figure 1.6). The physiological actions of NO are mediated by activation of soluble 
guanylate cyclase and subsequent increase in the concentration of cyclic guanosine 
monophophate (cGMP) in the target cells (Ignarro, 1991).
O2  + NADPH
L-arginine   \l/ ^  L-citrulline +
NOS ^
NO
GTP cGMP
Guanylate Cyclase
Figure 1.6 -  Biosynthesis of nitric oxide
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Nitric oxide synthase is a haem-containing enzyme with a sequence similar to 
cytochrome P-450 reductase. Several isoforms of NOS are now known to exist, two of 
which are constitutive (endothelial and neuronal) and calcium and calmodulin 
dependent, and one of which is inducible by immunological stimuli independently of 
calcium. The genes for these enzymes have been localised to chromosome 7 
(endothelial or eNOS), chromosome 12 (neuronal or nNOS) and chromosome 15 
(inducible or iNOS). Across species any one of the three isoforms is highly conserved 
with 85-90% sequence homology (Knowles & Moncada, 1994). In contrast however, 
the three isoforms share only 50-55% sequence identity with each other, although in 
certain regions of the proteins there is high sequence identity particularly in the domains 
that contain binding sites for various cofactors. These subtle but significant structural 
differences probably account for differences between the isoforms such as localisation 
(eNOS ~ membrane; nNOS and iNOS -  cytosolic) and affinity for calcium and 
calmodulin binding (Cooke & Dzau, 1997). The three NOS isoforms were originally 
named after the tissues in which they were first cloned and characterised. The 
constitutive NOS (cNOS) was first identified in the vascular endothelium and in the 
brain, spinal cord and peripheral nervous system, and have been designated the terms 
eNOS and nNOS respectively. The iNOS isoform is expressed only after activation of 
cells by infective or inflammatory mediators. It can be expressed in many cell types 
including vascular smooth muscle, cardiac muscle, and immune cells. As this is an 
inducible enzyme it produces substantially greater amounts of NO than the other 
isoforms. All three isoforms have now been identified in other tissues. The eNOS 
isoform being present in platelets, (Radomski, Palmer & Moncada, 1990) certain areas 
of the brain (Dinerman et al, 1994) and in cardiac tissue both myocardial and 
endocardial, while the nNOS isoform has been identified in respiratory tract epithelium 
(Kobzik et al, 1993) and in skeletal muscle (Kobzik et al, 1994). Although in general 
eNOS and nNOS are considered constitutive enzymes, under certain circumstances the 
expression of eNOS and nNOS is inducible. Shear stress up-regulates the expression of 
eNOS (Kanai et al, 1995), and pregnancy and exogenous oestrogen treatment induce 
both eNOS and nNOS expression (Weiner et al, 1994). Although iNOS is regulated by 
cytokines and induced during the immune response, in certain circumstances it can also 
be constitutively expressed, the enzyme having been identified in fetal tissues, (Baylis 
et al, 1994) in human bronchial epithelium and alveolar macrophages (Kobzik et al,
1993) and rat kidney (Mohaupt et al, 1994) in the absence of immune activation.
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1.7.3.3 Role of nitric oxide
Nitric oxide plays a diverse role in many physiological functions. Its formation in 
vascular endothelial cells, in response to chemical stimuli and to physical stimuli such 
as shear stress, maintains vasodilator tone essential for regulation of blood flow and 
pressure (Moncada, Palmer & Higgs, 1989; Vanhoutte, 1989; Luscher, 1991; Vane, 
Anggard & Botting, 1990). Nitric oxide produced by the endothelium also inhibits 
platelet aggregation and adhesion, inhibits leucocyte adhesion and modulates smooth 
muscle cell proliferation, (Moncada & Higgs, 1993) and is thought to retard the 
development of atherosclerosis. Nitric oxide is synthesised in neurones of the central 
nervous system, where it acts as a neuromediator with a variety of physiological 
functions (Garthwaite, 1991; Synder & Bredt, 1992). In the peripheral nervous system, 
NO is released from many nerve endings which mediate some forms of neurogenic 
vasodilatation in addition to regulating gastrointestinal, respiratory and genitourinary 
functions (Rand, 1992; Synder & Bredt, 1992). In addition, NO is generated in copious 
amounts during activation of the immune response (Nathan & Hibbs, 1991; Nussler & 
Billiar, 1993). Initially this was observed in activated macrophages where it contributes 
to their cytotoxicity against tumour cells, bacteria, viruses and other pathogenic 
microorganisms.
17.3.4 Oestrogen and nitric oxide
Evidence that the L-arginine / nitric oxide pathway differs between the sexes and that its 
function may be modulated by oestradiol, has suggested a potential contribution of 
endothelial nitric oxide to the cardioprotective mechanism of oestradiol.
Basal release of NO from endothelium-intact aortic rings from female rabbits is greater 
than that from males (Hayashi et al, 1992). Similar results have been reported from 
studies of spontaneously hypertensive rats in which inhibition of NO synthesis by L- 
arginine analogues potentiated agonist induced contractions that were more sustained in 
aortic segments from female than male rats (Kauser & Rubanyi, 1993). In guinea pigs, 
an in-vivo study demonstrated an increase in NOS activity and NO production in heart, 
kidney and skeletal muscle tissue after five days of oestradiol treatment in females 
compared with ten days of treatment in males (Weiner et al, 1994).
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Atherosclerosis impairs ACh mediated vascular responses in oestrogen deficient female 
monkeys, however long term oestrogen therapy protects against these impaired 
responses (Willliams, Adams & Klopfenstein, 1990). Acute responses to oestrogen in 
female monkeys with coronary artery disease have also been reported (Williams et al, 
1992). In human studies using postmenopausal women with proven coronary artery 
disease oestrogen attenuates (Reis et al, 1994) or abolishes (Gilligan, Quyyumi & 
Cannon, 1994) Ach-induced coronary artery vasoconstriction when administered 
acutely, although has little direct effect. Furthermore, the coronary artery response to 
ACh after exposure to oestradiol appears to be gender dependent (Collins et al, 1995). 
Improvements in endothelial dependent vasodilation in the forearm vasculature of 
postmenopausal women following direct intra-arterial infusion of oestradiol have been 
reported, but the effects were not sustained by systemic transdermal 17(3-oestradiol 
administration (Gilligan et al, 1995). Following short-term oestrogen deprivation 
impaired forearm vasodilator responses have been observed, however these effects are 
readily reversed by subsequent oestrogen replacement (Pinto et al, 1997). Similarly in 
the forearm vasculature of perimenopausal women, enhanced basal but not ACh- 
induced NO release following oestrogen supplementation has been reported (Sudhir et 
al, 1996).
A number of in-vitro studies using cultured endothelial cells have reported that 
oestrogen administration appears to stimulate NO production (Schray-Utz, Zeiher & 
Busse, 1993; Hayashi et al, 1995; Hishikawa et al, 1995), although there is considerable 
species variation and the mechanism for this up-regulation is unclear. Two candidate 
mechanisms exist. Increased expression of nitric oxide synthase (Kleinhart et al, 1998) 
or inhibition of production of superoxide anions, the principal inactivator of NO (Arnal, 
et al, 1996).
1.7.4 Endothelial cell proliferation
Oestradiol may also influence endothelial cell regeneration and angiogenesis. It appears 
to promote neovascularisation, as well as migration, proliferation and differentiation of 
endothelial cells (Morales et al, 1995). The ability of oestradiol to augment basic 
fibroblast growth factor-induced angiogenesis is lost in transgenic mice lacking 
functional oestrogen receptors (ER-a), providing evidence for receptor dependence
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(Johns et al, 1996). Oestradiol may also stimulate expression of endothelial growth 
factors such as fibroblast or vascular endothelial growth factors (Sheweiki et al, 1993).
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1.8 Aims and objectives of thesis
1.8.1 Introduction
Observational studies allow inferences and associations to be drawn from data, but they 
clearly do not establish cause and effect. In the absence of data from randomised 
controlled studies, the consistency of the data from observational studies of HRT and its 
effect on cardiovascular disease, was supportive of a protective role for oestrogen. 
However, after twenty years of observational studies the first clinical trials examining 
the role of HRT in cardioprotection are emerging (Hulley et al, 1998) and suggest that 
the preventative effect of HRT in primary and secondary heart disease is equivocal. 
Although a number of biologically plausible mechanisms have been proposed to explain 
the cardioprotective potential of oestrogen, whether these changes result in clinical 
benefits remains uncertain.
Like much of the research carried out in this area, the work presented in this thesis was 
based on the assumption that the consistency of the data from observational studies 
inferring a cardioprotective role for oestrogen, would be reproducible in basic science 
studies and that ultimately this would translate into a clinical benefit. In particular, this 
work sought to examine an expanding area of research which in the late 1990’s was 
perceived as an important potential cardioprotective mechanism worthy of further 
investigation both from basic science and clinical perspectives.
1.8.2 Aims
The aim of this project was to examine the vascular effects of oestrogen to test the 
hypotheses that:
1. Oestradiol modulates vascular reactivity
2. Changes in vascular reactivity may be due to a NO mediated effect
3. Oestradiol stimulates endothelial cell proliferation
The following studies aimed to examine the vascular effects of oestradiol using bilateral 
venous occlusion plethysmography to determine whether oestradiol had acute 
vasodilator effects in the forearm vascular bed of healthy postmenopausal women, and
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to determine whether HRT potentiated basal endothelial nitric oxide synthesis or 
release. To compliment this in-vivo work, endothelial cell responses to oestrogen were 
also examined at a molecular level by determining eNOS messenger ribonucleic acid 
(mRNA) expression in cultured human aortic endothelial cells (HAEC) using northern 
analysis. The oestrogen receptor status of the cells used in these studies was established 
using the polymerase chain reaction (PCR). Additionally, the effect of oestradiol 
treatment on endothelial cell proliferation, which is perceived to be of importance in 
atherosclerosis in vascular remodelling and repair, was examined in-vitro by studying 
the growth characteristics of cultured HAEC following addition of oestradiol.
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CHAPTER TWO
OVERVIEW OF METHODS
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2.1 Forearm Venous Occlusion Plethysmography
2.1.1 Introduction
Forearm venous occlusion plethysmography (FVOP) is a technique for measuring 
forearm blood flow (FBF), which is used to study forearm vascular haemodynamics and 
control mechanisms. The original technique which was described in the late 19^ 
century, used awkward water jackets to estimate changes in forearm volume. More 
recently following the advent of mercury-in-silastic gauges; coupled with the 
development of electrical calibration techniques and the use of computerised chart 
recorders, it has become a widely used research method. The advantage of the technique 
is that it allows vessels to be studied in their normal physiological environment, and 
enables assessment of the effect of vasoactive mediators on resistance vessel tone 
following direct infusion via the brachial artery. Adopting a bilateral approach with 
simultaneous measurements in both arms allows the measurements in the experimental 
arm to be adjusted for changes in the control (non-infused) arm, the results being 
expressed as a ratio of the two measurements.
2.1.2 Principal of forearm venous occlusion plethysmography
The principal of the technique is such that if venous return from the arm is obstructed 
while arterial inflow continues unimpeded, the forearm swells at a rate proportional to 
the rate of arterial inflow (Whitney, 1953). The result is a measure of total FBF 
expressed per unit volume of the forearm (ml/100ml forearm/minute), the main bulk of 
which corresponds to blood flow through skeletal muscle, the remainder being flow 
through the skin (Barcroft et al, 1943; Cooper et al, 1955). Since blood flow in the hand 
is primarily through the skin and there are large numbers of arterio-venous shunts 
present, it is necessary to exclude the hands from the circulation (Whitney, 1953; 
Sorrol, Walsh & Whelan, 1965). This is achieved by inflating a wrist cuff to 
suprasystolic pressures. Forearm blood flow is then determined from the gradient of the 
resulting plethysmograph trace recorded on the chart recorder according to the equation 
of Whitney (Whitney, 1953).
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2.1.3 Calculation of forearm blood flow
In these studies blood flow measurements were derived from the mean of five 
sequential recordings. The gradients were calculated from data points by acquiring their 
co-ordinates using MacChart Software (AD Instruments, London), and the information 
pasted into a customised spreadsheet (Excel, Microsoft Corporation, USA). For all 
subjects, each set of forearm blood flow recordings was analysed twice and the mean 
values used for the overall analysis. Data were expressed as a percentage change in 
forearm blood flow ratio from baseline (Benjamin et al, 1995; Petrie et al, 1998). Unless 
otherwise indicated, results are expressed as means ± standard deviations. Statistical 
significance was assessed using the Student’s t-test with 95% confidence intervals. A p- 
value of less than 0.05 was considered significant.
2.1.4 Plethysmography technique
Subjects were positioned supine on a bed with both arms supported on foam blocks, in a 
quiet, dimly lit, temperature controlled (25°C) room. Paediatric arterial occlusion cuffs 
(Hokanson SC5, PMS Instruments, Maidenhead, Berkshire) were placed around the 
wrists and inflated to suprasystolic pressure (200 mmHg) for three minutes during each 
set of measurements. Collecting cuffs (Hokanson SCIO, PMS Instruments) which were 
placed around the upper arms were inflated (40 mmHg) and deflated cyclically after 
fifteen seconds. A commercially available air source (Hokanson AGlOl, PMS 
Instruments) connected to a rapid cuff inflator (Hokanson E20, PMS Instruments), 
enabled rapid cuff inflation to be achieved. Mercury-in-silastic strain gauges 
(Hokanson, PMS Instruments) connected to the plethysmograph were placed around 
each forearm at the widest diameter. A strain gauge two centimetres smaller than the 
widest diameter was chosen. The distance from the olecranon to the position of the 
largest circumference was noted to allow for standardisation of the strain gauge position 
at each visit. After positioning, the strain gauges were calibrated for the chart recorder 
used (MacLab, AD Instruments, London), and test readings obtained.
A 27gauge unmounted steel needle (Cooper's Needleworks, Birmingham) was inserted 
into an epidural cannula and sealed in position with dental wax. The patency of the 
cannula was ascertained and the system was flushed with heparinised saline to maintain 
patency. The cannula was then inserted into the brachial artery of the non-dominant arm
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following infiltration with local anaesthetic (1% Lignocaine), and a constant infusion of 
normal saline (Iml/min) was commenced.
For each set of measurements, blood flow recordings (i.e. during inflation of upper arm 
cuffs) commenced forty-five seconds after wrist cuff inflation, and continued at 
intervals over the remaining one hundred and thirty-five seconds. The upper arm cuffs 
were inflated via a trigger switch under the operator's control, but deflated automatically 
after fifteen seconds.
At the start of each study, thirty minutes of test measurements were made to allow for 
acclimatisation to the inflation and deflation of the wrist and upper arm cuffs, and to 
allow for return to the resting state. Two further sets of recordings ten minutes apart 
were then made in order to determine the baseline forearm blood flow. Solutions of test 
drugs of increasing incremental doses which, were prepared by the sterile production 
unit of the hospital pharmacy, were then infused intra-arterially at a constant rate of 
Iml/min.
On the evening prior to the study, women were asked to fast from midnight, although 
they were allowed to drink water on the morning of the study. They were asked to 
abstain from driving on the morning of the study and arrangements were made for them 
to be brought to the unit by a relative or by taxi.
On arrival the subjects were familiarised with the staff, surroundings and equipment. 
Measurements of height and weight were made to enable calculation of body mass 
index (BMI), and baseline measurements of pulse and blood pressure were recorded. 
Venous blood was taken for routine biochemistry (including lipid and hormone profiles) 
and haematology screening tests, and a resting electrocardiograph was performed.
47
2.2 Cell culture techniques
2.2.1 Initiation and maintenance of cultures
Primary cell cultures can be initiated from normal (adult), embryonic and malignant 
tissues from which they are aseptically collected by dissection. The simplest method of 
culture is then to suspend the chopped material in serum containing medium and add to 
a tissue culture flask. The pieces of tissue then adhere to the substratum and cells 
migrate out from the cut ends. Alternatively the pieces of tissue can be immobilised in a 
plasma clot. The commonest way to initiate cultures from solid tissues is to 
disaggregate the tissue into single cells either mechanically or enzymatically (Folkman, 
Haudenschild & Zetter, 1979; Ryan, 1984).
After establishing the primary culture, the culture medium is replaced twenty-four hours 
after initiation from single cells, since cells which have not adhered are likely to be non- 
viable. Thereafter the medium is changed every two or three days.
Cells which have reached confluence are subcultured into fresh flasks and medium. This 
involves rinsing the flask with buffered saline, then adding trypsin to remove the cells 
from the substratum. To prevent further trypsin activity once the cells have detached, a 
trypsin neutralising or inhibiting agent is added. The cells are then separated by 
centrifugation, washed in medium, counted, and seeded into fresh medium at an 
appropriate cell density determined by the cell doubling time.
2.2.2 Counting cells
A cell count gives a measure of the status of the culture at a given time point, and is 
essential when subculturing or when assessing the effects of experimental treatment on 
cells. In general the cell count is expressed as number of cells per millilitre of medium. 
A number of methods for quantifying cells are available and these include the 
haemocytometer, the Coulter counter and flow cytometry.
A haemocytometer or counting chamber is a simple and reliable method of determining 
the cell count. It consists of a glass slide engraved with grids of a known area, onto 
which a glass cover slip of precise thickness is placed so that when correctly placed, the
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volume of liquid over the grid is known. The number of cells present can be determined 
from the corresponding grid areas. A refinement of this technique is to incorporate a 
viability test in which a dye is used to stain non-viable cells (dead cells are permeable 
and will take up the stain whereas living cells will exclude certain stains from crossing 
their membrane) and allows them to be excluded from the final cell count (McAteer & 
Davis, 1994).
The Coulter counter (Coulter Electronics Limited) is an electronic particle counting 
device which allows particles of different size to be counted. Cells suspended in saline 
are drawn through an orifice by the application of a vacuum. This results in a change in 
the electrical resistance to a current flowing through the orifice causing a series of 
pulses which is counted. Cell debris may also generate pulses and may lead to 
inaccurate counts, although most instruments have a threshold control allowing only 
pulses from whole cells to be counted (McAteer & Davis, 1994).
A flow cytometer is an instrument in which cells are made to flow in single file through 
an orifice where they intersect a laser beam. The cells will cause light to be scattered 
and may fluoresce if stained with an appropriate dye. An optical sensor makes multiple 
measurements on the cells as they pass through the machine and the information 
measured is transferred to a computer for analysis. Light scatter, fluorescence emission 
and optical density can all be measured making this a particularly useful and flexible 
method of cell analysis (Watson & Erba, 1992).
2.2.3 Characterisation of cultured cells
Cells in culture are not readily distinguishable by appearance alone. Most cells have 
either a fibroblastic or epithelial morphology when adherent, or a common rounded 
appearance if non-adherent. Thus it can be difficult, on the basis of appearance alone, to 
determine if the cells being cultured are the correct ones, or if they have been 
contaminated by another cell line. A number of methods are available for identifying the 
cells and the culture parameters. These include determining the cell growth, the cell 
cycle time, characterisation of the cells by staining and deoxyribonucleic acid (DNA) 
analysis.
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Cell division, which leads in an increase in cell numbers, results in the growth of a 
culture. The rate of growth of a culture under a given set of conditions can be a useful 
method of characterising a culture. Cell growth can be determined from the absolute cell 
number determined from the cell count or by determining the cell proliferation using 
growth curves (McAteer & Davis, 1994).
A typical growth curve for cells seeded from subculture (figure 2.1) consists of four 
distinct phases: lag, log (exponential), plateau (stationary) and decline. In the lag phase 
(lasting 1-24 hours) the growth is negligible and will be dependent on the cell line and 
cell condition prior to culture. In the log phase, there is exponential growth that can be 
used to determine the cell doubling time. When adherent cells become confluent 
division slows down and the cell growth is balanced by the cell death. If the medium is 
insufficient, cell death eventually exceeds cell growth and the cell number declines.
plateau
2 x 1 0 '
decline
" O
log
lag
2 x  10'
Time (days)
Figure 2.1 - Growth curve
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The cell cycle is defined as the time interval between divisions (McAteer & Davis, 
1994). It is divided into a number of phases (figure 2.2): Gi“ (gap), S (DNA synthesis), 
G2  (Gap 2 -  resting phase), M (mitosis). The length of the cell cycle varies between 
cultures, as does the length of the individual phases.
Cell Division
M
S
G2
Figure 2.2 - The cell cycle
An asynchronous culture is pulsed with tritiated thymidine and examined by 
autoradiography for radiolabelled mitosis. Cells which are first into labelled mitosis are 
those which were in the S phase at the time of the pulse. The time interval between 
removal of the pulse of radioactivity and the detection of the labelled mitosis represent 
the growth phase (G2  + M). The cell cycle time is represented by the interval between 
the midpoint of the first and second rising curves (figure 2.3).
•a
O)
I  cell cycle time
Time (hours)
Figure 2.3 - The cell cycle time
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Immunocytochemistry is the localisation of antigens in or on cells by the use of a 
specific antibody to that antigen. The antibody is then labelled by some means in order 
to permit identification. A variety of labelling techniques are available including 
fluorochrome, radioisotopes and biotin/avidin. The staining may be carried out in a 
number of ways. Direct staining is a one-stage process in which the cell is incubated 
with the labelled antibody. In contrast, indirect staining is a two stage process in which 
unlabelled antibody is first incubated with the cell. In the second stage, the antibody is 
located with a labelled anti-immunoglobulin. This method is more sensitive although 
there may be a higher background. For immunofluorescence the antibody is labelled 
with a fluorochrome which is a molecule that is capable of absorbing light of short 
wavelength and emitting light of longer wavelength. A further refinement of this 
technique is double staining to locate two different antigens at the same time. The two 
antibodies should be conjugated to fluorochromes whose emission spectra are far apart 
such as Texas red and fluorosceine isothiocyanate (FITC) (Dawson, 1992).
2.2.4 Human aortic endothelial cells
The cell culture experiments described in this thesis were performed using HAEC 
which were purchased from Clonetics Inc (UK Supplier TCS Biologicals, 
Buckinghamshire). Provided the supplier's recommended protocols, medium and 
reagents were used, the cells were certified for use through at least fifteen population 
doublings (approximately three passages).
The cells, which had been obtained from a healthy thirty-four year old Caucasian female 
road traffic accident victim, were shipped cryopreserved in dry ice at the third passage 
(the cells were cryopreserved in endothelial growth medium supplemented with 10% 
v/v fetal bovine serum and 10% v/v dimethyl sulfoxide (DMSO) as a cryopreservation 
solution to improve ceU viability and seeding efficiency on thawing). Prior to shipping 
the cells were performance tested and confirmed negative for human immunodeficiency 
virus (HIV) and Hepatitis B & C viral infections (PCR DNA negative), mycoplasma, 
yeast, bacterial and fungal infections. Additionally the cells tested positive for Factor 
VIII (von Willibrand factor) antigen and for uptake of di-acetylated LDL, but tested 
negative for smooth muscle a  actin.
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2.2.4.1 Preparation of Medium
Endothelial cell growth medium is provided by Clonetics as a Bulletkit® consisting of a 
basal medium (EBM) and individual growth factors conveniently packaged as single 
use aliquots (Singlequots®). The endothelial basal medium was stored at 4°C in a cold 
room, and the supplements stored frozen at -20 °C until required. The fully 
supplemented solution was stored under refrigeration at 4°C.
The following components were supplied with a Bulletkit®:
Endothelial basal medium (modified MCDB 131) -  500ml 
Epidermal growth factor (lOng/ml) -  0,5ml 
Bovine brain extract (3mg/ml containing 10[JLg/ml heparin) -  2ml 
Fetal bovine serum (2%) -  10ml
Gentamicin (50mg/ml) / Amphoteracin-B (50mg/ml) -  0.5ml 
Hydrocortisone (Img/ml) -  0.5ml
A complete bottle of endothelial growth medium was prepared thus. The supplements 
were rapidly thawed at 37°C and transferred with the basal medium to a sterile field. 
The contents were then mixed thoroughly by gentle inversion. The external surfaces of 
the vials and the EBM bottle were then decontaminated by wiping with 70% v/v 
ethanol. Each cryovial was then aseptically opened and the entire contents added to the 
basal medium using sterile Pasteur pipettes. The cryovials were then carefully rinsed out 
with some of the medium to ensure recovery of the entire volume of the cryovial. The 
complete medium was then thoroughly mixed and appropriately labelled.
Before use, it was recommended that the medium was equilibrated for temperature and 
CO2 and thus pre-prepared flasks were placed in a humidified incubator at 5% CO2  and 
37°C for at least thirty minutes. This was thought to be particularly important in 
ensuring a gentle recovery of cells after thawing.
2.2.4.2 Thawing and inoculating cells
A seeding density of 2500 cells/cm^ and a volume of 1ml of growth medium per 5cm^ 
surface area of flask was recommended by Clonetics. Cells were initially recovered into
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25 cm  ^flasks. Five millilitres of complete medium was added to the number of flasks 
required (see below) and the flasks placed in the CO2  incubator for thirty minutes. As 
unvented flasks were used, the caps were loosely applied (tightened then loosened by a 
half turn). Each flask was labelled with the passage number, cell type, strain number 
and date thus:
P4, HAEC, 2241,10/12/96
The number of flasks required was determined using the following calculation:
No of cells available = cm^ that can be plated
Recommended seeding density
Maximum no cm^of cells platable = No of flasks
Growth area of flask
Cells were removed from liquid nitrogen, placed on dry ice, and transported to the 
sterile field. The vial was then wiped with ethanol, and the cap opened slightly to 
release pressure then retightened. The vial was immediately transferred to the 37°C 
water bath and the bottom half dipped in the water, care being taken to ensure that the 
cap did not become submerged in the water. The vial was thawed over two minutes 
(thawing cells for more than 3 minutes results in less than optimal results) while gently 
agitating the contents. The cryovial was then removed, dried and transferred to the 
sterile field (where the previously prepared equilibrated flasks were ready to be seeded), 
rinsed with 70% v/v ethanol and dried. The contents were gently agitated using a pipette 
and the desired volume of cells pipetted into the culture flasks. The cells were carefully 
placed onto the culture medium surface in an arc thus spreading the cells over the 
surface, then gently mixed with the medium in the flask by a swirling action.
The growth medium was changed the following day within 24 hours to remove residual 
DMSO and unattached cells. Thereafter the medium was changed on alternate days, 
although the cells were inspected daily. Care was taken to ensure that the medium was 
aspirated from the opposite side of the flask to which the cells were attached and 
similarly, the fresh medium was added to the same side.
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As the cells became more confluent, it was necessary to increase the volume of medium 
according to the following protocol:
Confluence Feeding volume
<25% confluence lml/5cm^
25-45% confluence 1.5ml/5cm^
>45% confluence 2ml/5cm^
2.2.4.3 Subculturing human aortic endothelial cells
The cells were sub cultured on reaching 70-90% confluence since allowing the cells to 
become over-confluent resulted in irreversible contact inhibition and loss of cell 
viability.
The old medium was firstly aspirated from the tissue culture flask. The cells were then 
rinsed with 2-3ml of room temperature Clonetics Hepes Buffered Saline Solution 
(BBSS) which neutralises any traces of protein from the medium which would 
otherwise inactivate the trypsin. This was then aspirated and 3ml of Clonetics 
Trypsin/EDTA solution which had been thawed to room temperature was added 
(3ml/25cm^). After gently rocking the flask to ensure that all the cells had come into 
contact with the trypsin solution, the flask was examined under the microscope until 
around 90% of the cells had rounded up, the entire process taking 5-6 minutes. Finally 
the flask was firmly tapped to detach the cells from the surface of the flask. After 
release of the cells, the entire process was arrested by addition of Clonetics trypsin 
neutralising solution (TNS) (3ml/25cm^). The cells were then transferred to a sterile 
universal container before centrifuging at 2000rpm (4°C) for 5 minutes. (lEC Centra -  
7R, International Equipment Company, Dunstable, UK) The supernatant was then 
decanted and discarded, and the pellet resuspended in 4ml of fresh growth medium. 
After flicking the container to dislodge the pellet, the cells were mixed by triturating 
with a fine tipped Pasteur pipette before counting in a Coulter counter to determine the 
yield. The cells were then seeded into new flasks according to the seeding density 
described above. The medium was then changed after 24 hours and thereafter at 48 hour 
intervals until the next passage (70-90% confluence).
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2.2 4.4 Preparation of cells for storage in liquid nitrogen
After harvesting the cells as described above, the cells were resuspended in a 
cryopreservation medium consisting of complete endothelial medium and DMSO (ratio 
9:1; 1ml DMSO in 9ml complete endothelial cell growth medium). The cells were then 
frozen in a stepwise fashion thus: 30 minutes at -20°C, 24 hours at -70°C prior to 
transfer to liquid nitrogen.
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2.3 Molecular Techniques
2.3.1 Introduction
Ribonucleic acid is a macromolecular structure comprising of a polymeric sugar 
(ribose) 'backbone' linked to the nucleotide bases adenosine, cytosine, guanine and 
uridine. It exists predominantly as a single stranded polymer and within the eukaryotic 
cell is found in three forms: ribosomal (rRNA), transfer (tRNA) and messenger 
(mRNA), (Strachan & Reid, 1996). Ribosomal RNA is the most abundant species 
comprising 80-90% of the total, with tRNA making up 5-10%. In contrast mRNA 
comprises only 1-5% of the total and varies considerably in size. Messenger RNA is 
transcribed from the antisense coding strand of genomic DNA and its sequence is 
therefore equivalent to that of the sense complementary DNA sequence. In common 
with DNA, RNA possesses complementary base-pairing properties. This facilitates the 
analysis of RNA immobilised on filters and labelled with specific cDNA, cRNA or 
oligonucleotide probes, and is an important component of many techniques in molecular 
biology.
It is of paramount importance in the analysis of RNA to rapidly and efficiently protect it 
against the action of endogenous and exogenous ribonucleases (RNAses) which are 
present in all living cells and throughout the general laboratory environment (Chabot, 
1994), and also to protect it against physical and chemical damage during manipulation. 
This is particularly important during the extraction and purification of RNA from 
tissues and cells but also applies to maintaining valuable stocks of RNA.
There are several well-characterised classes of RNAses, which can broadly be divided 
into either endo- or exo-nucleases. They are cofactor-dependent and are very resistant to 
destruction even at high temperatures (>90°C) and across wide-ranging pH’s. 
Laboratory glassware and plastics are usually contaminated with RNAses. Therefore, it 
is necessary to set aside and treat equipment that is required and label for RNA use 
only. Glassware can be baked at 250°C for 4hours, 180°C overnight or soaked in 0.1% 
v/v diethyl-pyrocarbonate (DEPC) followed by autoclaving. Some plastics and 
electrophoresis equipment cannot be autoclaved and should therefore be soaked 
overnight in 0.1% v/v DEPC and then rinsed thoroughly with RNAse-free water. Where 
possible, the use of sterile disposable plasticware (e.g. pipettes, centrifuge tubes) is
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advisable and the use of filtered pipette tips can protect samples from RNAses present 
on pipette barrels. Disposable plastic gloves should be worn at all times to prevent 
contamination when handling items (Sambrook, Fritch & Maniatis, 1989).
Prior to autoclaving, 0.1% v/v DEPC should be added to most autoclavable reagents, 
dispersed by thorough mixing, then left to stand overnight. Solutions containing Tris do 
not benefit from DEPC treatment because it is inhibited by Tris. Non-autoclavable 
reagents, such as those containing sucrose, can be sterilised by filtering through a sterile 
0.2pm filter.
2.3.2 RNA extraction
There are a number of methods for the preparation of total cellular RNA, which broadly 
involve cell lysis separation of RNA from DNA, proteins and other macromolecules and 
finally precipitation and concentration of RNA (Grabowski, 1994). The phenoT 
chloroform method of extraction is probably the commonest rapid method in use today. 
It utilises the chaotropic and RNAse inhibiting properties of guanidinium isothiocyanate 
and the acidic nature of water-saturated phenol, to extract both DNA and protein, 
leaving RNA soluble in the aqueous phase. RNA is then carefully transferred to another 
tube (avoiding contact with the precipitated DNA at the interphase with the phenol) and 
precipitated by mixing with one volume isopropanol (propan-2-ol) at -20°C for at least 
one hour. At this stage the RNA can be stored at —20°C without risk of degradation. The 
whole sample or aliquots can then be centrifuged, the RNA pellet washed with 70% 
ethanol and resuspended in RNAse-free water (DEPC treated) on ice and stored at -  
70°C (Sambrook, Fritch & Maniatis, 1989).
2.3.3 RNA quantification and visual assessment of integrity
Assessing the integrity of RNA and the presence of any genomic DNA contamination 
requires ethidium bromide stained agarose gel electrophoresis of each sample alongside 
a standard RNA pool. Undegraded RNA is represented by the appearance of two 
distinct 28S and 18S ribosomal bands. Smearing between the two bands reflects limited 
degradation. The absence of ribosomal bands and smearing in the region of the loading 
dye indicates complete degradation. The appearance of bands larger than the 28S rRNA
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band reflects genomic DNA contamination, necessitating re-purification (Grabowski, 
1994).
RNA yield can be accurately quantified spectrophotometrically by measuring the optical 
density (OD) of an aliquot of each RNA sample in solution at its maximum absorbance 
wavelength, i.e. 260nm. An OD value of one represents an RNA concentration of 
40pg/ml, Measuring the OD at 280nm can assess the level of protein contamination. A 
260/280nm ratio of < 1.5 indicates considerable contamination, necessitating re­
extraction.
2.3.4 Analysis of RNA
A number of techniques are now available for analysing both the size and abundance of 
different RNA transcripts. Despite the advent of powerful techniques such as RNAse 
protection assays and the polymerase chain reaction, northern analysis or blotting has 
remained the standard method for detection and quantification of mRNA.
2.3.4.1 Northern analysis
Northern blotting is widely used to determine both the size and abundance of different 
RNA transcripts (Alwine, Kemp & Stark, 1977). It requires the use of relatively large 
amounts of total RNA (15-50|ig) or poly (A-) mRNA (l-10|Ag) per lane which can be 
compared to standard markers of known size. The RNA is electrophoresed through an 
agarose gel (1-1.5% depending on the size of the target RNA) in electrophoresis buffer 
at 80-100 mAmps for 3-6 hours depending on the resolution of homologous RNA 
species required. The RNA is transferred either by capillary blotting in a high ionic 
strength buffer, or more rapidly by electroblotting, to a positively charged or uncharged 
nylon membrane, immobilised covalently by UV crosslinking, (or non-covalently by 
baking at 80®C for 3 hours) and stored damp in plastic wrap at 4°C until required for 
probing. To orientate the location of samples on the filter it is important to use an 
indelible marker pen or a scalpel to clearly identify on which side the RNA is 
immobilised, and to identify the top and bottom of the filter. Specific RNA species can 
then be detected by hybridisation with a labelled probe. If radiolabelled probes are used, 
the intensity and position of the signal assessed densitometrically gives an indication of 
the size and concentration of the RNA. To improve resolution and accurately determine
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the size of the target mRNA species it is necessary to use conditions which will destroy 
secondary structures (i.e. heating RNA to 65°C for 10 minutes, then snap cooling on ice 
prior to loading of the gel) (Farrell, 1993).
2.3.4.2 RNAse protection assay
The RNAse protection assay (RPA) utilises highly specific single-strand (ss) cRNA 
probes or riboprobes, which form specific duplexes with the target mRNA. This results 
in high sensitivity and is thus useful for quantitation of very low levels of target RNA, 
but increases the risk of developing non-specific binding. Target mRNA is mixed with 
the riboprobe in hybridisation buffer and the RNA denatured before incubating at 45- 
50°C for 8-12 hours. Any RNA not hybridised is then digested with RNAse A (attacks 
pyrimidine residues) and RNAse Ti (attacks guanosine residues) at room temperature. 
The reaction is then halted and after addition of a carrier tRNA the duplex RNA is 
salt/ethanol precipitated, resuspended and denatured prior to electrophoresis (Higgins & 
Hames, 1994).
2.3.4 3 Polymerase chain reaction (reverse transcription)
This is the most sensitive technique by which a specific RNA species can be detected, 
and under the correct conditions quantified also. The principal of the technique is that 
by combining first strand DNA synthesis by 3'antisense oligonucleotide-directed reverse 
transcription and subsequent PCR amplification of this DNA using both the antisense 
and a 5'sense primer, yields many copies of double-strand DNA product from a single 
RNA transcript. The product can then be visualised on an ethidium bromide stained 
agarose gel (Brown, 1995).
2.3.5 Probe Technology
Nucleic acid probes are a widely used tool in molecular biology having numerous 
applications including detection of quantitative and qualitative changes in gene 
expression, gene amplification and deletion, chromosomal translocations, point 
mutations and detection of the presence of new genetic sequences in cells. The role of 
the probe is to hybridise to any complimentary sequence in hybridisation reaction
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mixture. A probe has a label incorporated into the molecule which will enable its 
detection (localisation and quantification) at the conclusion of the experiment.
Nucleic acid probes consist of either DNA or RNA molecules and can be either 
homogeneous or heterogeneous in nature. A homogeneous probe preparation contains 
only one type of probe molecule, whereas a heterogeneous probe consists of mixtures of 
two or more sequences which may or may not be closely related nucleotide sequences. 
DNA probes consist of a variety of molecules including cloned double-stranded cDNA 
or genomic DNA sequences and oligonucleotide probes. Ribonucleic acid probes 
include cloned cRNA and oligonucleotide probes. Both RNA and DNA probes produce 
hybrids with the bound RNA, however the RNA: RNA hybrids bind more avidly and are 
therefore more stable than DNAiRNA hybrids. Deoxyribonucleic acid probes can 
therefore be more readily stripped from the membrane to allow repeated probing 
(Hames & Higgins, 1988).
Nucleic acid probes can be isotopically or non-isotopically labelled by several different 
means and separated from unincorporated label in order to minimise background 
signals. Radioisotopes in general use are ^H but their choice depends on the
requirements for sensitivity, resolution and speed of development. For filter 
hybridisations, ^^ P gives high sensitivity and sufficient resolution, but remains the 
isotope of choice for probes used in in-situ hybridisation and in filter hybridisations 
where high resolution but not detection sensitivity is required. Non-radioactively 
labelled probes are generally less sensitive for filter hybridisations, but are more 
frequently used in in-situ hybridisation. They also have a number of advantages over 
radio-labelled probes including improved safety during synthesis and use, and the 
ability to prepare probes in batches, increased probe stability and detection in minutes 
rather than weeks. Non-iso topic labels include biotin, digoxigenin and fluoroscein, all 
of which are larger molecules than radiolabels, which therefore precludes incorporation 
into probes at high specific activity. Detection systems include secondary antibodies 
against digoxigenin or biotin which may be conjugated to enzyme reporters such as 
horseradish peroxidase, alkaline phosphatase or to chromogens and fluoro-chromogens 
(Hames & Higgins, 1988).
The most commonly employed methods of internally labelling double-stranded cDNA 
probes are nick translation, random priming and polymerase chain reaction; kits for
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which are commercially available. Nick translation uses DNA polymerase I (DNAse I) 
to randomly introduce nicks into the backbone of the double-stranded DNA and insert 
cDNA to expose 3'-OH groups from which DNA-dependent DNA polymerase I 
incorporates deoxyribonucleic acid triphosphates (dNTPs) sequentially in the 5'-3' 
direction. Concurrent 5'-3' exonuclease activity removes dNTPs from the 5'end. 
Random priming is a type of primer extension in which a mixture of small 
oligonucleotide sequences, acting as primers, anneal to a heat denatured double­
stranded template. The annealed primers ultimately become part of the probe itself, 
because the Klenow fragment of DNA polymerase extends the primers in the 3'direction 
incorporating the label. Random priming appears to work significantly better with 
linearised DNA molecules. The PCR is a useful method for probe synthesis as it 
requires very little starting template and the synthesised product is of uniform length. In 
the presence of an appropriate precursor, molecules are labelled continuously as they 
are being synthesised, thus ensuring a high degree of label incorporation (Higgins & 
Hames, 1994).
In comparison with DNA probe synthesis, there are relatively few methods for labelling 
RNA probes. In vitro transcription is the commonest method currently in use and 
enables large quantities of efficiently labelled probes of uniform length to be generated. 
Antisense and sense cRNA’s are transcribed in vitro from a cDNA template using 
bacteriophage polymerases. The transcription vector is first linearised at a site just 
downstream from the insert to yield a blunt end (5'). An antisense cRNA complimentary 
to the non-coding DNA strand and sense RNA complimentary to the coding strand is 
then synthesised from a bacteriophage promotor located upstream of the DNA insert. A 
number of kits are now commercially available to facilitate in vitro transcription of 
RNA probes.
2.3.6 Detection and quantification of RNA
Autoradiography is a simple and reliable photochemical technique in which the capture 
of ionising radiation and photons by a film placed in direct contact with a radioactive 
source provides a relatively permanent visual record of the decay events associated with 
unstable radioisotopes (Jones, Qiu & Rickwood, 1994).
6 2
In Northern blot analysis of gene expression a piece of high-speed medical X-ray film 
(e.g. Kodak X-OMATIC AR, Kodak Limited, UK) is placed in direct contact with the 
plastic wrapped filter membrane (this avoids the filter drying out). This technique is 
referred to as direct exposure. During direct film exposure, energy is adsorbed in the 
silver-halide grains in the film, with the release of electrons. The resulting negatively 
charged areas attract the positively charged silver ions, forming an atom of metallic 
silver. Exposure of the X-ray generates an invisible precursor to the visible image 
manifested when the film is immersed in a suitable photographic developing solution. 
The formation of the visible autoradiographic image can be done manually or by 
machine, the latter method having the advantage of being developed according to a 
standardised process. The final developed image may be assessed by visually or more 
accurately using densitometry.
Autoradiographic detection of ionising radiation can be enhanced by the use of image 
intensifying screen cassettes which are cassettes with screens consisting of a polyester 
base coated with inorganic phosphors. Low temperature autoradiography (i.e. -70 °C to - 
80 °C) greatly enhances efficiency when using image intensifying screens hence the 
cassettes are stored frozen at -70 °C. Before developing the cassette is allowed to warm 
to room temperature.
The duration of exposure of the film wiU be dependent on the apparent signal strength 
which can be assessed by placing a Geiger counter probe over the filter to determine the 
activity on the filter. A high activity will require a much shorter exposure time, although 
it is often useful to do an overnight exposure in order to assess the extent of background 
and non-specific hybridisation. Subsequent exposure times can be derived on the basis 
of the image obtained from this test exposure.
The signal density on an autoradiograph can be quantified by using a scanning 
densitometer. The autoradiographic film is placed on a scanner and scanned over a 
defined area of the densitometer grid system and the information obtained is then 
transferred to a computer software package. The position of the molecular weight 
standards can provide useful information regarding the size of the bands. An attempt to 
quantify the signal can be made by outlining the band to be measured, selecting a 
volumetric integration of the area defined and expressing the signal in relation to the 
background density.
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CHAPTER THREE
STUDY ONE
ACUTE EFFECTS OF OESTRADIOL ON FOREARM BLOOD FLOW IN 
HEALTHY POSTMENOPAUSAL WOMEN
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3.1 Method
The technique of forearm venous occlusion plethysmography previously described was 
used to determine the acute effect of an intra-arterial infusion of soluble 17(3-oestradiol 
on the forearm blood flow responses in a group of healthy postmenopausal women.
3.1.1 Recruitment Criteria
The women who participated in this study were recruited either via the gynaecology 
department of The West Glasgow Hospitals University NHS Trust, Glasgow, or in 
response to a request for volunteers in an article published in the Glasgow University 
Newsletter. All women gave written informed consent to participate in the study, which 
was approved by the ethics committee of the West Glasgow Hospitals University NHS 
Trust. All the women recruited had no personal history of CVD, hypertension or 
diabetes, no contra-indications to oestrogen, and were deemed to be fit on routine 
physical screening which included a pre-study electrocardiograph which was within 
normal limits. None of the women were smokers, and only one woman was a previous 
HRT user, although had not used HRT in the preceding twelve months.
3.1.2 Study Protocol
The study protocol adopted is shown in figure 3.1. Subjects were positioned on the bed 
as previously described in chapter 2.1.4. After thirty minutes of test measurements, to 
allow for return to the resting state, two measurements at ten-minute intervals were used 
to calculate the baseline forearm blood flow. An infusion of 20ng/ml of soluble 17(3 
oestradiol (Clinafla, Switzerland) was infused at a constant rate of Iml/min for ninety 
minutes. Blood flow measurements were made at ten-minute intervals during the 
infusion. Two further measurements at ten and twenty minutes post infusion were also 
made. To determine the local circulating oestradiol levels, the venous effluent from the 
infused arm was sampled from a subgroup of women at the end of the study.
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110
Figure 3.1 - Protocol for Study 1
A summary measure of forearm blood flow during the final thirty minutes of the 
oestradiol infusion was calculated for individual subjects and compared with the initial 
baseline measurements. An overall comparison of the results was then made using a 2- 
sample Student’s t-test with 95% confidence intervals.
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3.2 Results
Fifteen women were recruited to the study initially. One subject withdrew after initial 
counselling. Six subjects were withdrawn due to difficulty cannulating the brachial 
artery at the start of the study, or due to the needle becoming dislodged during the course 
of the study. All women with whom we had difficulty with the initial cannulation except 
one, agreed to return for a second visit. In each case the cannulation was not successful 
at the subsequent visit.
Eight women, aged between 52 and 66 years, successfully completed the study. The 
mean duration from the menopause was 8.4±4.21 years. One woman had undergone 
total abdominal hysterectomy with ovarian conservation for menorrhagia eleven years 
earlier at the age of 41 years, the remaining seven women had undergone a natural 
menopause. Only one woman had previously taken HRT, but not in the preceding 
twelve months. At the time of entering the study, aU women were biochemically 
postmenopausal, with a circulating oestradiol level <50pmol/L, and a mean FSH level 
of 102.5+25.00 lU/L.
All women who participated were normotensive (mean blood pressure 133/71), non- 
obese (body mass index 25.2±2.20 kg/m^) with a mean cholesterol level of 6.4+1.10, and 
were also non-smokers.
The results of this study are detailed in appendix 2, and summarised in tables 3.1 & 3.2, 
and in figure 3.2. These data have a 95% power to exclude a 13% acute vasodilator 
effect of a supraphysiological concentration of oestradiol in the forearm resistance 
vessels of a group postmenopausal women, although the original protocol aimed to 
exclude a 10% effect.
The mean forearm blood flow ratio at baseline was 1.12±0.34, and during the final thirty 
minutes of the infusion was 1.07±0.30 (95%CI -0.30, +0.40, p=0.76). The mean local 
circulating oestradiol level measured in a small subgroup of women at the end of the 
infusion was 2740 pmol/L.
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Subject FBF Ratio (baseline)
FBF Ratio
(final thirty minutes of oestradiol infusion)
1 0.74±0.14 0.72±0.05
2 1.39±0.08 1.35±0.13
3 0.82±0.00 0.95+0.09
4 1.07±0.03 0.96±0.12
5 0.70±0.07 1.13±0.05
6 1.37+0.23 0.67±0.08
7 1.26±0.10 1.24+0.19
8 1.60+0.05 1.53±0.10
Table 3.1 -  Mean FBF ratios at baseline and during final 30 minutes of oestradiol 
infusion (summary data for individual subjects)
Time (min) % Change in FBF ratio (mean+SD)
10 -0.69±17.1
20 2.10±36.3
30 2.57±23.2
40 2.40+28.7
50 -5.41+25.0
60 -4.40±34.7
70 -2.70+33.5
80 5.10±40.9
90 2.20±32.2
100 -4.60+33.5
110 -12.30+34.4
Table 3.2 -  Percentage change in FBF ratio from baseline during 
oestradiol infusion (pooled data for all subjects)
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3.3 Discussion
Sex steroids are vasoactive hormones which profoundly influence vascular tone in the 
reproductive system. In addition to their dominant role in reproductive physiology, they 
also influence the vasculature of many other systems, including the cardiovascular 
system. Direct effects of oestrogen on blood flow and arterial tone have previously been 
reported in both animal and human studies using a variety of species and vascular beds, 
and such effects of oestrogen on the vasculature may have an important influence on 
cardiovascular physiology and health.
Early animal studies reported that oestrogen induced dilation of small blood vessels in 
the ear of ovariecomized rabbits (Reynolds & Foster, 1940). A reduction in peripheral 
vascular resistance in non-pregnant oophorectomized ewes following oestrogen 
administration has also been documented (Magness & Rosenfeld, 1989). Relaxation of 
isolated perfused human umbilical vessels in response to oestrogen (Silva de Sa & 
Meirelles, 1977), and vasodilatory responses to 17p-oestradiol in pre-contracted rabbit 
coronary arteries (Raddino et al, 1986) was also suggestive of a direct effect of 
oestrogen on blood vessels. However, these early pharmacological studies used 
significantly higher oestrogen concentrations than those produced endogenously or 
given exogenously as replacement therapy, and failed to identify specifically which 
vascular cells were responding to oestrogenic stimulation. To evaluate the 
stereospecificity of the rapid vascular effects of oestradiol, more controlled studies using 
other steroids, non-steroidal oestrogens and anti-oestrogens will be necessary.
Further evidence for an acute vasodilatory effect of oestrogen has been acquired from a 
number of in-vivo human studies. Doppler velocimetry studies have shown the 
oestrogen administration increases blood flow to the vulva and thenar eminence (Sarrel, 
1989). Blood flow impedance in the internal carotid artery was assessed in twelve 
postmenopausal women using Doppler ultrasound and colour flow imaging, before and 
after oestrogen treatment. Pre-treatment, there was a linear association between the 
internal carotid artery pulsatility index (blood flow impedance downstream to the point 
of sampling) and menopausal age, suggesting that low circulating oestradiol levels are 
associated with increased blood flow impedance. However, after nine weeks of 
transdermal oestrogen administration, there was a significant reduction in the pulsatility 
index from the baseline pre-treatment level (Gangar et al, 1991). Acute administration of
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sublingual 17p-oestradiol to postmenopausal women resulted in an increase in forearm 
blood flow and a reduction in vascular resistance when compared to placebo (Volteranni 
et al, 1995). A beneficial effect of acute oestrogen administration on myocardial 
ischaemia in postmenopausal women with angiographically proven coronary artery 
disease, was observed after administration of sublingual oestrogen (Img). This study 
was a double-blind placebo controlled cross-over study, which examined the effect of 
oestradiol on exercise induced myocardial ischaemia in eleven women with chronic 
stable angina. Both total exercise time and the time to 1mm ST segment depression, 
which was taken as an indicator of myocardial ischaemia, was increased after taking 
sublingual oestradiol forty minutes prior to treadmill exercise, and was attributed to 
either a direct coronary relaxing effect, peripheral vasodilation or to a combination of 
both (Rosano et al, 1993).
It has been suggested that these rapid vasodilatory effects of oestrogen are mediated 
independently of the classic genomic pathway of steroid action, which involves receptor 
activation and gene transcription. There is increasing evidence suggesting that steroid 
hormones can bind to cell membranes and induce rapid cellular events within a few 
minutes of exposure (Moura & Worcel, 1984; Wehling, 1994). Indeed, the presence of 
membrane oestrogen receptors is thought to be partly responsible for the rapid 
vasodilatory effects of oestrogen, acting via rapid intracellular signalling pathways 
(Farhat, Abi-Younes & Ramwell, 1996).
A direct vasodilating effect of oestrogen was not demonstrated in this study as no 
significant difference in the mean forearm blood flow of the control to the infused arm 
following infusion of water soluble 17(3-oestradiol was observed. The results shown in 
figure 3.2, expressed as the percentage change in the forearm blood flow over baseline 
(where a positive value indicates vasodilation and a negative value vasoconstriction), 
clearly demonstrate no specific trend, although the spread of these data suggests that 
there is considerable inter-individual variation between these subjects.
The apparent lack of vasodilation observed in the human forearm in this study suggests 
that, if present, any vasodilator effect of oestradiol in this tissue is likely to occur over a 
longer time period and may therefore be mediated via genomic mechanisms. As 
supraphysiological concentrations of oestradiol were achieved and the infusion was 
continued for a duration close to the maximum achievable in studies of this nature, it
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would appear that the vasodilator effects of oestradiol are either tissue and/or species 
specific, or that it is not a direct vasodilator.
In this study water soluble oestradiol was purposely used as other studies examining the 
acute effects of intra-arterial oestradiol on the vasculature have previously employed 
ethanol (a known vasodilator) as a dilutant which may have prejudiced their results 
(Gilligan et al, 1994).
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CHAPTER FOUR
STUDY TWO
EFFECT OF 17P-OESTRADIOL ON BASAL ENDOTHELIAL NITRIC OXIDE
RELEASE
73
4.1 Method
Using the technique of forearm venous occlusion plethysmography previously described 
in section 2.1.4, forearm blood flow measurements were used to examine the effect of 
transdermal l?P-oestradiol on basal endothelial nitric oxide synthesis or release by 
measuring the responses to L-NMMA.
4.1.1 Recruitment criteria
The study was conducted as an unblinded ‘before and after’ study. Approximately half 
the women were recruited post-op eratively; the remainder had responded to an article 
on ‘HRT and heart disease’ published in the local press. In the post-operative women, 
the study was timed to start at three to six weeks postoperatively, to allow for 
stabilisation of gonadotrophins and other metabolic processes (Thorrell et al, 1994). All 
women gave written informed consent to participate in the study, which was approved 
by the ethics committee of the West Glasgow Hospitals University NHS Trust.
In keeping with the previous study we sought non-obese healthy women, with no 
personal history of cardiovascular disease, hypertension or diabetes, no contra­
indications to oestrogen, and who were deemed to be fit on routine physical screening. 
All women had a pre-assessment electrocardiograph which was within normal limits. 
Women taking regular medications with the exception of HRT were excluded, however 
all women who had previously been using HRT were asked to discontinue their HRT 
for four weeks prior to participating in the study.
4.1.2 Study protocol
Subjects attended for two identical study day’s four weeks’ apart. On the first study day 
the women had not used HRT in the preceding four weeks. A second study day was 
arranged after four weeks of transdermal 17p-oestradiol (Fematrix 80, Solvay 
Healthcare Limited, Southampton). The study protocol adopted is illustrated in figure
4.1.
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Figure 4.1 - Protocol for study 2
Subjects were positioned on the bed as previously described. After thirty minutes of test 
measurements, to allow for return to the resting state, two measurements at ten-minute 
intervals were used to calculate the baseline forearm blood flow. Intra-arterial infusions 
of ascending doses of noradrenaline (NA) (5,10,50,100 pmol/min), a control 
vasoconstrictor, were each infused for a period of seven minutes. Blood flow 
measurements were recorded three minutes after each infusion commenced, over a 
period of three minutes. Following a thirty-minute washout period during which a saline 
infusion was re-commenced, two further baseline measurements were recorded. In the 
remaining part of the study monomethyl-L-arginine (L-NMMA), a stereospecific 
inhibitor of NOS which gives an index of basal NO synthesis, was infused following the 
same protocol at 2,4,8 p,mol/min.
Mean blood flow responses for each dose of NA and L-NMMA were determined for 
individual subjects as previously described. An overall summary measure was then 
calculated for each dose of agent used, and the responses before and after oestradiol 
treatment compared using a 2-sample Student’s t-test with 95% confidence intervals.
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4.2 Results
Nineteen women were recruited to the study. Three withdrew after the initial counselling 
visit, prior to commencing the study. A further six women had to be withdrawn as a 
result of failed arterial cannulation. Where arterial cannulation failed on the second visit 
(i.e. post oestrogen) the study was abandoned, however if the arterial cannulation failed 
at the initial baseline visit, the women were asked to return for a further attempt. All 
women except one, who had a needle phobia, attended for a second visit, although 
subsequent attempts to cannulate were also unsuccessful.
Ten healthy non-obese, (BMI 24.8±4.7 kg/m^) normotensive (mean blood pressure 
124/70), women aged between 35 and 60 years, all of whom were non-smokers, 
completed the study. Three women had undergone a natural menopause (mean duration 
from the menopause 7.0± 3.46years), and all had been taking HRT prior to taking part in 
the study (Premarin or Trisequens). One woman had previously undergone total 
abdominal hysterectomy with ovarian conservation at the age of 45 years for fibroids. 
The remaining seven women were recruited postoperatively from the gynaecology ward, 
following total abdominal hysterectomy and bilateral salpingo-oopherectomy for benign 
gynaecological disease. The circulating oestradiol levels at baseline indicated 
biochemical postmenopausal status in all subjects at the time of entering the study. The 
mean circulating oestradiol level during the treatment cycle was 243±170pmol/L.
The results of this study are detailed in appendix 2, and are summarised in tables 4.1 &
4.2, and in figures 4.2 & 4.3. Responses to NA were similar before and after treatment 
and no statistically significant differences were apparent (95%Cl -28.2, +7.20, p=0.23). 
Similarly, no statistically significant differences in the vasoconstrictor responses to 
L-NMMA were observed before and after oestradiol treatment (95%Cl -31.2, +4.8, 
p=0.14).
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Noradrenaline infusion FBF Ratio (pre) FBF Ratio (post)
5pmol/min
lOpmol/min
50pmol/min
lOOpmol/min
-10.67±17.86
-6.02±19.97
-7.62±27.21
-13.00+43.20
+4.04±21.06
-3.50±18.87
-4.79+23.62
+1.18+29.51
Table 4.1 - Mean summary data for NA infusion before and after oestradiol 
treatment
L-NMMA infusion FBF Ratio (pre) FBF Ratio (post)
2pmol/min -13.84±14.52 -3.55±26.67
4pmol/min -30.87±12.06 -20.31±18.38
Spmol/min -18.30±37.90 -23.95±23.78
Table 4.2 - Mean summary data for L-NMMA infusion before and after oestradiol 
treatment
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4.3 Discussion
It is well recognised that vascular smooth muscle cell relaxation, causing blood vessel 
dilatation, occurs as a result of the release of a number of vasoactive factors by 
endothelial cells in response to a variety of chemical and physical stimuli including 
ACh, histamine, serotonin, blood flow and shear stress (Vanhoutte, 1989). One of the 
principal vasoactive mediators thought to be released as a consequence of this, is NO. 
Atherosclerosis is associated with impaired endothelial-dependent relaxation, and it is 
thought that this may be as a consequence of impaired production or release of NO. 
There is increasing evidence from both animal and human work to suggest that 
oestrogen stimulates secretion of NO, and may therefore protect the vasculature by 
facilitating the vasodilator responses in both normal and atherosclerotic arteries.
Basal release of NO from the vasculature is generally greater in vessels from female 
animals than in those from males, suggesting that female sex hormone status is 
important in regulation of basal vasomotor tone (Hayashi et al, 1992). A cyclical 
variation in expired NO production in women, with levels peaking in the middle of the 
menstrual cycle, is also highly suggestive of an influence of gonadal hormones on the 
synthesis and release of NO (Kharitonov et al, 1994).
A number of in vitro animal studies using a variety of species and vascular beds, have 
shown that oestrogen induces endothelium-dependent relaxation of vessels. Oestrogen 
facilitates the normal vasodilator response to ACh in rabbit femoral arteries (Gislard, 
Miller & Vanhoutte, 1998) and in porcine coronary vessels (Bell et al, 1995). Acute 
(Williams, Adams & Klopfenstein, 1990) and chronic (Williams et al, 1992) oestrogen 
administration attenuates or reverses the vasoconstriction effect of ACh in 
ovariectomised cynomolgus monkeys with coronary atherosclerosis.
In humans, there is also a suggestion of a role for the endothelium in the mediation of 
oestrogen-induced vessel relaxation. Studies of the coronary vasculature have shown 
that oestrogen attenuates or abolishes ACh-induced vasoconstriction when administered 
acutely in postmenopausal women with angiographically proven coronary artery disease 
(Reis et al, 1994; Collins et al, 1995). Similar responses to acute intracoronary 17|3- 
oestradiol have been reported in postmenopausal women in healthy coronary vessels 
(Gilligan et al, 1994). The response of coronary arteries is also gender dependent with
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evidence of 17(3-oestradiol-induced modulation of ACh-induced coronary artery 
responses of female but not male atherosclerotic coronary arteries (Collins et al, 1995). 
Studies of the peripheral vasculature, most commonly the forearm, have also reported 
beneficial effects of oestrogen on vascular reactivity. A study of forty postmenopausal 
women, (of whom half had risk factors for vascular dysfunction) in whom forearm 
vascular responses to the endothelium dependent vasodilator ACh were studied before 
and during intra-arterial infusion of oestradiol, demonstrated that oestrogen potentiated 
the vasodilator response to ACh in both healthy and potentially diseased blood vessels 
(Gilligan, Quyyumi, Cannon, 1994). Similar findings have been reported in a recent 
plethysmography study which examined changes in forearm blood flow responses 
induced by intra-arterial infusion of ACh at baseline, one month after bilateral 
oophorectomy, and after three months of oestrogen replacement therapy (50p,g 
transdermal oestradiol) in a small group of women (ten subjects) (Pinto et al, 1997). 
Endogenous oestrogen deprivation following bilateral oophorectomy resulted in a 
reduction in acetylcholine induced vasodilation compared with baseline, but this was 
subsequently restored by oestrogen supplementation. In contrast to these findings, a 
small randomised double blind placebo controlled study also examining forearm blood 
flow using venous occlusion plethysmography, showed no evidence of any alteration in 
the vasodilator responses to ACh following oestrogen supplementation (2mg oestradiol 
valerate daily for eight weeks duration) (Sudhir et al, 1996). However, enhanced 
vasoconstrictor responses to the nitric oxide synthase inhibitor L-NMMA was observed, 
suggesting that there was enhanced basal NO release in the forearm vasculature of 
perimenopausal women following oestrogen supplementation.
The results of this study do not support the hypothesis that transdermal oestrogen results 
in an improvement in basal endothelial NO synthesis in the forearm vasculature of 
healthy postmenopausal women. These data exclude a 10% absolute increase in basal 
NO release in the forearm vasculature following transdermal oestradiol treatment. This 
contrasts with the findings of other investigators (Sudhir et al, 1996). One possible 
explanation for differences between the studies may be the route of administration of 
oestrogen.
Transdermal oestrogen avoids any first pass metabolism, whereas oral oestradiol passes 
from the gut directly to the liver via the portal circulation giving high local 
concentrations, which profoundly affect hepatic metabolism. Hence any indirect effects
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of oestrogen on endothelial function mediated by changes in serum lipids will be much 
greater. Thus, although this study did not demonstrate an effect of transdermal 
oestrogen in the forearm vascular bed, it clearly does not exclude an effect of oestrogen 
on the forearm vasculature if delivered by an alternative route, or indeed an effect on a 
different vascular bed when delivered by the same route.
Results from other studies have also argued against a role for NO in oestradiol mediated 
cardioprotection. One study, conducted in castrated apolipoprotein-E deficient mice 
(which develop early atherosclerosis), demonstrated that oestradiol prevented fatty- 
streak formation despite inhibition of NO by N^ nitro-L-arginine methyl ester (L- 
NAME), suggesting that the anti-atherosclerotic effect of oestradiol is independent of 
NO (Elhage et al, 1997).
Interestingly in this study, no clear dose response effect to NA was observed, although 
the doses used were similar to those used in previous studies by our group in healthy 
male subjects and appeared adequate during pilot studies. The variability observed is 
unlikely to be due to the experimental conditions as this part of the study was performed 
prior to the L-NMMA infusions, which displayed less variability and a dose response 
element. Similar findings have been reported by another group who observed blunted 
vasoconstrictor responses to NA in postmenopausal women, suggesting that this is 
perhaps a true biological response (Kneale et al, 1997).
This study was designed as a randomised double-blind placebo controlled study, 
however there was considerable difficulty in recruiting patients to a study of this nature 
as most women approached postoperatively expected to commence HRT prior to 
discharge from hospital and were unwilling to have their HRT withheld for up to three 
months. The study protocol was therefore adapted to a ‘before and after' study to 
facilitate recruitment.
Although the procedure was generally well tolerated, the failure rate of intra-arterial 
cannulation was unusually high in this study compared to that encountered in previous 
studies in young healthy male volunteers conducted by our group. As assistance was 
sought from Dr J Petrie, Senior Lecturer, Department of Medicine and Therapeutics, 
University of Glasgow, who had considerable experience in performing arterial 
cannulation in male subjects, this was not felt to be related to the experience of the
8 2
operator, but rather that it was a feature of this particular sample group, and may be a 
reflection of different arterial physiology in this group.
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CHAPTER FIVE
STUDY THREE
THE EFFECT OF OESTRADIOL ON THE GROWTH CHARACTERISTICS 
OF HUMAN AORTIC ENDOTHELIAL CELLS IN CULTURE
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5.1 Methods
5.1.1 Establishing human aortic endothelial cells in culture
Using the protocols previously described in chapter 2.2.4, the cells were initially plated 
into seven small tissue culture flasks (25cm^). After reaching confluence, several flasks 
of cells were harvested, transferred to cryovials, and stored in liquid nitrogen for future 
use. The remaining flasks were subcultured into medium and large flasks to provide an 
adequate stock of cells for experimental purposes. Any surplus cells were subsequently 
harvested and stored in liquid nitrogen to maintain adequate stocks.
5.1.2 Characterising human aortic endothelial cells
After re-establishing the cells in culture, in order to clarify the nature of the cells and 
confirm that they were indeed endothelial cells, immunocytochemistry was performed 
on several flasks of cells. Assistance with this technique was kindly provided by Dr I 
Montgomery, Department of Physiology, University of Glasgow.
After fixing in methanol, specimens were washed several times in Tris buffered saline 
(TBS). Non-specific binding sites were blocked with normal serum from the animal 
supplying the second antibody (anti-rabbit raised in a goat). The primary antibody (anti 
human Von Willebrand factor raised in a rabbit) was then applied to the slides which 
were placed at room temperature in a darkened moist chamber overnight. The slides 
were then washed several times with TBS, before applying the second antibody 
conjugated with Texas Red for several hours in a moist darkened chamber at room 
temperature. The slides were then rinsed in several washes of TBS, followed by a short 
immersion in running tap water. The slides were then mounted in a non-fluorescent 
mounting media (Immuno-mount). The finished slides were then examined with 
epifluorescence using a Zeiss Axiophot Microscope (Carl Zeiss) at xl97 magnification. 
Photomicrographs were taken using Fuji Provia film (Fuji).
5.1.3 Growth studies
As the HAEC’s used in this project had not previously been cultured within this 
laboratory, two preliminary experiments was set up to ascertain the behaviour and
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growth characteristics of the cells, and to ensure that oestradiol would not be cytotoxic 
to the cells.
5.1.3.1 Preliminary growth experiments
In the first experiment half of the cells were exposed to a water-soluble preparation of 
17p-oestradiol (lOnM) (Sigma-Aldrich), with the remaining untreated cells acting as a 
control population. The cell growth in both groups was monitored on days four, six, 
eight, eleven and fourteen, by harvesting and counting the cells as previously described. 
A second experiment was performed to determine the cell growth in relation to different 
oestradiol preparations. In this experiment the cells were exposed to lOnM and lOpM 
concentrations of 17p-oestradiol and ethinyl oestradiol (Sigma-Aldrich). The cell 
growth on day four and day twelve was determined and compared with untreated 
controls.
On the basis of these pilot studies, it was decided to treat the cells with two doses of 
17p-oestradiol (lOnM and lOpM) and to harvest the growth curves on days four, eight 
and twelve. These doses of oestradiol were chosen as they are representative of the 
extremes of the physiological range and as similar concentrations had been reported by 
other investigators (Venkov, Rankin & Vaughan, 1996).
5.1.3.2 Growth curves
Four principal experiments were performed. All experiments were performed under 
identical standardised conditions using cells form the third to eighth passages. A total of 
twenty seven small flasks were required per experiment (three sample days examining 
three sample groups, with three flasks per group).
Briefly, cells were seeded in complete endothelial growth medium into small flasks at a 
density of 60,000 cells/flask. After 24 hours the medium was removed and replaced 
with serum free medium (standard EBM with antibiotic supplements only). After a 
further 24 hours the medium was replaced with fully supplemented medium with or 
without 17p oestradiol (lOnM or lOpM). The following day a number of flasks were 
harvested as described. Thereafter, the remaining flasks were fed and harvested on 
alternate days until day twelve according to the protocol summarised in table 5.1.
8 6
DA Y l Inoculation
DAY 2 Serum Deprive
DAY 3 Feed ± Treat
DAY 4 1®‘ Harvest
DAY 5 Observe
DAY 6 Feed ± Treat
DAY? Observe
DAYS 2"** Harvest
DAY 9 Observe
DAY 10 Feed ± Treat
DAY 11 Observe
DAY 12 3^** Harvest
Table 5.1 -  Growth curve protocol
A direct comparison of the mean cell counts for the control and oestrogen treated groups 
at each time point (day 4, 8 & 12) was determined for the individual experiments using 
simple 2-sample t-tests with 95% confidence intervals.
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5.2 Results
Figure 5.1 shows a photomicrograph of the human aortic endothelial cells used in this 
project after staining with FITC and viewing at xl96 magnification. These cells 
demonstrate a characteristic flattened epithelial-type cell morphology.
The results of the preliminary experiments are detailed in appendix 2, and are 
summarised in figures 5.2 & 5.3. The results of these studies demonstrated that it was 
possible to obtain reproducible cell growth using this cell population. Figure 5.2 shows 
that after the initial lag phase there is an exponential growth phase followed by tailing 
off of growth after fourteen days. The studies also indicated that the oestrogen 
preparations used were well tolerated by the cells. The results of these preliminary 
experiments were not incorporated into the final analysis of the results.
Four identical growth curve experiments were performed. Where possible, three 
measurements were taken per flask. The results of the individual growth curve are 
detailed in appendix 2, and summarised in figures 5.4-5.7. The results of the fourth 
experiment (figure 5.7) were excluded from the final analysis as the cell growth was 
erratic particularly in the control cells, and it was considered that this experiment might 
compromise the overall results and conclusions. Interestingly, the timing of this 
experiment coincided with a malfunction of the CO2  incubator, which may have 
prejudiced the results of this particular experiment.
Each experiment demonstrated a trend towards increased cell growth with time which 
was independent of treatment. The only exception to this was seen in growth curve one, 
in which there was a failure in proliferation of the oestradiol (lOpM) treated cells by day 
twelve. It was considered that this was a spurious observation, as it was not replicated in 
subsequent experiments. In general, the cell proliferation was enhanced by oestradiol in 
a time and dose dependent fashion.
No statistically significant differences between the growth in the control or oestrogen 
treated cells was observed on day four and eight. However, following treatment with 
lOnM 17(3-oestradiol a statistically significant increase in cell growth was consistently 
observed in each experiment (growth curve 1 -  P = 0.039, 95% Cl -0.277, -0.0008;
8 8
growth curve 2 ~ P = 0.007, 95% Cl -0.141, -0.029; growth curve 3 -  P = 0.013, 95% 
Cl -0.0537, -0.0082).
Although the individual measurements in each experiment were almost normally 
distributed, there was considerable variation in the absolute cell counts between the 
individual experiments which tends to skew the overall data set making pooling the data 
unreliable. However, this can be overcome by performing a log transformation of the 
data which then allows simple parametric analysis using 2-sample t-tests, with 95% 
confidence intervals. Again a statistically significant difference is seen following lOnM 
17(3-oestradiol treatment at day twelve (P = 0.026, 95% C l-0.63, -0.04),
89
Figure 5.1 - Photomicrograph of human aortic endothelial ceils stained with 
fluorosceine isothiocyanate and viewed with Zeiss Axiophot Microscope at xl96  
magnification
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5.3 Discussion
In the past there was considerable difficulty in establishing and maintaining primary 
human cell lines in culture, however the recent introduction of commercially available 
sources of human cells has generated renewed interest in the field of human tissue 
culture research. The cell culture work described in this thesis was developed from cells 
obtained commercially due to their relative ease of availability, and due to constraints of 
time.
Endothelial cells are now known to express functional oestrogen receptors. Studies of 
human aortic and umbilical vein endothelial cells and bovine aortic endothelial cells, 
confirmed that these cells expressed an abundance of mRNA for the classical oestrogen 
receptor, and furthermore demonstrated using electrophoretic mobility shift assays that 
each endothelial cell type contained a protein which reacted with anti-oestrogen 
receptor monoclonal antibodies specific to different domains of the oestrogen receptors 
(Venkov, Rankin & Vaughan, 1996).
Endothelial ‘injury’ is thought to be the key event in the initiation of atherogenesis and 
the development of atherosclerosis (Ross, 1993), and thus protection of the endothelium 
from toxic insults could represent a potential mechanism for protection against 
atherosclerosis. Furthermore, stimulation of endothelial cell growth and prevention of 
smooth muscle cell migration and proliferation should be of benefit for restoration of 
normal vascular function.
In cell culture experiments, 17(3-oestradiol promotes proliferation of human umbilical 
vein endothelial cells (Morales et al, 1995), although other studies using the same cell 
type have either detected no effect (Miller et al, 1994) or only a very weak effect of a 
stable oestrogen analogue (Corvazier et al, 1984). Similarly, there have been 
inconsistencies reported when using cultured bovine aortic endothelial cells with reports 
of enhanced (Piotrowicz et al, 1995) and reduced (Drummond et al, 1996) endothelial 
cell proliferation in response to 17(3-oestradiol treatment. These differences are 
probably a reflection of differences in culture conditions, species variations and 
variations dependent on different vascular beds, as well as the assays used for 
evaluation. Although readily available and more easily established in culture, human 
umbilical vein endothelial cells may behave very differently from endothelial cells
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derived from adult tissue and for this reason were not used in this work. Similarly, there 
is debate as to whether the endothelial cell responses to oestrogen are conserved across 
the species and therefore it was decided to use human cells in these studies. Accepting 
the limitation that endothelial cell behaviour may not be uniform across different 
vascular beds within the same species, human aortic endothelial cells were used for the 
purpose of these studies.
The results of this study confirm that high dose oestrogen treatment is associated with a 
significant increase in cell number after sustained treatment. However, as this was not a 
functional study, it does not explain the potential underlying mechanism. Two candidate 
mechanisms exist. Firstly, oestrogen may generate an increase in cell number by 
directly stimulating cell growth by the release of growth promoting factors. A recent 
study showing that oestrogen increased wound healing of the endothelial cell monolayer 
and enhanced the ability of endothelial cells to organise into a tubular network (equated 
to angiogenesis), would support this argument (Morales et al, 1995). Alternatively, it 
has been suggested that oestrogen may be acting as a survival factor preventing 
apoptosis, although to date only one study has reported this as a plausible mechanism 
(Spyridopoulos et al, 1997). In this study the authors examined the potential role of 
oestrogen as a survival factor by examining the ability of oestrogen to inhibit cytokine 
induced (Tumour Necrosis Factor a  (TNF-a)) programmed cell death in human 
umbilical vein endothelial cells. Their results indicated that oestrogen treatment resulted 
in a dose-dependent receptor-mediated inhibition of TNF-a induced endothelial cell 
apoptosis.
As the increase in cell numbers seen appears to be a time dependent effect it is therefore 
suggestive of an underlying genomic mechanism. Oestrogen may regulate cell 
proliferation through alteration of gene expression and synthesis of protein involved in 
the regulation of the cell cycle (Brown et al, 1984; Dubick, Dembiski & Shiu, 1987). 
Numerous genes have been identified in vascular tissues as potential targets for 
oestrogen regulation, including the prostaglandin cylo-oxygenase and prostaglandin 
synthase (Chang et al, 1980), collagen and elastin synthase (Cembrano et al, 1960; 
Wolinsky, 1972) as well as NOS (Weiner et al, 1994).
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Transdermal oestrogen avoids any first pass metabolism, whereas oral oestradiol passes 
from the gut directly to the liver via the portal circulation giving high local 
concentrations, which profoundly affect hepatic metabolism. Hence any indirect effects 
of oestrogen on endothelial function mediated by changes in serum lipids will be much 
greater. Thus, although this study did not demonstrate an effect of transdermal 
oestrogen in the forearm vascular bed, it clearly does not exclude an effect of oestrogen 
on the forearm vasculature if delivered by an alternative route, or indeed an effect on a 
different vascular bed when delivered by the same route.
Results from other studies have also argued against a role for NO in oestradiol mediated 
cardioprotection. One study, conducted in castrated apolipoprotein-E deficient mice 
(which develop early atherosclerosis), demonstrated that oestradiol prevented fatty- 
streak formation despite inhibition of NO by N° nitro-L-arginine methyl ester (L- 
NAME), suggesting that the anti-atherosclerotic effect of oestradiol is independent of 
NO (Elhage et al, 1997).
Interestingly in this study, no clear dose response effect to NA was observed, although 
the doses used were similar to those used in previous studies by our group in healthy 
male subjects and appeared adequate during pilot studies. The variability observed is 
unlikely to be due to the experimental conditions as this part of the study was performed 
prior to the L-NMMA infusions, which displayed less variability and a dose response 
element. Similar findings have been reported by another group who observed blunted 
vasoconstrictor responses to NA in postmenopausal women, suggesting that this is 
perhaps a true biological response (Kneale et al, 1997).
This study was designed as a randomised double-blind placebo controlled study, 
however there was considerable difficulty in recruiting patients to a study of this nature 
as most women approached postoperatively expected to commence HRT prior to 
discharge from hospital and were unwilling to have their HRT withheld for up to three 
months. The study protocol was therefore adapted to a ‘before and after’ study to 
facilitate recruitment.
Although the procedure was generally well tolerated, the failure rate of intra-arterial 
cannulation was unusually high in this study compared to that encountered in previous 
studies in young healthy male volunteers conducted by our group. As assistance was 
sought from Dr J Petrie, Senior Lecturer, Department of Medicine and Therapeutics,
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University of Glasgow, who had considerable experience in performing arterial 
cannulation in male subjects, this was not felt to be related to the experience of the 
operator, but rather that it was a feature of this particular sample group, and may be a 
reflection of different arterial physiology in this group.
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CHAPTER SIX
STUDY FOUR
DETERMINATION OF eNOS EXPRESSION IN CULTURED HUMAN AORTIC 
ENDOTHELIAL CELLS FOLLOWING OESTRADIOL TREATMENT
1 0 1
6.1 Method
6.1.1 Extraction and assessment of mRNA from cultured human aortic 
endothelial cells
Untreated (control) cells and cells which had been treated with lOnM or lOpM 17^- 
oestradiol for either twenty-four hours or seven days were used for these studies. Total 
RNA was extracted from the cells using RNAzol B (Biogenesis Ltd, Poole) according 
to their protocol. Within a laminar-flow hood (Bio Mat II Medical Air Technology 
Limited, Manchester), medium was extracted from the flasks using an aspirator system 
and discarded. The base of the tissue culture flask was covered with RNAzol B, and the 
flask gently agitated by rocking the flask back and forth to dislodge the cells. The 
volume of RNAzol B required was dependent on the size of the flask: 8ml/175cm^, 
6ml/80 cm ,^ and 4ml/25 cm .^ After harvesting the flask contents were transferred to a 
sterile plastic Falcon tube using a sterile 10ml pipette. A 1/10 volume of chloroform 
(i.e. SOOfxl, 600pl or 400pl depending on the size of the flask) was added to the Falcon 
tube which was vigorously shaken for fifteen seconds. The cells were then transferred 
on ice to a centrifuge and centrifuged for five minutes at 2500rpm (4°C). Glass Corex 
tubes which had previously been soaked in 3% w/v hydrogen peroxide, wrapped in 
silver foil, then baked at 220“C to destroy any RNAses, were labelled for each sample. 
After centrifuging (lEC Centra-7R), there was separation into three phases. The upper 
aqueous phase, which contains the RNA, was carefully removed using a sterile fine- 
tipped Pasteur pipette taking great care not to disturb the interphase containing DNA 
which separates the two layers. An equal volume of isopropanol (propan-2-ol) was then 
added to the Corex tube which was then covered with Parafilm (3M Products), mixed 
by inversion several times, and left to stand on ice for a minimum of fifteen minutes or 
alternatively was left overnight at -20°C to allow precipitation. Following precipitation, 
the RNA was pelleted by centrifuging at 10,000rpm (4°C) in a Beckman centrifuge 
(Model J2-21, Beckman) for fifteen minutes. The supernatant was then discarded and 
the pellet, which was visible as a white smear on the inside of the Corex tube, was 
washed with 2ml of 70% w/v ethanol then re-spun at 10,000rpm for a further fifteen 
minutes at 4°C. The supernatant was then removed using a sterile lOOOfxl pipette 
(plugged tip), and left to dry on ice. At this stage extreme care was taken to ensure that 
as much of the ethanol as possible was allowed to evaporate without allowing the RNA 
to dry out, in order to maximise the yield of RNA. The RNA pellet was then re­
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solubilised in DEPC water (lOOpl or 50pl depending on the size of the flask from which 
the RNA was extracted) and centrifuged briefly for several minutes at lOOOrpm. Finally, 
the contents were transferred to previously sterilised Eppendorf tubes and stored at 
-70^C. The integrity of the RNA was determined by ethidium bromide stained agarose 
gel electrophoresis.
6.1.2 Preparation of an agarose gel
An agarose gel was prepared by dissolving a known amount of agarose, measured in 
grams, in a given volume of Ix tris-acetate buffer (IxTAE). A 1% gel was prepared by 
dissolving Ig of agarose in 100ml of IxTAE for a standard gel (10cm), or 0.5g in 50ml 
for a small gel (5 cm). A 2% gel was prepared by dissolving 2g in 100ml etc. The 
solution was then microwaved on high power for one to two minutes until boiling, then 
transferred to a fume hood where ethidium bromide was added (2pil), the solution mixed 
thoroughly and left to cool until hand hot. The gel was then poured into a gel tray, a 
comb inserted and the gel was left to set for at least thirty minutes. Once set, the comb 
was removed and the gel tray placed in the gel tank with IxTAE buffer, sufficient buffer 
being added to submerge the gel completely.
6.1.3 Preparation of RNA for electrophoresis
Samples of total RNA (2fxl) were prepared in Eppendorfs for electrophoresis after 
addition of 3\il dH20 and lp-1 6x loading dye (agarose gel blue). An appropriate control 
sample, for example Lambda Hindi III (À.HIII), was also run on the gel to ascertain that 
the gel was run correctly.
After preparation of the gel as described above, the wells were loaded with 
appropriately prepared samples. Extra care was taken while loading each well to ensure 
equal and even loading. The gel tank (Hybaid) was then connected to an electrical 
power source (EPS 200/1000, Pharmacia Biotech) and run at lOOV for thirty to forty 
minutes. Once completed, the power source was disconnected and the gel carefully 
transferred to an ultraviolet illuminator (Chromato-vue, Mod TM-20) to allow 
visualisation. Good quality RNA can be clearly visualised as three distinct bands (figure 
6.1).
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Lane 1 2 3 4 5 6
Lane 1 & lane 6 -  molecular weight markers (X.H III)
Lane 2 -  control
Lane 3 -  control
Lane 4 -  17p-Oestradiol (lOnM)
Lane 5 -  17p-Oestradiol (lOpM)
Figure 6.1 -  Resolution of RNA transcripts by agarose gel electrophoresis
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6.1.4 Quantification of RNA
RNA yield was quantified spectrophotometrically using an Ultraspec 2000, UV/Visual 
Spectrophotometer, Pharmacia Biotech.
The machine was switched on approximately fifteen minutes before it was required for 
use to enable it to perform a self-calibration test. A standard 1ml cuvette provided with 
the machine was rinsed with distilled water (dHzO), then 1ml of dH2 0  was added to the 
cuvette which was placed in the spectrophotometer. The machine was then set to RNA 
mode, with the background correction off, and references set for the blank (dH20). A 
l[il sample of RNA was then added to the cuvette, the sample run and the results noted. 
This was repeated three times for each sample and the mean calculated. For each p-1 
sample, the concentration is expressed in p,g/p,l. The results were expressed as follows:
OD2 6 0 OD2 8 0  Ratio (OD2 6 0/ OD2 8 0) Concentration ([xg/p,l)
To avoid cross contamination between samples, the cuvette was thoroughly rinsed with 
dH2 0  between each sample.
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6.1.5 Synthesis of human eNOS cDNA probe
A human eNOS probe was prepared from a stock plasmid, pHu NOS endo PM831221, 
which was obtained courtesy of Dr Philip Marsden, University of Toronto, Canada 
(Marsden et al, 1992).
The concentration of the stock eNOS plasmid DNA was 5fxg/p,l. This was diluted to a 
concentration of Ifxg/pl with TE buffer (Ipl = 5p,g therefore lp.1 diluted to 5pi 
corresponds to Ipg/pl).
Diluted stock human eNOS plasmid DNA was thus used to prepare digests of cut (Ipl 
plasmid DNA (Ipg), Ipl EcoRl, Ipl lOx buffer, 7pi dH20) and uncut (Ipl plasmid 
DNA (Ipg), 9pi TE buffer) fragments. The cut and uncut fragments were then run on an 
agarose gel to assess the quality of the digest. A 1% agarose gel was prepared as 
previously described, and run at lOOV for 45 minutes. The gel was loaded thus: Lane 1 
(control) 4pl XHIII; Lane 2 (uncut fragment) lOpl uncut, 2pi Tris; Lane 3 (cut 
fragment) lOpl cut, 2pl Tris.
Having established that the above mini-digest was satisfactory, the process was repeated 
for the main digest using lOpl (50pg) of plasmid DNA. The main digest was prepared 
as follows - cut fragment (lOpl plasmid DNA, 5pi EcoRl, lOpl Buffer H, 75pl dH20); 
uncut fragment (Ipl plasmid DNA, 9pi TE buffer). The cut fragment was allowed to 
digest overnight at 37°C. The following morning a 1% agarose gel was prepared and 
loaded thus: Lane 1 (control) 4pl XHIII; Lane 2 (uncut fragment) lOpl uncut, 2pi Tris; 
Lane 3 (cut fragment) lOpl cut, 2pl Tris.
The gel was initially run at lOOV for forty-five minutes to determine if the digest had 
been satisfactory. The remainder of the DNA digest was then loaded onto the gel and 
allowed to run over several hours. On completion, the required band was cut from the 
gel and placed in a polythene membrane previously rinsed with dH2 0 , and the bottom 
was sealed with a clip. One micro-litre of IxTAE was added to the membrane which 
was sealed with a second clip, and placed in a gel tank and run for twenty minutes. The 
gel was then visualised under ultraviolet light to ensure that the band had completely 
resolved into the TAB. The liquid was then decanted into two Eppendorfs (0.5ml each)
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and an equal volume of phenol was added (0.5ml). The Eppendorfs were then 
whirlimixed (Fisons Whirlimixer, Loughborough) for thirty seconds prior to 
centrifugation for four minutes in a bench-top microfuge (Eppendorf Mod 5415C). The 
top layer was then removed using a fine tipped Pasteur pipette, transferred to a sterile 
Eppendorf tube and a further 0.5ml phenol/chloroform added, before re-spinning in the 
microfuge for a further four minutes. This step was then repeated, before adding 50pl of 
3M Sodium Acetate (1/10 volume) and lOOOpl of 100% ethanol (2x volumes). The 
digest was then transferred to a -20°C freezer for forty-eight hours. The digest was then 
removed from the freezer and transferred to a pre-cooled (4°C) centrifuge and spun at 
1400 rpm for fifteen minutes (Eppendorf Mod 5402). The supernatant was removed and 
the pellet washed with 70% v/v ethanol prior to re-spinning for a further five minutes. 
The supernatant was then decanted and the pellet allowed to dry in air for twenty 
minutes. The pellet was then re-solubalised in 25pi of buffer and refrigerated overnight 
prior to quantification. The fragment was quantified using a DNA spectrometer (Hoeffer 
Dyna Quant 200), and the concentration adjusted to 40ng/pl with TE buffer. The quality 
of the DNA fragment isolated and the completeness of the digest was then determined 
by running by running a small aliquot on a 1% agarose gel, with an appropriate DNA 
standard and a control (kHIH).
The above method of probe synthesis was also used to manufacture a GAP-DH probe. 
This had previously been prepared within the laboratory and was kindly made available 
for use by Dr J Brosnin, Lecturer, Department of Medicine and Therapeutics, University 
of Glasgow.
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6.1.6 Northern Blotting
6.1.6.1 Preparation
The gel tank, comb and tray were soaked in 3% w/v hydrogen peroxide (H2 O2) for one 
hour, thoroughly rinsed in DEPC treated water and allowed to dry inverted on a clean 
paper towel. The barrels of all pipettes were cleaned with 3% w/v H2 O2  then covered 
with plastic film. Finally the surrounding bench area was prepared by thoroughly 
cleaning the working area with 3% w/v H2 O2  solution and clearly indicating that it had 
been prepared as such.
6.1.6.2 RNA Sample preparation
The required amount of RNA (lOpg) was precipitated on ice thus: lOpl RNA (Ipl = 
Ipg), 3 volumes 100% ethanol (30pl), 1/5 volume sodium acetate (2pl), and added to 
appropriately labelled sterile Eppendorf tubes, which were transferred to a microfuge 
and spun briefly before being transferred to a -20 °C freezer overnight to allow 
precipitation.
The samples were transferred to a pre-cooled (4 °C) centrifuge and spun on maximum 
speed (14000 rpm) for fifteen minutes taking care to orientate the tubes correctly in the 
centrifuge (hinge of lid orientated to outside edge ensured pellet formation in line with 
hinge) as this aided subsequent identification of the RNA pellet. The supernatant was 
then removed and the pellet washed with 180pi of 70 % w/v ethanol before re-spinning 
at 4 °C for a further five minutes. With the supernatant removed the pellet was then 
left to stand to allow to dry for fifteen minutes, before the pellet was resolubilised in 
3.7pl of DEPC H2 O. To avoid obtaining a low yield of RNA, care had to be taken to 
ensure that the pellet was free of ethanol prior to resolubilising and that it had properly 
re-dissolved. 12.3 pi of fresh glyoxal solution was then added to the RNA, and the 
samples transferred to a dry heating block (Griffin Dri-Block Unit, Griffin & George 
Ltd, London) at 50 “C for one hour. After heat denaturing, the samples were then 
transferred to ice for snap cooling before adding 4pl of 5x RNA loading dye. After 
briefly spinning in a microfuge the samples were immediately loaded on to a previously 
prepared agarose gel.
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6.1.6.3 Preparation and running an RNA gel
A 1.2% agarose gel containing (O.IM NaP0 4  buffer) was prepared by dissolving 1.6g of 
electrophoresis grade agarose in 120ml DEPC H2 O by microwaving, and adding 13.3 
ml of O.IM NaP0 4  once cooled to 50 °C. The gel was then poured in the RNA 
designated gel tray and the comb added. To prevent leakage of the gel the gel tray was 
carefully sealed with autoclave tape. The gel was allowed to stand for at least 30 
minutes to set prior to loading.
The gel tank (Hybaid Ltd) used for RNA work differs from conventional gel tanks in 
that it has the facility to re-circulate the buffer whilst the gel is running to prevent pH 
changes. The previously prepared gel was immersed in IL of lOmM NaP0 4  tank 
running buffer, and carefully loaded with the prepared samples. A space was left 
between the molecular weight marker lane and the first sample to enable the marker 
lane to be cut off later and stained to confirm that appropriate transfer has taken place. 
The gel was run for four to six hours at lOOV to allow adequate resolution of the RNA 
samples, i.e. until the RNA had migrated approximately 10-12cm from the loading 
wells. Once completed the RNA could be transferred to an appropriate membrane.
6*1.6A  Capillary transfer of RNA
The RNA was transferred from the gel to a positively charged nylon membrane 
(Hybond N”^, Amersham International pic,) using an upward capillary transfer system.
Three Whatman paper ‘bridges’ (Whatman Labsales Ltd) were cut to the same width 
and approximately twice the length of the gel being blotted. A further nine pieces of 
Whatman paper were cut to the same size as the gel. A piece of membrane was cut to 
1mm less than the gel size, taking great care not to damage the membrane or handle it 
excessively. The ‘bridges’ were soaked in 20x SSC and laid over the base support 
smoothing out any air bubbles and ensuring both ends were in contact with the transfer 
buffer (20x SSC). The gel was then placed over the base support with the RNA surface 
uppermost. For orientation purposes the top left-hand corner of the gel was carefully 
removed using a scalpel blade. The membrane which had been pre-wet with 2x SSC, 
was the placed over the gel and the corner trimmed to match the gel. Any air bubbles 
were carefully smoothed out and the edges of the gel sealed with Parafilm to prevent
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‘short-circuiting’. Six of the previously cut pieces o f Whatman paper were soaked in 2x 
SSC and placed on top of the filter and a further three dry pieces were placed on top of 
these before placing a 3-4cm thick pile o f absorbent tissues on top o f the Whatman paper 
stack. Finally a glass plate was placed on the top to support a 500g weight. After 
confirming that capillary transfer was taking place the transfer set up was left overnight. 
This required approximately 1L o f transfer buffer.
After disassembling the transfer apparatus, the blot was air dried on a piece of clean 
Whatman paper for thirty minutes, then baked in an oven at 80°C for sixty minutes, 
before ultra-violet cross linking in a UV stratifier crosslinker (UV Stratalinker 1800, 
Stratagene). At this stage membranes were carefully stored dry prior to hybridisation.
To confirm that transfer has taken place the marker lane was carefully cut off and stained 
using methylene blue (0.04% w/v) in 0.5M sodium acetate, then rinsed in distilled water 
several times before air drying for 10 minutes. Visible bands confirmed that transfer had 
taken place (figure 6 .2).
Figure 6.2 -  Confirmation of transfer of RNA
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6.1.7 Prehybridisation and hybridisation of membranes
The prehybridisation/hydridisation solution was made according to the following 
protocol: Deionised formamide (20.0ml), 20x SSPE (10.0ml), lOOx Denhards solution 
(2.0ml), 10% w/v SDS (2.0ml), 0.4M EDTA (pH=8) (0.1ml), DEPC H2 O (5.9ml).
6.1.7.1 Prehybridisation
This solution described above was made up in a 50ml conical tube (Falcon), and 20ml 
added to the hybridisation bottle (Techne) and pre-warmed to 42°C prior to addition of 
the membrane for probing. Before adding the membrane to the hybridisation bottle, it 
was submerged in a tray of 6x SSC for five minutes. Extreme care had to be taken when 
transferring the wet membrane to the hybridisation bottle, to prevent damage to the 
membrane. The membrane was then prehybridised for a minimum of four hours at 
42°C in a hybridisation oven (HBl Hybridisation Oven, Techne,).
6.1.7.2 Preparation of probe
During the prehybridisation step, a probe was prepared using a random priming kit 
(Gibco, Life Technologies). GAP-DH and eNOS probes were prepared in sterile 
Eppendorf tubes as follows:
GAP-DH eNOS
Probe 1 pi (50ng/pi) 1.25 pi (40ng/pl)
DEPC H2 O 22pl 21.75pl
Thereafter the preparation of the two probes was identical and they were heated to 
100°C for five minutes before snap cooling on ice. The following reagents from the 
random priming kit were then added: dATP (2pl), dGTP (2pl), dTTP (2pl), random 
primer buffer (15 pi). The Eppendorf tubes were then placed in a microfuge and briefly 
spun for a few seconds, before being transferred on ice to the radioactive hood for 
addition of the radiolabelled (^ ^P, 18.5mbq, a  emmision) dCTP (5pi) and the Klenow 
fragment (Ipl). The probe was then carefully mixed in the radioactive hood, and left to 
stand for at least one hour prior to checking the incorporation of the probe.
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In duplicate, Ipl of the probe was carefully spotted on to a small piece of DE 81 filter 
disc (Whatman Labsales Ltd), allowed to dry, then placed in a scintillation counter tube. 
The tube was then placed in a perspex box and transferred to the scintillation counter 
(Tri-Carb 2100 TR, Packard Instruments). The scintillation tube was then removed from 
the perspex box once in the scintillation counter, transferred to a counting rack and run 
on a pre-set program. The activity in counts per minute (cpm) was noted. The tube was 
then removed from the counter and returned to the radioactive hood where a sequence 
of washings were undertaken thus: 5x washes Na^ HPO4; 2x washes d H2O (removes 
salt from filter); 2x washes 100% ethanol (dehydrates filter). Care was taken to dispose 
of the washes in an appropriate receptacle for handling radioactive waste. The filter was 
then left to air dry in the hood for around ten minutes prior to transfer back to the 
scintillation counter for re-counting. It is important to allow the filter to dry before 
counting since moisture has a deleterious effect on the count. The incorporation of the 
probe was thus calculated from the two measurements and expressed as a percentage:
Count 1 (pre-wash) 1164357 cpm 
Count 2 (post-wash) 946291 cpm 
% Incorporation 946291 x 100 = 81%
1164357
A percentage incorporation above 50% was deemed satisfactory for the purposes of 
northern blotting.
6.1.7.3 Hybridisation
The probe was then transferred to a dry block and heated to 100 °C to denature the 
probe, taking care to ensure that the probe was appropriately shielded from other 
laboratory personnel. It was then removed from the heating block, snap cooled on ice 
and immediately added to the pre-warmed hybridisation solution. The prehybridisation 
solution was then decanted off and discarded, and the hybridisation solution added. The 
blot was then returned to the hybridisation oven at 42°C and left overnight to hybridise.
The following day the hybridisation solution was decanted off and disposed of in a 
radioactive sink in the radioactive hood. The blot was then rinsed according to the 
following regime: 2x rinses room temperature; 2x SSPE (0.1% SDS); 2x washes 15
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minutes, 65 °C 2x SSPE; 2x washes 10 minutes, 65 “C Ix SSPE; 2x washes 30 minutes, 
65 '^ C Ix SSPE
The early washes were generally carried out in the hybridisation bottles, although the 
final washes were usually performed in flat plastic tubs which were manually agitated 
intermittently to aid the washing process. This also enabled the blot to be assessed 
between washes by listening to the radioactivity with a Geiger counter (Series 900 
Mini-monitor Mini-Instruments Ltd), as this provided a useful indicator of the quality of 
the blot and the need for further high stringency washes in the presence of high 
background noise.
After the final wash, the blot was carefully wrapped in cling film and exposed to 
radiographic film overnight. Once developed, the blot was re-exposed to film for a 
variable period of time dependent on the signal intensity and signal-to-noise ratio.
Care was taken to ensure that the blots were never allowed to dry out, and thus after 
probing they were stored in the freezer at -20 *^C until requiring to be re-probed.
6.1.7.4 Quantification of blots
After developing, the blots were scanned into a phosphoimager (Biorad Molecular 
Imager FX, Biorad Instruments, UK), and quantified densitometrically as previously 
described in chapter 2.3.6.
6.1.8 Determination of oestrogen receptor status
The oestrogen receptor status of the HAEC was determined using RT-PCR. The work 
was undertaken by Dr Rosemary Bass on behalf of Dr Steve Charnock-Jones, 
Department of Obstetrics and Gynaecology, University of Cambridge, who has 
considerable expertise in this area of reproductive endocrinology and who kindly agreed 
to colloborate. Full details of their methodology have been published previously 
(Maclaren et al, 1996). In brief, RT-PCR was carried out using 2.6\ig of RNA with 
primers to specifically amplify ERa and ERp cDNA’s. (Primer 1 -
GGAGACATGAGAGCTGCCAA and primer 4 -  TCATCATGCGGAACCGAGAT 
were used for the first round and primer 2 -  CCAGCAGCATGTCGAAGATC and 
primer 3 -  CTTTGGCCAAGCCCGCTC for the second round). Primers for ERp were
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designed from the published sequence (Primer 1 -  TTACAGCATTCCCAGCAATG 
primer 2 -  GAACCTGGACCAGTAACAG) and the amplified product was verified by 
cloning and sequencing.
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6.2 Results
Cells between passages three and six were used for experiments and the results of five 
separate experiments performed under identical conditions are presented.
The presence of mRNAs encoding both classical ERa and ER(3 in these HAEC was 
confirmed by RT-PCR. Figures 6.3 & 6.4 show samples of the PCR products for 
oestrogen receptors a  and p obtained.
Using northern blotting, GAPDH and eNOS signals were readily detectable and 
quantifiable. Figure 6.5 shows a typical radiograph of a northern blot after probing for 
GAPDH and eNOS genes.
After quantification of the radiographic images, no significant change in eNOS gene 
expression was observed following oestradiol treatment. This was independent of the 
dose or duration of treatment. (Control 0.496 ± 0.24; 17P-oestradiol (nM, 24h) 0.422 ± 
0.24, p=0.64; 17P-oestradiol (nM, 7d) 0.348 ± 0.17, p=0.30; 17p-oestradiol (pM, 24h) 
0.240 ± 0.13, p=0.11; 17P-oestradiol (pM, 7d) 0.290 ± 0.08, p=0.13).
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Oestrogen receptor a
LI L2 L3 L4 L5 L6
Samples loaded left to right -  lanes 1-6
Lane 1 -  molecular weight marker 
Lane 2 - control
Lane 3 - 17P-Oestradiol (lOpM, 24h)
Lane 4 - 17P-Oestradiol (lOpM, 7d)
Lane 5 - 17P-Oestradiol (lOnM, 24h)
Lane 6 - 17p-Oestradiol (lOnM, 7d)
Figure 6.3 -  PCR products for oestrogen receptor a
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Oestrogen receptor p
LI L2 L3 L4 L5 L6
Samples loaded left to right -  samples 1-6
Lane 1 -  molecular weight maricer 
Lane 2 - control
Lane 3 - 17p-Oestradiol (lOpM, 24h)
Lane 4 - 17p~Oestradiol (lOpM, 7d)
Lane 5 - 17P-Oestradiol (lOnM, 24h)
Lane 6 - 17p-Oestradiol (lOnM, 7d)
Figure 6.4 -  PCR products for oestrogen receptor p
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LI L2 L3 L4 L5 L6
4.5Kb
1.2Kb
eNOS
GAP-DH
LI “  control, L2 -  lOnM 17P-Oestradiol (24h), L3 -  lOnM 17p-Oestradiol (7d)
L4 -  control, L5 -  lOpM 17p-Oestradiol (24h), L6 -  lOpM 17p-Oestradiol (7d)
Figure 6.5 -  Autoradiograph of northern blot probed for eNOS and GAP-DH 
signals
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6.3 Discussion
This study was designed to parallel the in-vivo study discussed in chapter 4. The results 
of this study showed no evidence of an up regulation of eNOS gene expression in 
cultured aortic endothelial cells following exposure to oestrogen, and thus do not 
support the hypothesis that oestrogen is acting via a receptor mediated action to enhance 
basal endothelial NO expression in the human endothelium. These results were 
consistent with the results of the in-vivo study.
The presence of mRNA’s for both ERa and ERp receptors in the endothelium was 
confirmed by RT-PCR. Confirmation of the presence of oestrogen receptor is important, 
as it suggests that the negative findings reported do not reflect low or absent oestrogen 
receptor expression..
These results contrast with the findings of other investigators who have previously 
reported an up-regulation of eNOS by oestradiol in cultured endothelial cells. An up- 
regulation of eNOS protein levels in response to l?p-oestradiol has been observed in 
human aortic endothelial cells using Western blotting (Hayashi et al, 1995). In this 
study, the level of eNOS protein was determined after short (8h) and long (48h) term 
pre-treatment of cells prior to measurement of calcium stimulated (ionomycin) NO 
production. Similar findings have been observed in human umbilical vein endothelial 
cells and bovine aortic endothelial cells (Hishikawa et al, 1995). These investigators 
reported an increase in eNOS protein using Western blot analysis following oestrogen 
pre-treatment for a minimum of eight hours, an effect which was inhibited by addition 
of the oestrogen receptor antagonist tamoxifen. These effects were consistent in both of 
the cell populations studied. These findings suggest an involvement of the classic 
oestrogen receptor (ERa), a hypothesis which is supported by observation that knock­
out mice lacking ERa have reduced NO production (Freay et al, 1995). More recently, 
another group demonstrated that oestrogens increase transcription of the human eNOS 
gene and has suggested that this may be mediated as a consequence of enhanced activity 
of transcription factor Sp 1 (Kleinert et al, 1998). This study examined eNOS mRNA 
expression in human endothelial cells following incubation with 17(3-oestradiol and 
17a-oestradiol using RNAse protection assays. They also examined eNOS protein 
levels using western blotting techniques.
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Recently, it has also been argued that increased bioactive nitric oxide levels in response 
to oestrogen do not occur due to enhanced expression of NOS, but rather that they are as 
a consequence of inhibition of superanion production (Arnal et al, 1996). This study 
reported that treatment of cultured bovine aortic endothelial cells with ethinyl oestradiol 
had no effect on either the activity or expression of eNOS. They did however 
demonstrate an increased superoxide anion production correspondingly increased 
expression of mRNA for superoxide dismutase (SOD).
Other studies have also argued against the potential role of NO in explaining the non­
lipid-mediated component of HRT cardioprotection. Elhage reported that treatment of 
castrated apolipoprotein E-deficient mice (which develop early atherosclerosis) with 
oestradiol appeared to prevent atherosclerotic fatty streak formation and this effect 
continues to be observed despite inhibition of NOS using L-NAME suggesting that the 
anti-atherosclerotic effect of oestradiol was independent of NO (Elhage et al, 1997).
1 2 0
CHAPTER SEVEN
DISCUSSION
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7.1 Introduction
The high prevalence and significant morbidity and mortality associated with 
cardiovascular disease in women, particularly after the menopause, has promoted 
interest the possibility of a hormonally based aetiological link for the disease. However, 
despite the compelling evidence of cardiovascular benefit associated with oestrogen use 
in observational studies and a number of potential biologically plausible mechanisms to 
explain this effect, uncertainty about the effects of HRT remain.
Observational studies of HRT and its effect on cardiovascular disease are not controlled 
clinical studies, and are not uniform in terms of type or dose of oestrogen and current 
use, past use or non-use of oestrogen. Observational studies enable the reader to make 
inferences or associations from the data but not to determine cause or effect. Since the 
observational data on oestrogen and cardiovascular benefit were so consistent for so 
long, it was assumed that the results of the clinical trials would be supportive of the 
clinical effects of oestrogen. However, recently completed clinical trials do not clearly 
support the protective effects of oestrogen indicated in the observational studies.
In 1998, the Heart and Oestrogen Replacement Study (HERS) reported its findings 
(Hulley et al, 1998). This study was a secondary prevention study in 2736 women with 
established coronary heart disease. It found no significant differences between the 
women in the control and experimental groups with the primary end-point of the study 
being the occurrence of non-fatal myocardial infarction or death from coronary heart 
disease. It did however report an early increase in coronary events in the HRT group, 
which tapered off after two years and was balanced by a decline over the next two 
years. A possible explanation for the increase in cardiovascular events observed is that 
there is an early thrombotic risk associated with a delayed anti-atherogenic benefit or 
that certain subgroups of women are more susceptible to an early thrombotic risk. 
Another secondary prevention trial, the Estrogen Replacement and Atherosclerosis trial 
(ERA) is due to be reported shortly and early indications suggest that the results will be 
in broad agreement with the HERS study. The Women’s Health Initiative (WHI) is a 
primary prevention trial with over twenty-seven thousand women. This study initiated 
in 1994 which will be due to report its findings in 2005, recently announced that during 
the first two years of the study, a small increase in the number of myocardial 
infarctions, strokes and thromboses had been observed in the women taking active
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hormones, although the investigators speculate that this may disappear with time (WHI 
Update 2000, NIH).
7.2 Discussion
The studies reported in this thesis fall into two broad categories with two purely clinical 
studies and two laboratory based projects.
The clinically based studies used the technique of FVOP to study the forearm vascular 
haemodynamics in two groups of postmenopausal women, to establish firstly whether 
oestradiol modulated vascular reactivity and secondly to determine if changes in 
vascular reactivity were due to a NO mediated effect. The laboratory based studies 
sought to compliment these studies by determining the endothelial cell responses to 
oestrogen at a molecular level by examining eNOS mRNA expression using northern 
analysis and by directly measuring cell proliferation.
7.2.1 Forearm venous occlusion plethysmography studies
The technique of FVOP with intra-arterial cannulation is complex requiring 
considerable skill to master the technique. Within the department, most of the previous 
experience of this technique had been obtained in healthy young male volunteer 
subjects, and although the procedure was generally well tolerated by the women who 
took part in these studies (apart from discomfort associated with immobility and with 
the insertion of the intra-arterial needle) it was felt that overall this subject group was 
technically more challenging, with an unusually high failure rate which could perhaps 
be attributed to different arterial physiology in this group.
In study one, an acute vasodilator response to intra-arterial infusion of water-soluble 
oestradiol was not observed in the human forearm. This indicates that if present, any 
vasodilator effect in this vascular bed is likely to occur over a longer period time, 
possibly via the classic genomic pathway of steroid action.
The results of the second study did not support the original hypothesis that transdermal 
HRT causes an increase in basal endothelial NO synthesis in the forearm vasculature as 
determined by measuring the response to L-NMMA. Most other studies of this nature
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have used oral oestradiol preparations such as oestradiol valerate or CEE which may 
explain the negativity of these results, and does not preclude an effect of oestrogen on 
the forearm vasculature if delivered by an alternative route, or indeed, an effect on a 
different vascular bed if delivered by the same route.
Both of these studies were carefully designed to minimise the inclusion of patients with 
known arterial disease, as the arterial physiology of such patients will be very different. 
The results of these studies are further strengthened by adopting a bilateral approach, 
and expressing the results with respect to the control arm.
7.2.2 Growth studies
As these experiments were the first to be performed in the laboratory using HAEC there 
was considerable interest in the success of establishing and maintaining these cells.
After characterising (to confirm endothelial nature), then observing the growth 
characteristics of the cells by undertaking pilot studies, standard growth curve studies 
were performed to determine the cell proliferation in response to oestrogen exposure. 
The results of these studies confirmed that prolonged exposure to pharmacological 
doses of 17(3-oestradiol resulted in a significant increase in absolute cell number, either 
as a direct consequence of stimulating cell growth or by prevention of cell death and 
thus prolongation of cell life. Further studies are indicated to clarify the underlying 
mechanism.
7.2.3 eNOS mRNA expression
Expression of mRNA for the eNOS gene was confirmed by northern analysis, however 
the results of these studies did not support the hypothesis that oestrogen up-regulates 
eNOS mRNA expression.
The presence of mRNA for both ERa and ERp was confirmed by RT-PCR. Clarifying 
the oestrogen receptor expression was important as it suggested that the negative 
findings were not a consequence of an absence of the receptor. This raises the question 
that there is an alternative mechanism to explain the presence of increased NO levels in 
response to oestrogen, which have been reported. One possible explanation is that there
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is an inhibition of superoxide anions resulting in reduced clearance of nitric oxide. This 
may be manifest by increased expression of the SOD gene as this is the principal 
inactivator of superoxide anions.
7.3 Future studies
The work presented in this thesis has hopefully provided a framework from which to 
build a number of future studies.
Unfortunately, FVOP is a highly invasive technique which requires acquisition of 
considerable skill, however recent advances in ultrasound technology have provided an 
alternative method for assessing vascular reactivity in vivo and may ultimately form the 
basis of future work.
Having ascertained that it is possible to establish and maintain commercially available 
human aortic endothelial cells in culture, will allow the planning of future studies 
involving several key areas of interest. Firstly, to determine the basal and stimulated 
rates of NO production by the cells, using a NO microsensor. Secondly, if NO levels are 
enhanced in response to hormonal stimulation, to determine if this is due to inhibition of 
superoxide anion production rather than enhanced eNOS production. This will be done 
by direct assessment of superoxide anion production using a superoxide assay 
developed within the group, and by assessment of SOD mRNA expression using 
northern analysis. In addition it is intended to develop the RNA work further, in 
particular to establish RT-PCR and RNAse protection assays within this area of work.
The results of the growth studies provided interesting data on the effect of oestrogen on 
absolute cell number. However, the underlying mechanism to explain the observations 
made is not clear from studies of this nature. It is therefore proposed that a study is 
undertaken to examine the cell cycle to establish whether this effect is due to a true 
increase in proliferation or if it is due to a reduction in apoptosis.
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7.4 Conclusion
With the exception of the growth studies which yielded interesting results requiring 
further evaluation, the negative results of the remaining carefully designed and well 
executed studies, while at variance with the results of other investigators, nevertheless 
generate interesting new data which appears to be in broad agreement with the albeit 
limited results of the randomised control studies currently available.
It appears therefore that the paradox of coronary risk and the menopause is an issue 
which has not been fully resolved, and there remain many unanswered (and perhaps also 
unasked) questions which continue to fuel the HRT / cardiovascular debate. The results 
of the forthcoming large-scale randomised controlled studies are therefore awaited with 
interest. Hopefully, these results will complete our understanding of this complex issue 
and enable us to offer women advice based on the evidence, rather than on an 
association from observational studies.
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APPENDIX 1 
SOLUTIONS FOR MOLECULAR BIOLOGY
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Solutions for molecular biology
The reagents used in the work described in this thesis were purchased from Sigma Ltd 
(Poole, Dorset, UK) or from Fischer Scientific Ltd (Loughborough, Leicestershire, UK) 
unless otherwise stated. Disposable plasticware was purchased from Fischer Scientific 
Ltd (Loughborough, Leicestershire, UK).
Buffer H
50mM Tris HCl 
lOnM MgCU 
lOOnM NaCl
InM dithiothreitol @ pH 7.5 
Deionised Glvoxal (6M solution = 40% w/v)
Stock glyoxal solution was deionised by stirring for one hour with mixed bed resin 
(5mg resin/100ml glyoxal) until the pH is above 5. The deionised glyoxal was then 
gassed with oxygen-free nitrogen, split into small single use aliquots and stored at 
-70°C.
Denhard’s solution flOOxf
lOg Ficoll (20mg/ml)
lOg Polyvinylpyrrolidone (20mg/ml)
lOg Bovine Serum Albumin (fraction V) (20mg/ml)
dH20 to 500ml
After preparation the solution was filtered and stored at -70°C.
Diethvlpvrocarbonate treated water (DEPC HiOl -  0.01% DEPC in water 
50pi of DEPC was added to 500ml dH20, the bottle cap loosened and allowed to stand 
in a fume hood for several hours before autoclaving. This procedure was undertaken in 
a fume hood due to the toxicity of DEPC.
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Disodium Ethvlene Diamine Tetra-acetic Acid (Q.5M EDTA)
EDTA 186g
dHzO 800ml
Sodium hydroxide pellets were dissolved in solution as required to achieve pH 8.0.
Ethanol (1Q%\
70 ml of 100% ethanol (analar grade) was made up to a final volume of 100ml with 
dHzO to give a 70% solution of ethanol.
Ethidium Bromide (lOmg/ml)
0.5g of ethidium bromide was added to 50ml of dH20, and stirred for several hours to 
ensure that the dye had completely dissolved. The solution was stored in a container at 
room temperature, wrapped in aluminium foil.
Formamide
Analar grade formamide from a fresh unopened bottle was split into 20ml aliquots and 
stored at -70°C until required. Analar grade formamide can be used directly in 
hybridisations without the need for deionising.
Fresh Glvoxal Solution
DMSO 80pl
O.IM Na Phosphate 16pl 
Deionised Glyoxal 27 pi
This provided sufficient glyoxal solution for 10 samples.
156
Gel Loading Dve (6x)
0.25% Bromophenol Blue 
0.25% Xylene Cyanol 
40% (w/v) Sucrose Solution
Made up to total volume 10ml.
Hvdrogen Peroxide (3% HoOo)
100ml of 30% H2 O2  stock solution was diluted to IL with dH20 to give a 3% H2 O2  
working solution.
RNA loading buffer (5x)
0.4% w/v bromophenol blue 0.16g
50% v/v glycerol 20ml
O.IM Na-phosphate buffer @ pH7 4ml
dH2 0  16ml
The bromophenol blue was added to a flask and the solutions added to a final volume of
40ml. The flask was then sealed and incubated at 37°C for approximately one hour to 
dissolve the components, treated with DEPC then autoclaved. The stock was then 
aliquoted into small volumes and stored at -20 °C.
Sodium dodecvl sulphate (10% SDS3
50g of analar grade SDS (Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, 
UK) was dissolved in 500ml of dHaO.
Note -  due to its potential respiratory irritant effect extreme care must be taken when 
weighing out this reagent and a suitable facemask should be worn.
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Sodium phosphate fO.lMf gel buffer fpH 7)
0.5M NaH2P0 4  (30g/500ml) 78ml
0.5M Na2HP0 4  (35.5g/500ml) 122ml
dH2 0  800ml
The solution was then DEPC treated prior to autoclaving.
Sodium phosphate tank running buffer (0.01M3
O.IM NaP0 4  (stock solution) 100ml
DEPC H2 O 900ml
Saline sodium citrate buffer f20x SSC3 (pH 7)
NaCl 175.3g
Na Citrate 88.2g
The salts were dissolved in 800ml initially and the pH adjusted to 7, before making up 
to a final volume of IL. The final solution was autoclaved following DEPC treatment.
SSC6x
150 ml of 20x SSC was made up to a final volume of 500ml with DEPC treated water to 
give a final concentration of 6x SSC.
2xSSC
50 ml of 20x SSC was made up to a final volume of 500ml with DEPC treated water to 
give a final concentration of 2x SSC.
158
Saline sodium phosphate EDTA buffer (20x SSPE"! (pH 7.4)
NaCI 175.32g
NaH2P04 27.60g
NazEDTA 7.45g
The salts were dissolved in 800ml of dHzO, and the pH adjusted to 7.4 before making 
up to a final volume of IL. The solution was then DEPC treated and allowed to stand 
before autoclaving.
SSPE 2x
20x SSPE 40ml
10%SDS 4ml
dH20 356ml
The final solution was autoclaved following DEPC treatment.
SSPE Ix
20x SSPE 20ml
10% SDS 4ml
dH20 376ml
The final solution was autoclaved following DEPC treatment.
Tris acetate EDTA buffer f50x TAE^
Tris base 242g
Glacial acetic acid 57.1ml
0.5M EDTA (pH 8.0) 100ml
This stock solution was then further diluted with dH20 to the desired concentration, for 
example, a Ix solution of TAB was prepared by taking 10ml of 50x stock TAB and 
diluting it to 500ml.
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Results -  Study 1
IM FBF: left arm FBF: right arm Ratio left/right % change
Baseline 1 3.87 4.38 0.88
Baseline 2 3.04 4.98 0.61
Dose 1 3.09 4.42 0.71 -5.34
Dose 2 3.06 3.96 0.78 4.74
Dose 3 3.00 3.86 0.78 4.80
Dose 4 3,20 4.02 0.81 8.60
Dose 5 3.00 4.05 0.75 0.01
Dose 6 2.33 3.84 0.62 -18.10
Dose 7 2.92 4.51 0.64 -13.42
Dose 8 3.28 4.39 0.76 0.98
Dose 9 2.97 4.02 0.75 0.09
Post dose 1 3.01 4.34 0.70 -6.82
Post dose 2 3.00 4.20 0.75 0.70
SC FBF: left arm FBF: right arm Ratio left/right % change
Baseline 1 1.94 1.34 1.47
Baseline 2 2.26 1.74 1.31
Dose 1 2.14 1.47 1.46 5.39
Dose 2 2.20 1.37 1.62 16.80
Dose 3 1.86 1.18 1.62 16.86
Dose 4 2.03 1.25 1.61 16.77
Dose 5 2.06 1.52 1.38 -0.23
Dose 6 1.94 1.55 1.27 -8.42
Dose 7 2.24 1.59 1.42 2.12
Dose 8 2.16 1.50 1.46 4.94
Dose 9 1.89 1.64 1.16 -16.25
Post dose 1 2.04 1.74 1.22 -11.73
Post dose 2 2.01 1.76 1.16 -17.08
SF FBF: left arm FBF: right arm Ratio left/right % change
Baseline 1 9.74 12.70 0.82
Baseline 2 9.67 12.50 0.82
Dose 1 9,49 14.19 0.78 -5.30
Dose 2 9.21 15.60 0.66 -20.30
Dose 3 9.64 13.56 0.69 -15.12
Dose 4 9.02 15.94 0.80 -13.80
Dose 5 8.79 11.66 0.68 -16.06
Dose 6 9.74 12.92 0.82 -0.72
Dose 7 9.60 9.68 0.98 4.50
Dose 8 9.30 9.38 1.04 30.01
Dose 9 10.06 14.70 0.99 40.50
Post dose 1 
Post dose 2
10.34 16.85 0.65 -18.17
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MY FBF: left arm FBF: right arm Ratio left/right % change
Baseline 1 3.85 3.59 1.10
Baseline 2 4.15 4.00 1.04
Dose 1 4.15 4.52 0.92 -13.26
Dose 2 4.69 5.36 0.89 -17.06
Dose 3 3.80 3.70 1,04 -2.61
Dose 4 4.79 5.14 0.93 -12.89
Dose 5 5.00 6.16 0.82 -23.62
Dose 6 5.00 6.85 0.75 -31.41
Dose 7 
Dose 8
5.61 6.74 0.84 -21.70
Dose 9 7.70 7.18 1.08 0.48
Post dose 1 
Post dose 2
7.00 6.54 1.06 -0.44
JM FBF: left arm FBF: right arm Ratio left/right % change
Baseline 1 2.92 4.73 0.63
Baseline 2 3.04 4.10 0.77
Dose 1 3.48 3.60 0.85 21.21
Dose 2 4.03 3.64 1.28 83.52
Dose 3 3.86 3.88 1.02 44.49
Dose 4 3.70 3.94 0.96 37.49
Dose 5 3.84 3.86 1.02 45.17
Dose 6 3.62 3.14 1.15 63.99
Dose 7 4.12 3.48 1.18 68.86
Dose 8 4.61 4.11 1.14 74.68
Dose 9 4.70 4.57 1.06 52.20
Post dose 1 3.78 3.46 1.10 55.74
Post dose 2 2.89 3.34 0.88 24.28
AM FBF: left arm FBF: right arm Ratio left/right % change
Baseline 1 1.89 1.28 1.60
Baseline 2 1.96 2.42 1.14
Dose 1 2.11 2.18 0.96 -29.20
Dose 2 1.86 2.04 0.93 -31.84
Dose 3 1.51 1.73 0.88 -35.77
Dose 4 1.31 1.64 0.81 -40.80
Dose 5 1.96 2.30 0.86 -37.08
Dose 6 2.34 3.76 0.63 -54.08
Dose 7 1.92 2.57 0.76 -44.90
Dose 8 1.82 3.26 0.56 -59.20
Dose 9 1.92 2.86 0.70 -49.07
Post dose 1 3.66 2.62 0.74 -45.93
Post dose 2 1.64 2.90 0.58 -57.14
1 6 2
MM FBF: left arm FBF: right arm Ratio left/right % change
Baseline 1 2.14 1.76 1.15
Baseline 2 2,40 1.76 1.36
Dose 1 2.95 2.00 1.53 22.13
Dose 2 2.38 2.04 1.22 -2.34
Dose 3 2.22 1.74 1.29 3.12
Dose 4 2.06 1.25 1.78 41.51
Dose 5 1.83 1.64 1.02 -18.20
Dose 6 2.55 2.19 1.26 0.24
Dose 7 4.44 4.54 0,98 -21.16
Dose 8 2.20 1.57 1.42 13.56
Dose 9 
Post dose 1 
Post dose 2
2.09 1.70 1.32 5.60
JM FBF: left arm FBF: right arm Ratio left/right % change
Baseline 1 2.58 1.68 1.55
Baseline 2 2.40 1.46 1.65
Dose 1 2.25 1.30 1.76 -1.12
Dose 2 1.68 1.36 1.34 -16.41
Dose 3 2.20 1.34 1.68 4,78
Dose 4 2.72 2.06 1.32 -17.48
Dose 5 2.18 1.28 1.70 6.72
Dose 6 1.90 1.42 1.61 13.44
Dose 7 2.42 1.57 1.68 4.56
Dose 8 2.70 1.86 1.46 -2.00
Dose 9 
Post dose 1 
Post dose 2
2.16 1.48 1.46 -15.60
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Results -  Study 2
S F D l FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.56 1.93 1.33
Baseline 2 2.51 1.90 1.33
NA 5pmol/ml 2.86 2.58 1.12 -15.80
NA lOpmol/ml 2.54 2.28 1.10 -14.85
NA 50pmol/ml 2.40 2.31 1.04 -21.52
NA lOOpmol/ml 2.28 2.30 1.00 -24.27
Baseline 3 2.94 2.50 1.18
Baseline 4 3.08 2.52 1.23
L-NMMA 2pmol/min 1.91 2.45 0.78 -34.86
L-NMMA 4[Amol/min 1.98 2.67 0.74 -38.14
L-NMMA Sumol/min 1.70 2.48 0.70 -42.32
SFD2 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 3.02 2.67 1.14
Baseline 2 3.53 2.82 1.32
NA 5pmol/ml 2.56 2.50 1.02 -16.38
NA lOpmol/ml 2.49 2.34 1.08 -12.04
NA 50pmol/ml 2.96 2.43 1.23 0.41
NA lOOpmol/ml 3.19 2.82 1.16 -5.73
Baseline 3 3.26 2.80 1.20
Baseline 4 3.77 2.75 1.38
L-NMMA 2|xmol/min 3.92 2.66 1.15 -11.08
L-NMMA 4pmol/min 3.74 4.08 0.92 -29.08
L-NMMA Sumol/min 2.32 3.84 0.60 -52.90
JH D1 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.26 2.65 0.86
Baseline 2 3.16 4.00 0.80
NA 5pmol/ml 2.94 4.65 0.64 -22.98
NA lOpmol/ml 3.09 3.36 0.71 -14.06
NA SOpmol/ml 2.95 3.92 0.76 -8.07
NA lOOpmol/ml 3.35 4.43 0.76 -7.47
Baseline 3 1.96 3.40 0.68
Baseline 4 1.62 2.56 0.80
L-NMMA 2[xmol/min 1.09 1.98 0.54 -20.42
L-NMMA 4(imol/min 0.98 2.24 0.43 -38.47
L-NMMA Spimol/min 0.84 2.14 0.38 -45.22
JHD2 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.28 3.81 0.60
Baseline 2 2.08 3.14 0.66
NA 5pmol/ml 1.73 3.58 0.48 -23.31
NA lOpmol/ml 1.81 3.06 0.59 -6.71
NA 50pmol/ml 2.16 4.16 0.52 -17.65
NA lOOpmol/ml 2.19 4.15 0.54 -15.90
Baseline 3 2.00 3.62 0.56
Baseline 4 2.14 3.71 0.58
L-NMMA 2|imol/min 1.75 3.67 0.48 -15.63
L-NMMA 4pmol/min 1.28 4.65 0.28 -51.46
L-NMMA 8|xmol/min 1.26 3.78 0.34 -41.48
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DM D1 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.54 2.92 0.88
Baseline 2 2.84 3.35 0.85
NA 5pmol/ml 2.98 3.90 0.76 -11.42
NA lOpmol/ml 3.08 4.20 0.74 -14.56
NA SOpmol/ml 2.61 4.36 0.66 -30.56
NA lOOpmol/mt 2.10 4.54 0.46 -46.42
Baseline 3 3.24 3.96 0.82
Baseline 4 2.87 3.52 0.82
L-NMMA 2|xmol/min 2.78 4.28 0.66 -20.13
L-NMMA 4[xmol/min 2.94 4.52 0.66 -19.88
L-NMMA Sumol/min 2.90 5.06 0.58 -28.76
DMD2 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 3.68 2.06 1.80
Baseline 2 3.79 1.84 2.06
NA 5pmol/ml 3.32 2.04 1.68 -13.06
NA lOpmol/ml 4.60 3.26 1.42 -26.67
NA SOpmol/ml 3.64 2.18 1.68 -12.94
NA lOOpmol/ml 3.46 2.14 1.62 -16.23
Baseline 3 3.78 2.22 1.70
Baseline 4 3.94 2.30 1.78
L-NMMA 2pmol/min 3.30 2.64 1.28 -26.21
L-NMMA 4pimol/min 3.07 2.23 1.38 -20.38
L-NMMA Sixmol/min 3.99 2.80 1.42 -18.02
P H D l FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 1.43 1.13 1.26
Baseline 2 1.29 1.63 0.80
NA Spmol/ml 1.11 1.14 0.99 -4.02
NA lOpmol/ml 1.24 1.13 1.23 18.82
NA SOpmol/ml 1.28 1.04 1.32 27.34
NA lOOpmol/ml 1.16 1.04 1.17 13.40
Baseline 3 1.94 2.45 0.81
Baseline 4 2.00 1.57 1.29
L-NMMA 2p,mol/min 1.54 1.32 1.16 10.93
L-NMMA 4^mol/min 1.40 1.54 0.92 -11.66
L-NMMA 8M>mol/min 1.70 1.29 1.38 31.26
PHD2 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 1.31 1.36 0.98
Baseline 2 1.32 1.30 1.02
NA Spmol/ml 1.62 1.24 1.30 30.67
NA lOpmol/ml 1.26 1.20 1.06 6.67
NA SOpmol/ml 1.74 1.28 1.36 37.24
NA lOOpmol/ml 1.74 1.48 1.17 17.62
Baseline 3 1.87 1.60 1.19
Baseline 4 1.98 1.78 1.18
L-NMMA 2|xmol/min 2.04 1.70 1.20 2.28
L-NMMA 4{xmol/min 2.30 2.87 0.82 -31.16
L-NMMA 8(xmol/min 2.04 2.04 0.99 -15.97
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L H D l FBF; left arm FBF; right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 1.22 2.38 0.52
Baseline 2 0.86 2.12 0.40
NA 5pmol/ml 0.72 1.70 0.42 -7.12
NA lOpmol/ml 0.72 1.32 0.54 17.05
NA 50pmol/ml 0.88 1.35 0.65 41.52
NA lOOpmol/ml 1.84 2.08 0.89 93.18
Baseline 3 1.64 2.52 0.65
Baseline 4 1.08 1.68 0.66
L-NMMA 2pmol/min 0.70 1.54 0.46 -30.59
L-NMMA 4pmol/niin 0.56 1.52 0.38 -43.07
L-NMMA Sumol/min 0.50 2.06 0.24 -63.39
LHD2 FBF; left arm FBF; right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.16 2.17 1.00
Baseline 2 1.97 2.06 0.96
NA 5pmol/ml 1.78 2.02 0.90 -7.54
NA lOpmol/ml 1.65 1.98 0.84 -14.12
NA SOpmol/ml 1.84 1.68 1.10 11.88
NA lOOpmol/ml 2.66 1.66 1.62 65.06
Baseline 3 1.74 1.97 0.89
Baseline 4 1.66 1.88 0.90
L-NMMA 2^mol/min 0.93 1.64 0.57 -36.31
L-NMMA 4{Amol/min 0.91 1.68 0.55 -38.92
L-NMMA Sumol/min 0.63 1.82 0.34 -61.74
P W D l FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.20 2.46 0.92
Baseline 2 2.38 2.48 0.96
NA Spmol/ml 1.65 2.52 0.66 -29.94
NA lOpmol/ml 1.77 2.73 0.66 -29.58
NA SOpmol/ml 1.42 2.81 0.50 -46.14
NA lOOpmol/ml 1.00 2.30 0.44 -53.40
Baseline 3 2.76 1.40 2.04
Baseline 4 2.52 2.84 0.90
L-NMMA 2^mol/min 2.24 2.04 1.32 -10.27
L-NMMA 4(imol/min 1.85 2.30 0.82 -44.54
L-NMMA 8)jimol/min 1.60 2.48 0.64 -56.18
PW D2 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.44 1.43 1.82
Baseline 2 2.31 1.52 156
NA Spmol/ml 2.31 1.17 2.00 18.04
NA lOpmol/ml 2.40 1.55 1.57 -7.18
NA SOpmol/ml 2.24 1.33 1.72 1.60
NA lOOpmol/ml 2.50 1.48 1.83 7.41
Baseline 3 2.10 1.49 1.42
Baseline 4 2.05 1.54 1.36
L-NMMA 2pmoI/min 2.58 1.72 1.42 2.48
L-NMMA 4(Amol/min 1.97 1.82 1.09 -21.67
L-NMMA 8ymol/min 1.96 1.58 1.27 -8.94
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M P D l FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.80 3.03 0.90
Baseline 2 2.82 2.70 1.06
NA Spmol/ml 2,79 3.46 0.82 -16.40
NA lOpmol/ml 2.40 3.31 0.75 -23.52
NA SOpmol/ml 2.58 3.72 0.70 -28.46
NA lOOpmol/ml 2.53 3.58 0.72 -26.42
Baseline 3 3.24 4.12 0.79
Baseline 4 3.02 2.30 1.32
L-NMMA 2pmol/min 2.60 2.60 1.02 -3.96
L-NMMA 4(xmol/min 1.82 2.24 0.82 -22.86
L-NMMA 8pmol/min 2.12 2.41 0.93 -12.34
MPD2 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.94 6.29 0.48
Baseline 2 3.42 5.26 0.66
NA Spmol/ml 2.70 4.31 0.63 12.38
NA lOpmol/ml 2.78 4.27 0.64 15.14
NA SOpmol/ml 2.26 5.83 0.38 -31.02
NA lOOpmol/ml 2.70 4.77 0.57 0.85
Baseline 3 2.78 4.83 0.57
Baseline 4 3.88 2.98 1.36
L-NMMA 2|xmol/min 3.46 2.38 1.53 58.50
L-NMMA 4|xmol/min 2.49 2.62 0.96 -0.47
L-NMMA 8p,mol/min 2.46 2.11 1.18 22.22
V H D l FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.05 1,16 1.88
Baseline 2 2.32 1.28 1.84
NA Spmol/ml 1.54 1.25 1.28 -31.44
NA lOpmol/ml 1.70 0.88 2.73 -25.74
NA SOpmol/ml 1.70 0.92 1.99 6.70
NA lOOpmol/ml 1.56 1.56 1.04 -44.06
Baseline 3 2.14 1.14 2.04
Baseline 4 2.22 1.60 1.42
L-NMMA 2pmol/min 1.68 1.25 1.42 -18.02
L-NMMA 4p,mol/min 1.88 1.90 1.06 -39.15
L-NMMA 8[xmol/min 1.08 1.04 0.88 -47.88
VHD2 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.08 1.22 1.72
Baseline 2 2.16 1.17 1.88
NA Spmol/ml 1.86 1.10 1.70 -5.48
NA lOpmol/ml 1.65 1.14 1.54 -31.97
NA SOpmol/ml 1.49 1.20 1.30 -27.74
NA lOOpmol/ml 0.98 0.96 1.03 -42.78
Baseline 3 1.46 1.37 1.10
Baseline 4 1.40 0.86 1.64
L-NMMA 2pimol/min 1.15 1.00 1.19 -12.44
L-NMMA 4^mol/min 1.02 0.92 1.42 7.97
L-NMMA 8M>mol/min 1.22 1.17 1.04 -23.58
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M M D l FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 1.44 2.14 0.68
Baseline 2 1.40 2.49 0.58
NA Spmol/ml 1.60 1.98 0.82 29.52
NA lOpmol/ml 1.46 1.88 0.78 24.08
NA SOpmol/ml 1.15 2.24 0.52 -17.98
NA lOOpmol/ml 1.12 2.78 0.40 -36.02
Baseline 3 3.20 3.52 0.90
Baseline 4 1.12 1.70 0.72
L-NMMA 2|imol/min 1.06 1.57 0.68 -15.80
L-NMMA 4|xmol/min 0.89 1.71 0.53 -34.96
L-NMMA 8|imol/min 0.88 1.50 0.60 -26.96
MMD2 FBF: left arm FBF; right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 2.12 1.86 1.15
Baseline 2 2.54 1.61 1.60
NA Spmol/ml 1.89 1.44 1.92 40.58
NA lOpmol/ml 1.75 1.18 1.64 19.96
NA SOpmol/ml 1.89 1.18 1.68 22.17
NA lOOpmol/ml 2.78 2.02 1.38 0.30
Baseline 3 2.50 1.76 1.44
Baseline 4 2.75 1.93 1.48
L-NMMA 2(imol/min 2.24 1.36 1.72 18.24
L-NMMA 4^mol/min 1.68 1.24 1.40 -3.39
L-NMMA 8umol/min 1.98 1.70 1.22 -16.16
IC D1 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 0.80 1.40 0.66
Baseline 2 1.03 1.08 0.98
NA Spmol/ml 0.92 1.14 0.84 2.94
NA lOpmol/ml 0.92 1.28 0.84 2.15
NA SOpmol/ml 0.91 1.13 0.82 1.00
NA lOOpmol/ml 1.02 1.30 0.82 1.48
Baseline 3 1.26 1.40 0.94
Baseline 4 1.08 1.54 0.77
L-NMMA 2[xmol/min 1.00 1.22 0.82 4.76
L-NMMA 4|xmol/min 1.06 1.52 0.70 -15.94
L-NMMA 8pimol/min 0.86 1.22 0.71 -18.82
ICD2 FBF: left arm FBF: right 
arm
Ratio: left/right % change FBF 
ratio
Baseline 1 1.48 1.26 1.18
Baseline 2 1.47 1.24 1.20
NA Spmol/ml 1.22 1.00 1.24 4.51
NA lOpmol/ml 1.06 1.19 1.47 21.90
NA SOpmol/ml 1.10 1.48 0.81 -31.88
NA lOOpmol/ml 
Baseline 3 2.51 1.64 1.54
Baseline 4 2.20 1.56 1.45
L-NMMA 2fxmol/min 1.38 1.14 1.26 -15.31
L-NMMA 4p,mol/min 1.58 1.32 1.27 -14.92
L-NMMA 8umoI/min 1.48 1.31 1.15 -22.90
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